var title_f22_2_22560="Stasis dermatitis petechiae";
var content_f22_2_22560=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F72689&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F72689&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Petechiae in stasis dermatitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Numerous petechiae are present on the lower leg in this patient with stasis dermatitis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_2_22560=[""].join("\n");
var outline_f22_2_22560=null;
var title_f22_2_22561="Coude catheter orientation during placement";
var content_f22_2_22561=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F87816&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F87816&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 542px\">",
"   <div class=\"ttl\">",
"    Coude catheter orientation during placement",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 522px; height: 512px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_2_22561=[""].join("\n");
var outline_f22_2_22561=null;
var title_f22_2_22562="Patient information: Rocky Mountain spotted fever (The Basics)";
var content_f22_2_22562=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/87295\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_picture\" href=\"UTD.htm?30/54/31589\">",
"         Ticks that can carry Rocky Mountain spotted fever",
"        </a>",
"        <li>",
"         <a class=\"graphic graphic_picture\" href=\"UTD.htm?38/1/38942\">",
"          Rash caused by Rocky Mountain spotted fever",
"         </a>",
"        </li>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?14/51/15155\">",
"         Patient information: Insect bites and stings (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?29/40/30338\">",
"         Patient information: Lyme disease (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?27/0/27649\">",
"         Patient information: Lyme disease prevention (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?31/17/32022\">",
"         Patient information: Lyme disease symptoms and diagnosis (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?5/41/5778\">",
"         Patient information: Lyme disease treatment (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?13/10/13474\">",
"         Patient information: What to do after a tick bite to prevent Lyme disease (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Rocky Mountain spotted fever (The Basics)",
"    </div>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H179306380\">",
"      <span class=\"h1\">",
"       What is Rocky Mountain spotted fever?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Rocky Mountain spotted fever is an infection that causes a fever and a rash of red spots. You can get this infection if you are bitten by a tiny insect called a tick. When a certain type of tick bites you, it can transmit the germ that causes Rocky Mountain spotted fever from its body to yours.",
"     </p>",
"     <p>",
"      The ticks that can carry the germ that causes Rocky Mountain spotted fever are called the American dog tick, the Rocky Mountain wood tick, and the common brown dog tick (",
"      <a class=\"graphic graphic_picture graphicRef87133 \" href=\"UTD.htm?30/54/31589\">",
"       picture 1",
"      </a>",
"      ). These ticks normally feed on animals, including dogs.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H179306412\">",
"      <span class=\"h1\">",
"       What are the symptoms of Rocky Mountain spotted fever?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The symptoms can include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Fever (in almost all cases)",
"       </li>",
"       <li>",
"        Headache (can be severe)",
"       </li>",
"       <li>",
"        Flu-like illness",
"       </li>",
"       <li>",
"        Muscle and joint pain",
"       </li>",
"       <li>",
"        Nausea, with or without vomiting",
"       </li>",
"       <li>",
"        Belly pain (especially in children)",
"       </li>",
"       <li>",
"        A skin rash (described in more detail below)",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      The rash caused by Rocky Mountain spotted fever causes big red blotches that turn white if you press on them (",
"      <a class=\"graphic graphic_picture graphicRef87132 \" href=\"UTD.htm?38/1/38942\">",
"       picture 2",
"      </a>",
"      ). The rash usually starts on the ankles and wrists and spreads to the body. It takes a few days to show up, so it&rsquo;s not always obvious right away that Rocky Mountain spotted fever is to blame for the other symptoms. Over time, the red blotches form tiny bruises.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H179306444\">",
"      <span class=\"h1\">",
"       Should I see a doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;See your doctor or nurse right away if you were bitten by a tick and develop a fever and any of the other symptoms above. Even if you were not bitten by a tick, see your doctor or nurse if you have a fever and a rash.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H179306459\">",
"      <span class=\"h1\">",
"       Is there a test for Rocky Mountain spotted fever?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes, there is a blood test that can show whether you have Rocky Mountain spotted fever. But the results of the test take a long time. Doctors usually must diagnose the infection based on symptoms and begin treatment as soon as possible. Doctors can also look for the germ that causes Rocky Mountain spotted fever in a sample of skin. But that test can only be done after the rash shows up.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H179306474\">",
"      <span class=\"h1\">",
"       How is Rocky Mountain spotted fever treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;It is treated with antibiotics to fight the infection. If there is a chance you have Rocky Mountain spotted fever, it is important to start these antibiotics as soon as possible. The infection can be deadly if it is not treated in time.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H179306489\">",
"      <span class=\"h1\">",
"       What can I do to try to avoid getting bitten by a tick?",
"      </span>",
"      &nbsp;&mdash;&nbsp;You can:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Wear shoes, long-sleeved shirts, and long pants when you go outside. Keep ticks away from your skin by tucking your pants into your socks.",
"       </li>",
"       <li>",
"        Wear light colors so you can spot any ticks that get on your clothes.",
"       </li>",
"       <li>",
"        Use bug spray to keep ticks away.",
"       </li>",
"       <li>",
"        Check your body for ticks after being outdoors or with dogs. Be sure to check your scalp, waist, armpits, groin, and backs of your knees. Check your children, too.",
"       </li>",
"       <li>",
"        If you live in a place that has deer or mice nearby, take steps to keep those animals away. Deer and mice carry ticks.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H179306504\">",
"      <span class=\"h1\">",
"       What if I am pregnant?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you are pregnant, be sure to tell your doctor. Some of the antibiotics to treat Rocky Mountain spotted fever are safe to take if you are pregnant, but others are not.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H179306519\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?14/51/15155?source=see_link\">",
"       Patient information: Insect bites and stings (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?29/40/30338?source=see_link\">",
"       Patient information: Lyme disease (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?13/10/13474?source=see_link\">",
"       Patient information: What to do after a tick bite to prevent Lyme disease (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?27/0/27649?source=see_link\">",
"       Patient information: Lyme disease prevention (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?31/17/32022?source=see_link\">",
"       Patient information: Lyme disease symptoms and diagnosis (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?5/41/5778?source=see_link\">",
"       Patient information: Lyme disease treatment (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?22/2/22562?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 87295 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-197.136.42.3-EB31556FB1-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_2_22562=[""].join("\n");
var outline_f22_2_22562=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H179306380\">",
"      What is Rocky Mountain spotted fever?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H179306412\">",
"      What are the symptoms of Rocky Mountain spotted fever?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H179306444\">",
"      Should I see a doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H179306459\">",
"      Is there a test for Rocky Mountain spotted fever?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H179306474\">",
"      How is Rocky Mountain spotted fever treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H179306489\">",
"      What can I do to try to avoid getting bitten by a tick?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H179306504\">",
"      What if I am pregnant?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H179306519\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/87295\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?30/54/31589\">",
"      Ticks that can carry Rocky Mountain spotted fever",
"     </a>",
"     <li>",
"      <a class=\"graphic graphic_picture\" href=\"UTD.htm?38/1/38942\">",
"       Rash caused by Rocky Mountain spotted fever",
"      </a>",
"     </li>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?14/51/15155?source=related_link\">",
"      Patient information: Insect bites and stings (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?29/40/30338?source=related_link\">",
"      Patient information: Lyme disease (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?27/0/27649?source=related_link\">",
"      Patient information: Lyme disease prevention (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?31/17/32022?source=related_link\">",
"      Patient information: Lyme disease symptoms and diagnosis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?5/41/5778?source=related_link\">",
"      Patient information: Lyme disease treatment (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?13/10/13474?source=related_link\">",
"      Patient information: What to do after a tick bite to prevent Lyme disease (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_2_22563="Barrier methods of birth control";
var content_f22_2_22563=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Barrier methods of birth control (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?22/2/22563/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/2/22563/contributors\" id=\"au7462\">",
"       Mimi Zieman, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?22/2/22563/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/2/22563/contributors\" id=\"se4464\">",
"       Robert L Barbieri, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?22/2/22563/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/2/22563/contributors\" id=\"de4555\">",
"       Vanessa A Barss, MD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?22/2/22563?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      BARRIER BIRTH CONTROL OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     Barrier methods of birth control physically block or otherwise prevent sperm from entering the uterus and reaching the egg for fertilization. Barrier contraceptives include the condom, diaphragm, and cervical cap. These methods:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Have fewer side effects than hormonal contraceptives",
"      </li>",
"      <li>",
"       Offer effective protection against certain sexually transmitted diseases (STDs)",
"      </li>",
"      <li>",
"       Are available without a prescription (condom and spermicides)",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Spermicides (contraceptive creams or gels) are chemical substances that destroy sperm. They are available over the counter and are typically recommended in combination with some barrier contraceptives to maximize the contraceptive effect (see",
"     <a class=\"local\" href=\"#H14\">",
"      'Spermicide'",
"     </a>",
"     below).",
"    </p>",
"    <p>",
"     This topic discusses barrier methods of birth control, including the condom, diaphragm, cervical cap, sponge, and spermicides. A discussion of hormonal and long-term birth control methods is available separately. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?21/32/22021?source=see_link\">",
"      \"Patient information: Hormonal methods of birth control (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?4/16/4355?source=see_link\">",
"      \"Patient information: Long-term methods of birth control (Beyond the Basics)\"",
"     </a>",
"     .) An overview of all birth control methods is also available. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?8/60/9157?source=see_link\">",
"      \"Patient information: Birth control; which method is right for me? (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      CHOOSING A BIRTH CONTROL METHOD",
"     </span>",
"    </p>",
"    <p>",
"     It can be difficult to decide which birth control method is best due to the variety of options available. The best method is one that will be used consistently, is acceptable to the woman and her partner, and which does not cause bothersome side effects. Other factors to consider include:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Efficacy",
"      </li>",
"      <li>",
"       Convenience",
"      </li>",
"      <li>",
"       Duration of action",
"      </li>",
"      <li>",
"       Reversibility and time to return of fertility",
"      </li>",
"      <li>",
"       Effect on uterine bleeding",
"      </li>",
"      <li>",
"       Frequency of side effects and adverse events",
"      </li>",
"      <li>",
"       Affordability",
"      </li>",
"      <li>",
"       Protection against sexually transmitted diseases",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     No method of contraception is perfect. Each woman must balance the advantages of each method against the disadvantages and decide which method she prefers. A list of questions that are useful for defining a person's preferences are provided in the table (",
"     <a class=\"graphic graphic_table graphicRef67965 \" href=\"UTD.htm?13/9/13467\">",
"      table 1",
"     </a>",
"     ).",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H3\">",
"     <span class=\"h1\">",
"      EMERGENCY CONTRACEPTION",
"     </span>",
"    </p>",
"    <p>",
"     Emergency contraception (EC, also known as postcoital contraception or the morning-after pill) refers to the use of drugs to prevent pregnancy in women who have had recent unprotected intercourse (including sexual assault), or who have had a failure of another method of contraception (eg, broken condom). Since barrier methods can have high failure rates in couples during typical use, it is recommended that couples choosing these methods have a supply of emergency contraceptive available at home to use if needed (condom breakage, forgot to use method). Emergency contraception is discussed in detail in a separate topic (see",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?23/32/24068?source=see_link\">",
"      \"Patient information: Emergency contraception (morning after pill) (Beyond the Basics)\"",
"     </a>",
"     ).",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H4\">",
"     <span class=\"h1\">",
"      CONDOMS",
"     </span>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5\">",
"     <span class=\"h2\">",
"      Male condom",
"     </span>",
"     &nbsp;&mdash;&nbsp;Male condoms are a thin, flexible sheath or cover that is placed over the penis to prevent semen from entering the partner's body during sexual intercourse. To help ensure optimal effectiveness and protection, people who use condoms must carefully follow instructions for their use.",
"    </p>",
"    <p>",
"     Spermicidal condoms (those that are packaged with spermicide applied to the condom) are no more effective and expire faster than condoms without spermicide, and therefore are not recommended.",
"    </p>",
"    <p>",
"     When used properly, condoms can also reduce the risk of sexually transmitted infections such as HIV. Studies have found the following:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       There is a decreased risk of gonorrhea, chlamydia, trichomonas, syphilis, HIV, and HPV (human papillomavirus, which can cause genital warts and cervical cancer) in women whose male partner consistently uses condoms. (See",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?3/60/4035?source=see_link\">",
"        \"Patient information: Genital warts in women (Beyond the Basics)\"",
"       </a>",
"       and",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?7/53/8019?source=see_link\">",
"        \"Patient information: Cervical cancer screening (Beyond the Basics)\"",
"       </a>",
"       and",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?1/60/1986?source=see_link\">",
"        \"Patient information: Testing for HIV (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"      <li>",
"       In a study of HIV-negative women whose only risk for infection was a stable relationship with an HIV-infected man, none of the women who consistently used condoms became infected.",
"      </li>",
"      <li>",
"       Regular use of latex condoms appears to decrease the risk of HIV infection by about 69 percent.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Oil-based lubricants (eg, suntan oil, petroleum jelly, whipped cream) should not be used with latex condoms because this can cause breakage of the condom. Water-based lubricants are safe (eg, K-Y&reg;, Astroglide&reg;).",
"    </p>",
"    <p>",
"     Most condoms are made of latex, which can be a problem for people who have an allergy or sensitivity to latex. Polyurethane condoms are available as an alternative to latex. Animal skin condoms (eg, lambskin) are not recommended when there is a risk of HIV infection because they do not effectively prevent transmission of HIV.",
"    </p>",
"    <p>",
"     When couples use condoms perfectly, only two women will become pregnant during the first year of use. However, when used in typical fashion, 18 women out of 100 will become pregnant.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h2\">",
"      Female condom",
"     </span>",
"     &nbsp;&mdash;&nbsp;The female condom is worn by a woman to prevent semen from entering the vagina. It is a sheath made of nitrile and is prelubricated with a silicone-based lubricant. There is a soft, flexible ring at each end (",
"     <a class=\"graphic graphic_picture graphicRef59955 \" href=\"UTD.htm?10/25/10641\">",
"      picture 1",
"     </a>",
"     ). The edges of the ring at the closed end of the sheath are squeezed together and then inserted as far as possible into the vagina; upon release, the ring will open to hold the condom in place. The ring at the open end of the sheath remains outside the vulva, resting against the labia. The patient should check to make sure the condom is not twisted.",
"    </p>",
"    <p>",
"     When couples use female condoms perfectly, only five women will become pregnant during the first year of use. However, when used in typical fashion, 21 women out of 100 will become pregnant.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H7\">",
"     <span class=\"h1\">",
"      DIAPHRAGM/CERVICAL CAP",
"     </span>",
"    </p>",
"    <p>",
"     The diaphragm or cervical cap is placed over the cervix before intercourse. Pregnancy is prevented by blocking sperm from entering the uterus and killing sperm with the spermicide (see",
"     <a class=\"local\" href=\"#H14\">",
"      'Spermicide'",
"     </a>",
"     below). &nbsp;Both require fitting by a trained clinician, and the fit should be checked after childbirth and weight loss or gain of more than 10 pounds (4.5 kilograms).",
"    </p>",
"    <p>",
"     Both devices can decrease the risk of certain sexually transmitted diseases and infections, including gonorrhea, chlamydia, and pelvic inflammatory disease. However, the diaphragm and cervical cap are less effective than condoms in preventing the spread of HIV infection. Diaphragms and cervical caps are not recommended for women at high risk for HIV, who are HIV infected, or who have AIDS as they do not appear to prevent transmission of the virus.",
"    </p>",
"    <p>",
"     In most studies, the failure rate (number of pregnancies) was higher for users of the diaphragm or cervical cap compared to hormonal methods of birth control (eg, the birth control pill).",
"    </p>",
"    <p>",
"     When couples use the diaphragm perfectly, only six women will become pregnant during the first year of use. However, when used in typical fashion, 12 women out of 100 will become pregnant.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H8\">",
"     <span class=\"h2\">",
"      Diaphragm",
"     </span>",
"     &nbsp;&mdash;&nbsp;The diaphragm is a soft dome-shaped cup made of latex rubber or silicone with a flexible rim. Before intercourse, the hollow of the dome is partially filled with a spermicidal cream or jelly and then the diaphragm is inserted deep into the vagina and positioned so that it fits over the cervix (",
"     <a class=\"graphic graphic_picture graphicRef50226 \" href=\"UTD.htm?36/58/37805\">",
"      picture 2",
"     </a>",
"     ). It must be left in place for six to eight hours after sexual intercourse, and then should be removed. If the woman has sex more than once during this time, an additional dose of spermicide should be inserted into the vagina.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9\">",
"     <span class=\"h3\">",
"      Precautions",
"     </span>",
"     &nbsp;&mdash;&nbsp;Most women can use the diaphragm; however; it is not a good method for those who have an",
"     <span class=\"nowrap\">",
"      allergy/sensitivity",
"     </span>",
"     to latex, silicone, or spermicides; significant pelvic relaxation (uterine prolapse, cystocele, rectocele, poor vaginal tone); frequent urinary tract infections; HIV infection or are at high risk for acquiring HIV; or have difficulty with the insertion process. Women with a history of toxic shock syndrome should not use a diaphragm.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10\">",
"     <span class=\"h2\">",
"      Cervical cap",
"     </span>",
"     &nbsp;&mdash;&nbsp;The cervical cap is available in latex (the Prentif cap) or silicone rubber (FemCap) in multiple sizes. Similar to the diaphragm, it is partially filled with spermicide and placed over the cervix. It can remain in place for up to 48 hours.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H11\">",
"     <span class=\"h1\">",
"      OTHER BARRIER METHODS",
"     </span>",
"    </p>",
"    <p>",
"     The contraceptive sponge blocks sperm from entering the uterus and contains a spermicide to kill sperm. It can be purchased without a prescription.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13\">",
"     <span class=\"h2\">",
"      Sponge",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Today sponge is a 2-inch wide circular disk that is",
"     <span class=\"nowrap\">",
"      3/4",
"     </span>",
"     of an inch thick and attached to a loop that is used for removal. It contains a spermicide, and is moistened with tap water before insertion deep in the vagina.",
"    </p>",
"    <p>",
"     The sponge can be left in place and used repeatedly for up to 24 hours.",
"    </p>",
"    <p>",
"     When women with no previous births use the sponge perfectly, 9 will become pregnant during the first year of use. When used in typical fashion, 12 women out of 100 will become pregnant. The failure rate is higher in women with previous births.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H14\">",
"     <span class=\"h1\">",
"      SPERMICIDE",
"     </span>",
"    </p>",
"    <p>",
"     Spermicides are chemical substances that destroy sperm. They are available in most pharmacies without a prescription. Spermicides are available in a variety of forms including gel, foam, cream, film, suppository, and tablet.",
"    </p>",
"    <p>",
"     Spermicides may be used alone, but are more effective when used in combination with a condom, diaphragm, or cervical cap. Effectiveness is reduced if the patient does not wait long enough for the spermicide to disperse before having intercourse, if intercourse is delayed for more than one hour after administration, or if a repeat dose is not applied before each additional act of intercourse.",
"    </p>",
"    <p>",
"     Local irritation of the vagina is not uncommon with spermicide use, and spermicide-coated condoms are associated with an increased risk of urinary tract infection in the female partner. In the United States, the only spermicide available is nonoxynol-9; use of this spermicide alone is not effective in preventing transmission of sexually transmitted infections, including HIV.",
"    </p>",
"    <p>",
"     When couples use a spermicide alone perfectly, 18 women will become pregnant during the first year of use. When used alone in typical fashion, 28 women out of 100 will become pregnant.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H15\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H151\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H23444652\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?13/56/14211?source=see_link\">",
"      Patient information: Choosing birth control (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?35/25/36242?source=see_link\">",
"      Patient information: Vasectomy (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?1/57/1940?source=see_link\">",
"      Patient information: Screening for sexually transmitted diseases (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?9/61/10195?source=see_link\">",
"      Patient information: Syphilis (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?4/44/4803?source=see_link\">",
"      Patient information: Urethritis (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?18/17/18707?source=see_link\">",
"      Patient information: Hormonal birth control (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H23444669\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?21/32/22021?source=see_link\">",
"      Patient information: Hormonal methods of birth control (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?4/16/4355?source=see_link\">",
"      Patient information: Long-term methods of birth control (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?8/60/9157?source=see_link\">",
"      Patient information: Birth control; which method is right for me? (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?23/32/24068?source=see_link\">",
"      Patient information: Emergency contraception (morning after pill) (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?3/60/4035?source=see_link\">",
"      Patient information: Genital warts in women (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?7/53/8019?source=see_link\">",
"      Patient information: Cervical cancer screening (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?1/60/1986?source=see_link\">",
"      Patient information: Testing for HIV (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H17\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/19/32058?source=see_link\">",
"      Overview of intrauterine contraception",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/13/42201?source=see_link\">",
"      Contraception: Overview of issues specific to adolescents",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/45/34522?source=see_link\">",
"      Depot medroxyprogesterone acetate for contraception",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/5/31833?source=see_link\">",
"      Emergency contraception",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/13/5334?source=see_link\">",
"      Female condoms",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/58/37800?source=see_link\">",
"      Fertility awareness-based methods of pregnancy prevention",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/47/3832?source=see_link\">",
"      Hormonal contraception for suppression of menstruation",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/38/20070?source=see_link\">",
"      Barrier contraception: Diaphragm",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/62/30696?source=see_link\">",
"      Male condoms",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/24/39306?source=see_link\">",
"      Overview of contraception",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/5/18522?source=see_link\">",
"      Overview of the use of estrogen-progestin contraceptives",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/52/9031?source=see_link\">",
"      Progestin-only pills (minipills) for contraception",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/7/39034?source=see_link\">",
"      Risks and side effects associated with estrogen-progestin contraceptives",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/healthtopics.html\">",
"      www.nlm.nih.gov/medlineplus/healthtopics.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Institute of Child Health and Human Development (NICHD)",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;Toll-free: (800) 370-2943",
"     <br/>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nichd.nih.gov/\">",
"      www.nichd.nih.gov",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Women's Health Resource Center (NWHRC)",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;Toll-free: (877) 986-9472",
"     <br/>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.healthywomen.org/\">",
"      www.healthywomen.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Planned Parenthood Federation of America",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;Phone: (212) 541-7800",
"     <br/>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.plannedparenthood.org/\">",
"      www.plannedparenthood.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The Hormone Foundation",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp; (",
"     <a class=\"external\" href=\"file://www.hormone.org/\">",
"      www.hormone.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"UTD.htm?22/2/22563/abstract/1-5\">",
"      1-5",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 25, 2012.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?22/2/22563?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22563/abstract/1\">",
"      Fu H, Darroch JE, Haas T, Ranjit N. Contraceptive failure rates: new estimates from the 1995 National Survey of Family Growth. Fam Plann Perspect 1999; 31:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22563/abstract/2\">",
"      Steiner MJ, Dominik R, Rountree RW, et al. Contraceptive effectiveness of a polyurethane condom and a latex condom: a randomized controlled trial. Obstet Gynecol 2003; 101:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22563/abstract/3\">",
"      Gallo MF, Grimes DA, Schulz KF. Non-latex versus latex male condoms for contraception. Cochrane Database Syst Rev 2003; :CD003550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22563/abstract/4\">",
"      Gallo, MF, Grimes, DA, Schulz, KF. Cervical cap versus diaphragm for contraception. Cochrane Database Syst Rev 2002; :CD003551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22563/abstract/5\">",
"      Kuyoh MA, Toroitich-Ruto C, Grimes DA, et al. Sponge versus diaphragm for contraception. Cochrane Database Syst Rev 2002; :CD003172.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f22_2_22563=[""].join("\n");
var outline_f22_2_22563=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           BARRIER BIRTH CONTROL OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           CHOOSING A BIRTH CONTROL METHOD",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H3\">",
"           EMERGENCY CONTRACEPTION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H4\">",
"           CONDOMS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H7\">",
"           DIAPHRAGM/CERVICAL CAP",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H11\">",
"           OTHER BARRIER METHODS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H14\">",
"           SPERMICIDE",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H15\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          PICTURES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_picture\" href=\"UTD.htm?10/25/10641\" title=\"picture 1\">",
"           Female condom PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_picture\" href=\"UTD.htm?36/58/37805\" title=\"picture 2\">",
"           Diaphragm PI",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          TABLES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_table\" href=\"UTD.htm?13/9/13467\" title=\"table 1\">",
"           Contraception guide PI",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f22_2_22564="CT scan SMA syndrome";
var content_f22_2_22564=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F77492%7ESURG%2F76655&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F77492%7ESURG%2F76655&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    CT scan of the abdomen in a patient with SMA Syndrome",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 218px; height: 148px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    There is a distended, contrast-filled stomach (closed arrowhead) and a dilated, contrast-filled proximal duodenum (open arrowhead). The duodenum can be seen narrowing as it approaches the aorta where it is compressed between the aorta and the SMA.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reprinted from Ross J Bellavia, MD and Sheila Berlin, MD from Rainbow Babies and Children's Hospital in Cleveland, OH (uhrad.com). Reprinted with permission from Sheila Berlin, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 570px\">",
"   <div class=\"ttl\">",
"    Abdominal CT scan showing superior mesenteric artery syndrome",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 550px; height: 288px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Computed tomography of the abdomen with intravenous contrast showing a narrowed angle between the superior mesenteric artery and the aorta measuring eight degrees.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Abu-Zidan FM, Hefny AF, Saadeldinn YA, El-Ashaal YI. Sonographic findings of superior mesenteric artery syndrome causing massive gastric dilatation in a young healthy girl. Singapore Med J 2010; 51:e184. Copyright &copy; 2010 Singapore Medical Association.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_2_22564=[""].join("\n");
var outline_f22_2_22564=null;
var title_f22_2_22565="Short leg splint";
var content_f22_2_22565=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F55706&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F55706&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 534px\">",
"   <div class=\"ttl\">",
"    Short leg splint",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 514px; height: 214px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCADWAgIDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD528CeENV8ca+mjaCkL3rRtKBLJsXavXmvSP8Ahmj4h/8APtpv/gYP8KP2RCF+MduSQALK4JJ/3RXV/wDCQ6l/wsT/AIW79mv/APhH/wC2v7O+1bovI+wY8nO3fv3Z+b7u3P8AFmgDx/xL8Ntf8Oazc6VqgtEvYI1kaNJt24MMjBxWTdeFdRtEt3uBEiTkAHJ4ycc8e9fQfxzla3+L2p3sDKXitrQgEBgwKt/hXnXi+f8A4SKz3WEn2NossYi2NxJ6j26cVSQm7K7PMbjTJoJdjvHu9s/4VPp+g3l/nyfLABwSzYH8q7w6Ol4qbkAeRQ2VB5buM+xzVW5099HYxK+MDecnFVyoz52YUvgm9ihjlkv9NVXBPMj/AC47H5awrnTZbcSlnjZIztLKTg/TIrt9V1zSriG0gtoA98XVppiSQODlVrkNXlEoLo2VY9M4wfpUpaFt62Ran8K38GjW+pySW/2eeEzoAzbtu7bg8Yzn3rCRC7hVGWJwK6CLXbm50mW1uJiYra0WCCNm4UeYCcD35p/gGxtb7XFW+OIUG4nOMCm0rKxS8yo/hy7jtftEstuiE4UMxy30GKgj0O9kGVj4PTg8/pXuF/Y2kjiaGC3mjjGFO9VRB25NZuq3D2lqZLia3soehYHcx/Hms+ZFRTltH8TyWTw9exQSSy+VGEGQHbBb2UY5rTg8A6/cWMV3DbRvDJ02yqSPqO1dfb2vh7Uf3s3iK1jY/eDq+7+VdJpJ07T7C/bTr9723hhLk7cBiOeKObokKpaK31PGrzw5qNlP5N1F5UxxhGzlsnAxxzzUDaTLuYRTQygdChbDD1GQK27/AFO81KG8vbqUtNwoOeFGei1ux6dELW0AG1hEoJ9eBWtSKjp1CnFyV2clJ4auoFtje3FlafaV3xCabll9eAcfjiquoaPcWEQa4aMOW2hBuJI/vA42kfQ1DMBI8soy26RsH2rU0rXJ9PtlhWJZI152yHK9fTt+FZSfKzaFJSV72Kuk6I2pnbDf2MUv/POZ2Q/+g4P51Nqnhm802ye5uJrRkQgFY5NzHJA9PetWZdF1qJpBEbO+PGxTwx9ux/Ssi+0Ke2tbmcJMyW+3zCYyAuTgZP1pp3IcLLVGv8OPhzr/AMQ5r6Lw3HbO9kqNL50wjwGJAxnr9013H/DNHxD/AOfbTf8AwMH+Fb/7Jn/IH+JH/YLX/wBBmrV+B6Wtn4r+GtzpUul31zcWNzBfW+kwiKa1GMiS8IZvMPOBuCdBgGgzPn7W/DN9ouq3unag0CXVnO9tKoYsA6nBAIGDXQaH8Ltc1nWLbTbeewjnuPuNLI4UcZ5whPb0r27SvF+n6V8VPG9tqaW9vZQXc5edky0kpncqOAc4UmtoarpU3jPQNR0h1a1uJ1CsqkDO4o3BHHNUkm7BKa5VpZnlA/Zr8ZE4+36D/wCBEv8A8arOvvgH4qs52ilvNGLL3WaTH/ouvtAACT8a5LxHPaSahLi7gPTGHB7VSir6k3Z8zWH7OnjG+t1mgu9FKMSOZ5f/AI3Vhf2afGhkdPtuhhlAYgzy9Cf+uXtXssXj82HiRtAewujaW8X2lblIDKs5JH3Sp+Uc45HUHp36PxJP8RA8N14Pg0e7trkh8aiTFNDHtBCsAcE7i3I7Y471lD2jqSU4pR6O+r9VbQlydtFdnz0f2ZvGoUMb7QgCwX/Xy9Scf88qpeI/2e/E3h2OJtT1bQFaXPlpHJcSM2MZwBDnAyPzr3lvGHxC0i9DeKtO0LStIhDySXLMXV9nzfIFfcc4zyBXh3jz4w674r8Q3+r6XczabYWka2tvGignaWJLHIOCSoP4AVrOKT0FTnKW6s/keX+L/DVx4X1P7DeXVrPNtDHyN+AD671U/pW5p3w01e+8Oyaut3psSrAbpLSaV1uJYhj51TbwpJwCSAe1RaH9l8QXl/q/jHWtiwKoR5sySTuTwoUDJAGSeg6DvXpN5deGNF03zBf3b2NwY5pluubvUGT7qBAB5cecE56gYzUOyXmU272PF9A0WTWdUFgl1aWk5yF+1MUVmH8OQDzXQTfDfW4pvK32jN/suxH/AKDXM65eDUNYvLwQiDz5Wk8sHhcnNfSUH7N2oaMYNQuNen1bThCHntrBGikc8fIPmO5MZ5GD6AdQmn0NE0t0eGHwDrB8l0Ns9tLKYBcK7eWHAyRnHOO+M471ky6FNDfLaz3NrG5x87M20fjt/HHWvXvj1rUdpd+HbTTFOnR21tIiW8a4WJcgDGOh4I6VweiT6bc26/2lqTRxySZmgERKOOuSeefoAaunFSV2ZSm1qka/h/4KeItehkl0+/0Zokx8xnkwQe4whqjrvwn1zRroW9xeaVLKccQzO3J7fcrofHeqy2GhaMdCvHtfD80MhjSCUo07qxUkjhiOOM8dawNBjvNG01tbnuGe7vl2WcKvu68F29x2qeRpczZPO7EbfCnW0iEk15pUQPUNM+R7HCdawPEXhK/0KzS6upLeWB5PKDw7yCcE9WUehr0fwrrLeH7V9Ov57B5DIZHkkO4q5/gA/ib3rD+K3iEapaJaBpGMUyOV2/LH8rDaSOM9/wA6mzFGcm7FH4d/CbxR8QNMub/w7FaPb283kOZpxGd20N0+hFdX/wAM0fEP/n203/wMH+Fdh8BYtVn/AGcviFF4fWV9TeaRYlizvIMMe4Ljndt3YxznGK9o+Er+AZINHbwwNPGufYFFz9kXbNkKof7UF/j3Z5l+YndjvTNz4y+H/wAOdX8c6rf6dpM9jBcWab5PtUjKCM44Kq2a6PVPgT4q03W9M0y4uNKMl+HMcySSmJCu3hz5eQTuGOOxra/Zx1U2Xxiksi2Yr1LiMD/aHzc/98n8699+MGrSaF/wiVyqI0NxrEdpIW6rvVipH4rWc5NTUe5airHz1efs4+MLWze6kvtCMaYyFnlzycf8864nxP8ADrVvD15bWt1c6fPNOpfFvKzbADj5sqMf/Wr7l8cGVfh/4jltiVmi0+aaMqMncqFhj34r4JutZ1C8MkzTNErHLSs3zt/wLr+VFGfOncHGzJ9P8D6nqDOLWW0IUgFndkUf8CZQP1rprb4I+LLmISW506RT02TMf5LXNWmsvFOh0m3P2kDJuLxzI31APAqzceKPFCL/AKV4o1FBnO2Od/0AIxWzXZEOLezLX/Cp/FaPMtzYPbGPODLHJtkx6MFK/mRXJTaTPaajJY6my6fcRnDC5Vxj/vlT+fSu60D4veMfD6ZttfvryM8GC/AnjcdwQx3Ae4Ip3ihLHxpLpk1lt07VFXZdxXE5kXaTuVlbJOACRtPPQZJpuz2ViXdPXY5OLwtdXLqlhd2N65x8tvIWP4ggVW1Pw/dadeSWs0kDyx4DiJiwU+mQOorrdPufDfh7VoX0+6F15GElmkB2zH+Ihey4OPwzW74p17wFO8kOl2jCZ1ytzbq6gOT3Vuv5UrIaktbnly6TOfvPCn+8x/wrasvBN5eQiWG/08RnjLvIv80rTn0eQQJcrFc/Z36s0ZULz1PqK3dJtrqYx2+mJaBAM7ihbA9WJOKaj3FWlypcm7Ofg+GmqTkCPUtIJPbz3/8AiK1ovgp4icx5vdIQSDcpeWQAj1/1fSu98K2kyapGdX1bS2tFBLRxqpLHsPlr2G0vNOvraOG4e2liiAClQU2ge/pSbinYyiqrVz50X9nnxc2Nt5opB6ETS/8AxurcP7NHjeUZW40YD1M0v/xuvpTQvF+kadA4sbqK4t158nJJH+4T/wDqrptI1q78RQGfTXhitlYqzE/Mp9COoqkkzphKFTRWT9T4k0T4LeJNYmSK2udLR2lkhxLLIMMhIOcIfSt+T9mzxoqEreaDI3ZVunBP5xiva/CSx2Mkk1wfNigv7rcVON/znkH3rduvGtypKWVuluvQFFy35nmsqD9pe/RnSqCloj4+8UfDTxL4X1ex0/XLSK2kvt32eXzleN9v3uVyRjI6jvWr46+DviTwZp1he6lNptxFeuUQWsrsVO3PzbkX9M17Z8QIY9bsob28Ej3tlIHhdjwu75SMfT+VbH7S+r2Wi+HPDL3yPJmRzHGnViIwO/GOeaVR8taMejJqUVTR8pf8InqgwDHHuP8ADuyf0qleaNdWlk91L5flJKsLbWyQxDHH/jpq5r/iW61WTEQ+yWwJxFG3J/3iMZ/KrKWIj+Gc98R80+rxQg+yQyH/ANn/AErV26HMcvRRRUAdN8O/Fep+DfE8Oq6JLDDd7Gh8yaPeqq2AxI+lesah+0R46tzH5Oo6e6uTgmyU/wAjXj/hDSV1e8u43QukNsZmwcEDeq5/8ep6aDIdSuLaK4j8+2wyo+QXGM8VaV0S5JPU6/UfHet+JNdu9Z1GSGS6uoFglHkhRhPu4HbvVeTfMsU9thomByncHuPwrlk1EwXUf2pD5igxyjbg47EVpXl+umWflxuD5w3pgZP1FO3UG9bdDo9BvLgQzRERQvG/mRk5LMp+9+GefxqxeaK99cmfULoXMGMgLwK5LSPEUEV5bGRHUn907nHyq3BP4cH8K6/SpFvL6SCKVnWF8Tt2X2ye5pN9TKzvYz2tLWxtW8q1O5jgMqnj8ua5XxFZSvdGWGIFH5wi8gkdCBXa+JPEMNtdyQ2MKRRxgLjrk45PNcrG0+pyiRyylSf9njOc8dBQndXZUU7nO3tqLaGLdxI+SVP8Iro/AMcRknkkR5CWVFjQZLn0rE1PM17IoBKouAfpXcfCRhDDdT28bTX0bZRVTcVBHX9KGa35Vc1bm1v3mCLEhlX/AFcK8pF9cdWqvHY3tvM0mpRPdwyArLGzcMP6Guz07WDfarbaO9+Be6hKIIzCg/cv6Hp1xjrXdt4O1SG1i+1zzXl3H0eOUKD6Bl6Ee/Ws5e5bm6mSqVGrR0R88a/4Z0ew01tQga7lgZtm0AboCem8enbNctput3Wn289vGf3Uy7CD2U9a9z8Wxa5oa3KazZ2s2mSoY5THGAVDDgsCMlcketeV+PdCt9C0/SDF5MjXUO7zYjkEjGee/UVpCSt5hdt2kYtzdBrOC1QDM0gcnvjoP5mu4ut0dpPKv3YYyfyBNZFtoM8cFnJcR20kcaqwboy9/wAea69LRZvCd60g4nDJnOOOlZ1aib5u52Qi0kjx2Fv3SrxgZNP3DFbNz4WukgaW1YuinBDAfzrKn028gzuiyo7qeKTV3cuMnBWsbHgKyXVfFNrbNu2gM5K+wr0f4j2slv4J1EeYQN0YZR/F+8Xr9K634LfCgaLYNrPiUMuo3UeIbcH/AFEZwct/tH9BVP41afb2/g7WjaSO0cTQr83qZE/xpydrIxcnK7Z5H8N/iLrnw9bUZvDssCTXgjSQTQiQELuI69Otdt/w0t8QieLnTR9bMV4vETk4xkjHNWUjiVf3m0+5b/CqMm7Hp3gm11X4g6/rVzDai41m7la6nfiONQTliM8DJPSvUV8Lap4f07Qf7RSGOe3uS+EkDYHmBuv51wH7OWmi98RapJ5sq2CWvzJFKyHcWGMkY969g8Y6VZ2mlwywJIG3HJeVnzjnuTRF6omT0PYV+eUYHBNeRavbrHqdwuMYkYfqa9Y0pvMtraTqGjU/oK858TxbNbvMf89Cat7jicnDZIdRnuH5LqsfU/dGf8a9QTwvbS6ZZyaemnW7CMNK94sswIx2Acc+ua87k+Qtg12muajfHwTaWek2091qF8ggRYVyQMfMT6DHc+tRJvZFXSTZ8+/FHxjpkmo6jp5Z3QEIYUjKRMuOseScA9f8a8vtJxbeDrjadrT3eMZ5Kqo/+Kr6gtv2d5PEXk3PjC+SzkQkCGxAZtn90ueB+Rx613/hr4EeANBVMaKNRkQ5EmoOZuf93hf/AB2hLTVmSjdHwXpFlqN7eoNItbq4uUYMi28bOwPbgD2r1bwr8BfiD4oIvbuzXTVk5M2qyFHP/AAC4/ECvuPT9NsdNi8vTrO2tI8AbIIljGB04Aq3TujRb3PlbSv2Wb6zuIL648Q6bdXMJEgtZrJ2gdwc4c7wWX1GBmvdfh5B4x07Sbi38aNpt1cxzHyJdOJCGEgYG0gEEHI+mK7SipeoW1ueU/Fz4RaB8TIhcSO+m69EmyK7QZyMk7ZE43DJPPB9+1fPmo/sy+N7G8jW0bTNRtt3zNFcmIke4YcfhmvtggEcgGqlwJ4VL27b1HVD1H0qeeUNbXBo+GviN4K1aO+trPU9J/sSSwtVSKOadXjnjB6q4O0nrnHQnmuBSxv7rUjYNcxRoqF2PmbkRR2GP6V94/EjwdY/Ejwld6LqQWO6AMlpcY+a3mA4P0PQjuCe+CPg3QLeXTvFUlldwb54XeCSLORvU8g+wK81cKinG8TNxsjrfAHguTUNTgm1Cb7MWJaIY3HHY4I5Y9unrVn4s+EbvRPDcV/cGJIZL4RJGhPJKOxY+52113gW0l13WkkkWWSK2OZXVtqof971+nQVy3xy8a/8JCiaXaKDYWVwMSA53OFYdfxNZucpTFDXWQ74L+NfFfhrQNVtvC89ukHmG6lSS3EjEgIpIyemMcVs6l+0V4+tLuSBL7TnKcE/Yl6/nXNfCkFvD14YHKXSzSeWQcZ3RBSD6ggniue0KwsbHxHp9x4gEjQSXeMD7pIPf1AJGa25bnTJKCTfU6jw5YP4P+LPg9ZCZNSZ4rm/2dEMxOUx7IRn3Jr6R/aGtBN8L7m6A/eaddW14h/u7ZVBP/fLNXzZ8RdatNP+KCatb3xlvLdRHcRCMja4XHB6EYI/KvrPxxbpr/wm1lLfMou9Ilkix1YmIsuPxArnxD1jIcNmdLpYTUdGVTylzbbTn0Zcf1r86YrFf7Smtblnla3do2z8oBBx/Svvf4MagdU+HPh66c5ka0jD5/vADNfEfxfhfTfiZ4qsI18mJNRnIA7qzlh+hFTR92ckU2upmXl7FDuaAAHG3zAOvsKZpmjz3weQK7ztjyVxncfXHWqGkRSXd/bQxQiXDfd/qTXo+iaRf6j46svD/hra2ovGWeWViiswBLFT3AAPT0PJruUbq7MJSbdkaKeEfD1jo5GsK/8AaEoyoAMsin/cX69P1rE1fwo1jpK6uLa5s0iYC3uYbRlVW/hMvLAZOB1644r6p8D/AAytdERLzXZV1PUgBhGX9zF9F/iP+02T6Yr0G4jtNQ02bT76GKa0njMckDKCrKRgjFVUxENkio4aa1kz84GuYIJluJbSG7a4HmsCSoViTlcDjrz9CKSy1T+zdXe7SwjEbgjyHzgA+h69RXunhf4b3vh/4s69oE1ql7of2U3ETzRhleNn/d5zxuB3A/Q1qeKfgfo2qxM2lSyaVegEqgJeAn/dPK/gce1Z2dro1jhJVFdfceZ6V8Wbmy0uOxg8PWEoySGdmYkk+la914mvdHt4ZxoUVtezANKvmAJN6lkxx7EfrXmB/tbw1rF5YkCK6tZGjlRkDhWHGeR+tWrrxFrdwN14/wBpUjBZxuyB71FrbmKi1ouh69D8TdLGiyXwvVtJkO02K2qNKXx0BPBH+10qI/E6HXdKnsYbnVLa/cKVikjjxKufmVSPb9BXlek6nAZPNvNKEpH3GQfdPqK7fT7TRvFcQW6SazvrZllWTZtZlHoTx/nNONNPUzq1OW66HQadeSwICSUPXDYBzV5fFMumuzpLJGsmBIFbAb6jvXGeJ9U0vQoGi07fcXr/ACjeeE965LXdYnexgRn3PsBkb1Y1pzK5yxoyVqi0PqXwlot1rfgi5n0uJprkNN5a+aEBLbTjk4ycd+lcJquq+M9DV438Ja5MoHDLZO4B/wB5QRj8a2vBvxCXSPBWhWsaqreUHlAbkkgEE/hiu40j4oWkgxK7qRXDCfsm1bc96Lna8WfOdp421fV/EkOm6naS2gkY/u5FIbI55BA9K9E/bOMo0rwgspQgyXJTaMYXbF19+tejeOdVtPE/hfzoiHMF5EgYryM9efxry79sy9guYvCEVs5cRG7RztIAYeSCOeuKG3OqpLsY1ebl953Z8y16j4nsTY/A/wAOgjDS3onbj++spH/joFeYxI0siRoMu5CqPUmvfPjXYpp/wr0y3XgQX9vboD6JbyD/AArqitGcp4BRRRUAdb8NruSy1i8lifaTZure43LkH2q9eaPDq9y11pyTW91u3t5uWic57Hqv6/hWV4BiafVbqJSoL2zD5mwPvL3r1LTdasrCeHT/ALVHJIAAY4R5gX644qeZxehvCEZR1OK8UWFtfabPczA21/bD50I6n+oPY1wsQe5liiyWYkIvtzXtvjuPStZ0ia1hmhi1EANECyx5x/CfXPvXmC2kWheVNcTAXxGfL28J9D3+ta05pq5zypulpuVdW0pbEZVDgjGX9fb3rs/B8cWmaAJYi01xeqJCey4JGMe3NcZqmsTammxvKVB3zg1t+H9QlHhmOKL78Urx4A5IOGH9fyoldoIprcj1KFWv5XVizu2cHsanjeGytJld8ytwSOQBVMicTH92wY881T1Fp4omjdCjHndIMDHtUrUrRFJ7gF3lbCxn5QO7e9dh4RN9Z+D9XvtInSBtjrNJuw4jG3p7k9Me9cfpdhHf3cdv5p8xj87dQq9yPU16I2hlPCLHSpPLszK4unkOMKqggn6k8D1rSPxJESejZH8Nde0Tw34li1XXre5uFiXdb+Rj93IeNxUkZ4zX1VDeQX1pb3lsPMtriNZo3IwSrDIOOvevlHwH4Fv/ABfMshdLTSVcCW5k7jjKoO5wevT3r6gH2GG2htrQqI4EWKJFbBCgYAx9BUZlyOSs9eoUnYh13T7XXNPmsbxEeKRSuG5xnivmzxX4a/cHRLLzJJLPUGW2RuSY3VjtB9mX9a+hbq5WKN5N/IBPWvnnxfqWpw+Nrt9Km+zhpFUsB22gufzY1zYdtXKnG7TLupafHpdjJtNyJZVTzIpHJRJMclR2HWt6MiPwhZROhO8DOPc5rC17UZr61Vbjl9ww2ewHr3rdv5wtlYwSIiqqheG46Ac0pa2OlaGPdbIYsKwVGHAYdWHY5/nmuesljn8Q6XFcy+UJLlBI7n5FAYdT/kV0UkE/nOjjOEPzHDEeh+lU9N0y2l17SIGZZVuLmKNSuAMlxkfTrVxYN2R9GeL/ABlYaN4eN7ql/b+SeB5W1nk9lA6mvnj4h+PrHVPDOp6a9rdwXl8Ip4gwUqF8wNyc8HavpXoHxV0jQ7jTtaaC1SEaKFt4tnyBruXa7HjrtQqOf7xr591y4k+ymB280AABmAJUZHAPWr5EjLeJm6NLaw3Ja8tWuhj5YlONx96aJIBkuhGQf3avwT2zS6UShlkQM0i4CBVyc8/l0609LO5B86ewdoy2WkKsAPxHAqjO1tT0L4f+M9Y8Fox0vSIdQt7yMO4VWUK3IHI/rXRTfFTWNenlsNVsbSxWIZEcYJOT6kk9qr23hq31LwYlwbZUt7dFcW3GXIzubzFJ3A578jFYPjnTrHRdR0ufSY/LsLqJZ4TgAlWAODjuDlT9K66FCNSn7S+q/r9Tjq4hKr7NLfr/AF6H2b4ImN34T0a5PJktYyT77a5HxnHt1u59yD+lbfwcuhdfDbQ3XnbEU/JiKoeN1VtXkZSCCq/yrnlpKx0x2Mfwj4aHiLVJkmlaK0gAaRlHLZ6KD27817Dp1pZ6TaR2tmmyJBgc5P4k9a4X4bp5Fhezg8yy7cfQf/XrppJzk96THc3DdRDqTVXVtYstJ0y41C+mWK1gQySOewFZBmbPJFYfj+3+3eCdXjk+4kO9hjIIBBI/SolpFtDjrJI5Kf8AaI0MzyJaabfSopwrlAA3vyaW2/aC01nxcaTeqv8AeXB/rXnGn6fZ3S7PLjAPX5cVpjwvpJcHyR83oa81Vqz6ndKhTR6L/wAL78OGNWSy1FmP8PliqF98Y9VvspoHh8wqek98+APfaOv51ycGn6faEmC2jBxwSM4rK1/xBaaZGolfJLBVRBksTwAAOSapVastLk+ygldmxqWu+J9TBOqeIZ4geTFZgRqPx6/rXJxeIfFPhPVvtWma5f3trIcGGdjMM+5J4/Cs3U5dbvrMXVpG0RAJMEy7WAHp7+3asfw9qOszwTeSi/aUkK7cF/mU+v65PFXGhOL5jN16Di43PWJ/2jY9P0i8+06I8+q28QxJHINgZuFLd8ZxXhnw88Pa3421jUNSZhFHI7PealLhEjDMXc56biT2p3i7wVe6ZobXNv508026S7fzRtUD5sEepPb2rn/Bsk13eWthcveSWByJLeKUx+YmdxX0C55Ldewrula3u6HEpKSuen3msxpZ3Ph/wrdS22gQuReasBlpT0KxD+Jj064HU1w/j0Wa+FbSPTtONvbxXIRZ3OXkyrfe9T3z+XFd5N9kvclLeK10614jRRtRQOwFeefEfxLb6pbx6dp6D7LBKHMg/iYAjj86hImMm5abGh8L4Ls6JdXFvtkjW4IaHHzfdXkf4Vr+K9FHiW3WeO4ma4gXakRwMew446VW+Dswi0S6B6G5P/oK13t3py3R+0W58q49R0b2Irmjj/Z1HCpt3PZjRU6avqfPWvJqTX8kuqrIbhuGkdMbsDHbrX3Z8G9Tm1b4W+EGjg+1QyWn2a5l8wL5WxSucfxZKhcD1zXz1qkS3EbWuoQqrZzhlzn3Br6N+BdmLDwBbRHalsZHe3UddhPX8TmunERUqfNB3RjKkqaumYf7NtwyeDr3S5W/faVqVxZOP7u1zgflivnL9qyy+x/GjVZAMC6hgnHv+7Cn9VNfVWg+GD4d8QeJYtOvPJTW3e/ikVAWglbhjg8HBwRXz7+2dpclv4x8P6kzb0udN+zlyMFnjkYkn6iRayi/3l77mM0ef6Bov9jaNbX90pMtwQ4VTknOdi/Xqfw967T9nmOS++Nkuou/mpYW0jyzcEbivl4B9PmIHstcE95ctpekm28yRQwxGD0Z1Kgj3r2T9nnwxdWFhdapJGY1umIPTlAeMn65r0KztGyMsPDmqXZ75qeuwpmOKQAjucjPtmr1gvmxKwydwzzwRXl+vlWnG2RsbtwXPFdr4b1VbuziWCUZQAOD1BriWr1PY5Pd0JvFqz2Nm17BEjumFk3jPyVwGteJ4jGxupIo8KThSAfyr1eZ4p7OaG4/eRSIVcHpg9a+BfFP9oWHiLUdNupp98EzRNuPJUHj8CMVsp8i1MW5R6F/4ryx2/i1NU0u7EhuYl8wg5ywGDn1BAFc6+q2MipLFYmCVVPmRRykRufVQenuPyrpvDunJdEb4422jIZxnH0rf17w7pP/AAjd1KbaIXTFcTBcMDnrWP1mKlbuc9Si5NzTscpo/jNYI5i9nar90QpjAQAc/XNYur+K9T1G9jlMwRIWJiSMbQM/zqpfx21u3lwBZj0BAxzTbbTQ0ZaVvm6gDtXRzNnAoRTvYW38+4neWZmYfectzUeoXBeBEI5LFs+3arF3MIYQgbhuuKz7smS4CICcYUAc5pXOiaVj6I8I6MmqeBre8MUbFLB4wSxBT92dpAHXnFeW+I9SutJs0+zX4W5MoARdrfJg5yCCRzivfvh1YvD4AutPliJntwLd/LwQgMR5PPT6c89K+X/FUyzS2+GV2CkFwuD9D61lS+0muprUbSTTO3+GPjLW7/XYdHurnzrO4kWR1KgHcp4PFei/trFftXhBEIwI7rOPXdF/hXkfwRi834gWQ9B/NlH9a9O/bPljHiTw3axKqhLSWYhRjl5OT9SVrB29ukuwNt0tTxb4d2P9o+N9FtyAV+0rIwPdU+cj8lNe0ftEKV+H2kL6XyyN9XSX+iCvPvgNZG48Xz3JXItrVtp/22IUD8i1ek/tJKB4GttpBUarHGCPRIZF/nmu6Pws5mfNlFFFZjLulWst5cmKFivy5Y5xxkf/AFq9C0DTYtB0+S6PzXLKSg7sccAVyHgohdXdnAKrCxI9siuxAj1W8tJr5GFosf7pGO1WyeTjuMcdep9sUn2NoWSv1L/h7wta3emrc6rAkl5KTK/mEh8k8HOeAB7GtPXvBemazYwQRzSWN1DHiAk7oj7fiep/Solu1ijCQqWskJ2QE8oT3U+ntVi3vptyxxbpS5wq4yWJ9qht9DRRVrM4PTPhrq811MupPBp8ETbfMdg3mf7oHUe/FadlaaRomtm00u6m1CDAE906ARRTZwoGPXkfiK980P4ff23o0tv4guvs5cbTbxnc0eRwSc/KfavHfF6aToPh7XvDWmsJHtWx5p6zEMPm/KnCbm2kjnnFR2Y8atolvxOWupyeQqhQo/OsDxnqumXmlJ9ntxFMjk44IYH3/pXDx3aL+9kZnY849+/+NVbu7kuWG/gDoK05UncyXM3qEU5jvI5l+QqwPycV6b4Yi1jxtpB0DRIt88t6Zp3Yfu4o1CgO56YGTx1Jxwaxvh78KPFvj2CS60DTx9hjbYbu4kEUZb0Unlsd8A471738Dfh54i+HWq63D4ns0jtriOIxXUEwkikxuyo7g9OoFEpOC5zWnBVJKJ6R8LvAuk+F9OaFw2qX5x5t5eKHY4HCoDwiDso6e9dD4p8M6Tq1qY5rRIJMHbNAoRlPrx/WjRy8cRLHl2zWu77ojuOa43KTV2zs5IqVlsfKWva1fWXiPUPDkrNeanZtj90p3SocFM+/zD86gsfCMs97NdXbedd7fLMQHyIDyfqcjr7V1vxRW18NfEmXUVgcya3BGTOX2IjQgKUzgnLDHHHSsqfXZZImitbCGNy3zKCx3Ec4+bb+VXd8qsYuEYzaZz/jKxt7K1tYY/vlyShIJQge1R+C4r290BdSvXaaN5ZNjMuRtDbcenaqHi241GdHuLuGHyVUqro6g7m9QCcD3qx4UvZbDQLKwCKpSHLDzjhskk/KuD3quX3b3C+p1Wn6XbPO5aB32jyw6qSCeoOe3pxUPiXwbY6zYyWRlkt5eHYREFQQee3P6Vztj4u87xSmjq8dvaumTdRxNvXA+6dxOAcYz7iuqgmtrTz1jmdZXAxIWLnPQcHqKiV4vQpWkjO0Lw6miaI1jdahJc2D3JmZpR/y02henvtHUmuU8f8AhiztvCuoahDw8LIUUHoGdRjr716FJebYC11HCUMnKngkdiABwDzWJ8UoIx8OdSc+UzIIQjKfmx5qdfepjJ8y1BpKLSPJvhvaS3mrSRxAgEKC/lCRV69Qa9Dh1Wfw9bSPqEFzDd/6tpZFBSY9wgB2kd+egrzTwXrc2iNdS28ZaSZo4VYSBNpO7HX8ee1dJ4r8R+Ihp9nBq1pD5PnZhkkkWTJwey9RzXS77HBKnzPU6PwhrEd1fX13eIzxsnlLaRJtLMx4wq8fU/hXoA8O6c+iG1utEE7Wts62yPGzGJmbJxnvkk14nYWN9pyxavqf2nyVcFBGfLzzwUXt9SK1bXxNZmcvNFqjEnOPtPX6mtsO+RNIVWKlbbQ9s8Pz6lpmmx2Ftc3NhCqny0RQqqf6c1t2lzK+nRvrOoLPc8mX5w/lr2+7+ftXj2n+KtNhUi30RpNxBPn3TEH6gVc1Lxbc3dpFbpa6bZwMSPs8e6Myj3Ocn6VdSdo3sZpW6novwG8bnxPqfinTWiWFbK4RrcB925CWUnPrlQfxr1+RdowBXgv7Pug2Gj+JftltJcW8l3FJG1tM4YSk4YMpxnjB/M19BTqT0AGKxumro2i7opBcnnpT7+3Fzouo2+A3m28iYPf5TTH8zPG0VasQ7PtfacgjNLfQfU+Z7bfbqqhTxxxWmLplRVkcqRyT/Kr9lYSSanNFKg/dyMvA4yDis/xJYw2uoO93OsaBQsaM+0O2D1rzIvWx6c9FdmNr2vR20iWqTr5sg4UNyB61x03iWTTbFr61P2iWOdmOEIbyyMcN2wea6DSvCtjdamuoXkMkjiRZJJWlUbhnpt/u/TnFeTabok+t61cabpEPmT75DtUlVVAx5J9On6V3U4RjtueZUqurvt2Nf/hOrvUdQYzeYqSZyAxNSw3c+iXjX9jeuHnGJYB8yOPcVu6T8A/GN7po1GC60a1iOQUa++cL6naCPwzW14p+C/jnV72ObQ7XS5LCOJYY2tL1FEu3+NxnG89615H0CPs10OL8S+NNbvtAlt5mItpCU3FACwPpx0rE0O5uNG0qRhtR79R83BYRg+vbJ7f/AFqoeI9K8Q6E32LX7G+svmZFW5iKhyp52kjDD3BIrdW1hlsrAzg70tlUrnjipfu6Mcopq0UZN9ql3qe21ikk8kcbFJ5rT8SeFp9I8FW2oXMRiaW7SMBuGIKOc49OK9E+FHhyW6vluY7aIQryGdcAD1qX9oyWFPD1naW6523iM8nqfLcYqefWyJUbM5j4Rru8P3XP/L03/oC16NbNjZnp0rzz4QA/8I9dHt9rI/8AHFr0ONNuV5PvXjYn+LI9yh/DQ69sor2Dy5lyexHUH2rtvhp4kNjapol05zaoDHJ2dCTj8RiuWiXcgzxxzUenxpF4iiRQAtxbyL9WUhh+PWnhajjL2d9GKvBSjc9ki1DPiixVnBR4JTuJ6dOK4f8Aam0Sw174atq0dyrXmiSI4VTnKSlVKsOx5Vh9PekgludB1/wTa6jK14t/LPbvcMAuG2AgbR0BBx/wGrvxz0C30/4NX9vpaGCGG5gdo16FQ4UD6DIP4V388Y+91/q5wpS5lY+Q9Bur+ySUQoSsibE3/wAHzZyPevq/wFqUVh4Vt1tJPMs5oQFHpxjH1HOa+YrWIugU/hXsXwsc2NpNp07f6NcfMgJ4jf8A+vV/WOZ8sjohTUHp1O8NhPfXiyRNuU9FAyQamttG1HTdXFzODDHKpDDd37cVB4buJE1MxllSNOMMe/tW/wCJbl4/K+fcoIOccHNbI6YSbNbTppzBtZgYjkE56V80/tB2axePmnjh2/aLeORnHQnGD/KvoCK/YW6leVPoK8z+LOnw6pqEYkxvWEHpUYmXLTuyKqdzy/wxu8twi7iVrX8Xzm28HXEwBYo6Ej2zj+ZFUtEgNpqQhUkqDiug17TVvfB2rQtjJhMgJ7FTuH8q401zJmL2Z4myO9xFcy7T5gyqqMAe1X40LjYOC/yk+mayrFmL/M5YLwv09q2ojjBUZK/MffHavWWx5c3djvEGhQ6Gtq91596swbBWQR4I9sGofh5Ytq/jvRdPhUILm+iB7lVDZOD16ZqPxLq9zq8vmXm0CNSscajCoOv512/7MWjjVPijBLIqtHZ20s3zZxuK7R/6F+lRKVkbcup9IJa/2XrPiKz8tIkkiguFVWzwdyk5/CvHfHvwUWGCW8s7pooA24M438H1I5/SvafFMEtr4tTzyBJeaW4IXOMxyAjgk9mrVtzLc2UBuYpmiKgqIkB3fU9qzpu1SSNJ6xTPl34R+FtR0L4k2Rv4QbZyojnQ5jk/eIeD9AatftXb5viFp6AzPHHpqIryksWYyysQD3+8B7cV7V4hWGLxt4ftYLJbfbLLMZFTHmAJxz3watX1pA2vHUJdLsp55kES3MkSMdg/hZvvDms9PrD8kU1+6SPDv2erRLeW8llYb2mQuoOSqRqWyR+J/Ktz9omT/i3mjJIwE73yTMuefmjlJP5tXcX3gTwxqOrNctosRuQCJPJkcAjv9wjIrk/2k7e0t/hzpy2UMgVtTjLSOc7j5MvfqfrXXzq1kc7g9z5moooqBGp4eneC/JijMsjrsVQepLCu/ub1LHSCjRBgq7VVhlSg6BT1XqT9Sa4PwxHv1QEOEZFypPqSF/rXV6pPM9pdRusb4Xyy69x6/XNOybSNItpNlnTrj7TbpNbyGNW58tznHNdNouuw6LD51tD/AMTqRiFmlGUt1xj5OxY+p6D3rzvRNQSxsZgY3ky2UA45xVrTfE0VteRPqVi1xZhstEsmCw9MkVU6Em3ZaDjVjZcx7RH4kbwr8O7+bUWkk1HWS0kalzuZMbS5PUEjp9RWV8DvhLceO3k17xFJLb6KXPlAH55znopPRR0JP4etc5oFw3xZ+JdvZm2FrpHljzIWbd5cKjnaQBgkn8z7V9h20lnpOm29lYxrDa26LHHGOgAGAKw9o8Oml8T/ACKjSdXXoeGeI/2W9MvNUeXR/EjafaMSfJez84r7ZDqP0H9a5vQ/2YtSh8d2lvrOoW9z4YXMslzBmOSQAj90UJypb1BIAB5zgV9IjVUZsE1ZGpxlQhYYrJV5bmjw2mhu6ZYWmlafb2Om28VrZ26COKGJQqoo7ACpLqGK6t3hmUNG4wQawo9WlwFjZWA9RUj635KMz7CFGSOlX7aL3Mvq9RPQxgWsrt7af70ZwPcdjWkZB5JIOD6Vmvqena/dW89nJ++iJ8xD1x703XbryrOVoSN6IW6+lc7la9nodsYybSkrPqeafFjw2PGOmyWS3bWkltOJVl27sY6gjI/nWKPAlhOIpvMnupiQUIYq2celdZ4Le51KK+k1KFled967xwR/+qtiLQ9RvVjktikywZQpHIA4z0JHf6Uk5NWiLEqKlzM8u1LwzpdjDuEEZGTvVpCwz0Oc8Vzl5pkvg/UrW98ozaJMwOMZNv8A7JPPHoe1e1ajZXFlb7dSt3igVT5jeSSAfUcHI9RXESvplstwYZ4LvT3yr2s3GwH0zzj+Va0/a7qLa9GcspU9nJJ+o+x0fR9Si/tCwtZQwBYyIVcA56MG/lTvs1ncDymAW7Iwiy/Io55Nch4YvZNA8SsNCn+1aVJ8xgY8oP7h65x2NdHJ4yiu9Qmit9Ns/OJPzzOq4289SMCuhZbiqmsI6een5mEsww1PSU9fLX8i1aaTbtfFbcxPBGPMQvIGKD1+ma474wxF/BurTxygxAQgosYAU+YuRnrnvXRWfim3SFlmsc7mLfujkjPUAHjFc58UNT0m9+HutmCR1vG8jETLs/5apnjoTjNTPAYqg05w07rUcMdhqyahNX7bfmeTeAPsgXUWvtLF7GAmZGj3iAfNk+2ePyrc0xdIm1CO3NqzAEmMlgQo65X/AOtWH4F1W607TdejtTGUuIAjo2cscMBj/vo11/g34oX3hrQRa+TZmNEITdH84YDgA9QCabbWxzzV3a43xbd6XfeEYpdFnka5W8UTbwWUgo3GfUYB/GuHjivt2VaED6VtXeq3usWzX980T3F1N5ty0QA3kj5NwHAIGQPY1EmM9uK6Ka0JSUdESWUd+I90l5HCg5JCgYrShu0s9esBod+1zrUn7nzrm1Mypn+KMdPb7prqvCPh7RtX8N3U2u+YsKSeY7LKse5VxhFz1LHOfQCuisrmFYZl0jwmLOKVSWvvN+cKR97e3Xjt09qitNJWHFOT06GR4J0XXtJ+Lnh3VNX11L9muAsoLtkBgV246cbugr62njAQ5PPavifQIZ7Xx5o8ttfjUbcX8JcBsuv7wcsvb+VfbV38indWcHeJok07N3Mlm5xyKs2Z/erk96rM27jGRU1sCrjnI96pPUGeV67I2neItWQYV/PYqfQE5/rXiXjzxBZahrLG8e4la0JWFFAKZ7sfU9q9m+NM40zUtTmj2+cYhKue2V/xr558P2lvf6ahu5R5pTceDknJzXHRp+/JvodGKq2hGK6l22kXVLcfZpb1duGKp8oA989RXRfBWxvfD3hvxjqk+nia986KwAbqMHdJ8w+qnjrgVw82rw2dhPCBP5+AsewYH4mvVfhB4+8LaBoF1puuTxxXkk7zkT7gHDAAHOCCcDHOOldUNGcydz0rwDNJrekyyTKFtWJjKEcNx0x7Zrc8Fvp9tNLp2jSItvbknyl4AJJyQPrmuY1fxFPaRWVz4atrYI4yYrnJVlbow2+1b3hzxNoccbzTolpeMu+5ZIdiMw4JBPJFbg5HjP7ZGryS6r4b0gy7khgkumX3dgo/9AP51wvgXQbnxPqkFjbISkePMfsAPWq/7RPiKDxJ8Ub+ayffbWkcdoj+uwZb/wAeZqxfDfxC1jQdGfS7KRYrZyS7ooEjZ7FutZVI87sildI988ReJ9H8JadLo2lSs93EgEhjTgn0z6V5h8VfGVr4m8DWUQsY7e+jvUeSRGyHAjkHPvyKwdUmu5tFTWbiyvBaykRiV12qxBGcE9TzmuZ1h0exT7NcxzQGQHbnDqcHqp/nzUukoNXIXM2ejfBrnw9djt9qP/oCV6GvJyK84+Dj40K6X1uWP/ji16REpY14uJ/iyPcofw0WI34+lQmcQ6zoly2Nq3qIx/2XBU/zFPQHOR064qn4gX/iUzSR5DQ7Zl+qsD/Ssab5ZxfmatXTR6D8Uw0GjaNqCwSQjSNbtX818YkRxsYrg5wN+DnHIrrviTYzan8P/E6vOJLd7DzIoPLA2Mnzlt2ec4HHbHvWV4/g/tz4Q600Zy32H7XGR6x4kGP++a3rG9i1Tw7bWrCRm1LT22lULIAYxnLdB97jPWvQqKyaX9f1Y8xPRPsfGukw751GeN1ekRH7PpzMgBdF3AjqCOlcJoUf/ExKEHhsYr0K2svtQ+ysdglGOO1c1+aUUvI7WdV4atoNUtrG8d2MkgyxDdDnmu8vbWOSxMco3oeh96808BWbWbCLzZXWMnG4AcV6VshuVRSgUAd8nJ9ete3yNGftV0KapAiKfNBI4IJ4rznx0w/ty4VOQkSg89OM16vaabbpJuWOLJOc7a88+Kdr9n8QyyIDtmtkfPbjK/0rlx0WqPzQ/ac8rHjtm5/tSZumG7muunYzeHdRRcjdayA/98muTsY/9OlJ7seK7KxtWvLOa1yAs8bR7j2yCP61x3tYR8+6Pby3MwSFdzdTk4AFddDpPkabcXN1JtCqdioc5981x7R3GmXbx3EGTE5Rg2cEg461dn1afUXigdhBaxDAjj4UfX1r17t7Hm8i+0Ra1PHKY0iGe7N6ivoP9kjRZY4dQ1VAoaVTy44KAhR+pb8q+cp/mLiM7i7eWuO/r+uK+0/gHpP9laXPamJylvbRQu6gcPyzfmawry9+EO7/ACNqK0k+iX5mv8Qp4D4o0J41ClmltncAjdvjyOvutXNEaWfTYEN7tjGYzHsxtweuR1qv8So4YtIgu1gjjmtLyCZmxhiN4Bz+DGrnha3aXz0UlRBcHceMEH1yKHpW9UPeBxvixm/4WfZI0rSCz0xpCxORl2wP5VsTW9xDeWL+UIbYLmRy7bpMjngcY/OudvZBf/EfxHKreakbwWSEeirkgfia9Ka4tmsYnA2ow+RducEfWopLmqzZVR2jFHNWVjDJbO0KXnDEHzBtZx7E14/+0epg+HumWiRzJHFqYyHTHPlyYGeuete6vcSLJJ+/ikAGQHyu72HHFeOftUusngPSm80lxqKZjDZHMUnP14/WuhGUj5booopmZYtJ3t5C8bYbHHvyD/SrJ1K6lVozIcM245PB+tZ4ro7Lw1ci0W5uoX3OMxwngkeren0rajSnUlaCIqVY017zM43GZDE7FsNgNHnn866PWvDkVppenypdSLczoWljuVAVR6qw7ex54rDhtNQ068juobV1liYOhAzgj2NaF7rFxrm62v3kilkYEsVz07Y9K1nGsrImM4NXTGeB/Fdz4S8SwalZZaJfkljz99D1/HjNfZ2ja3Hruk295avvhmQOp+or438JaP8AavENnaRiFpJpNkb3I2r7sRnhQPWvpjwBqGiWN9N4d0jUJ702kYaS4kUKkkhPzeWB0UccVw4qlpzPc9DA19fZ9Du/LdVJU5rD1bVbmyjEiK2w8DgkmukjdFGNwz1NJ5MN3cxR4y7MEQehPeuBq+x2udnqVPDc+qX1kZLfT5WOcFmIUfrVLxNH4ojiY2+lSOADzkEAY9q9csreKztI4YVCxooUAVI5DoR6jFb/AFVNatnJDHOnPmUUzxj4c6ZdWWlSXl5KYpLliFWQbSMcdPwrqrOxe8vIbOTLrId8zHoV9Kq6hdeTey2d1HdW87KY48xb42Geo4611vhnT5LWEzXP+tdQoBGMKP8AE1hTg5yUV8z0MdVfK6st5bf8Aoa94WQWol0MCC4j58sfdcdxjsa+ffjcJtHutH1vT7uW1vnJtbjynKM4wWUnHphh+Ir6uU5r5z/a88M3MmlaRr9jGzWttOyXgUfd3gBJD7ZGCfcV3KlaopRPKVe9Nwnr2OK0r4s+L7S3XbqpuEA+5cASZ+uef1rY/wCFn2HiSKaz8R+GY7hfLMk13YrteNVGS3I6D3yP0rzHT4hDpcEkqMHmBdGPQoDjP5g1cht4oNEvboTpJJcYhMSuUKggnnswyFyPb6Gui2t0c6tbU7GfR9MutOnl8JX6awCBIkIYQXMPPJZCPnGO6/lWHapprSS2880lvKvRLmPZvPpnOCeveuIihurbXoo4JHtrhWGGZxFtGM5ySAOOn1FdPovjfT7uB7XxrYPdtLGv2e8jcI0ZzyzDB3/j+Oa66GPrUtJSuvv/AK+TRx18uo1NYqz+7+vuN/yPs6qwKqgGMOMZ9veuT+IswPhy8Uqu47OV6H51rp9UtJ9LsotStphqWiXD7Y5gcAN12Z58p8fwnKnqPbk/iAFn0DUZrV5JYFZMlo9jKC643L2+o4NenPERnQlJvdOz6P8A4PkzyqeEcK0ba2av3X9d1dHm+j3psXkkXqNp+uDVjybZ78SysfJZt3zck/7PFVNMiglEqzKC3G07sY6/nV+HT5rW0N29qzwB9vnZHlhvTn2r5tn0Nknc3bt9PNpZiytvIk5EhQny3wTg4/vc9ajj5ZQzBQTyx6D3qbRtLfVdD1rVLaULHaBJBBtwAOA2Ofc/XFR6NZy6vqNvYwAFp22nPQL3J9gOa2ptKNmYN3ehv6FF/bheRty2qZWxSZMwxL/ff1Zu3Wn6tpetxyrNc6g8zR42BvmjwOgGOgrtb/wrorWcMd0ZpzGu1GZ8JGoH8KDgfXr71wN9ts9ROlxzzyShA0Eivh0/2G9eOa43Jzeh1pRgrWNLw/aWuo67pt6ymw1azu4Xkkh+UOu8ZJr7huE3oW2lq/P/AES+vn8TaZbIyyTPeQwluikM4HPtX6C3JCpznjpWsPhMXHlk+xhyRuD8sRHNWLGBi43K2KJLkKSABUtlMzSDnjNUI+df2sr1dPikaP8A108kEAz6BS5P6AV4h4Qne88mKzBF1GNzKc4Vc9z6c16z+13PbHVrBJzyZJGAHfCqP61wvgKa2Phz7TGscc7u0crlfmYLjHP0NZR0i35lVveaXkYfipEju5zHPFI2MEqMAccisDV7D7bp0N/b5aRIR5q5GAAcZH5j8617vT4pJpMM8o3E9ccVPozQabLHN5Qaa3JIST5kbnkEHqCOKpTViFBrY1Jvi1Pc6bFBLZNFcxIFSSFgEQAYACkc9O5ql4q+ItvrXh2ewFlcLdyxqhlZwFHzAsdo9cfrXR6lo/h/xhpb3ugRLa3iD99YrjKMf4o/Ue1VNF+Dd4k6XN+zTwbd4hjIRgf9snp9Bmr9vpqCUU9TA0P4V6lqum216NQsIorhA6DcScH14xkd667w54M0bwzMZ7q8t9SvAAeYcrGf9nJ/WoNRu18H2klpvkjLMzRIf3mAMDn0rjz4xv8AUZ8zrAyA4Kx/K+PXnrWdqkldbG9obNnReLtbg1e7XTpJporSR1QhjlEyMbgo4+vevP8AXtHl0uBhNGrYmKrPGcq64PT8s1c12drhoZ7YMYlYfO33j6Z9K9G+Negx6V4F0FxlLlWhhuI8dX8pzuHrnFatOEYp7mba5vd2Mf4Rvt0W59Dcn/0Fa9MtJMleOvrXmHwldTpNzGCpf7QW255xtXnFelwDGAe/avFxP8Rnr0H+7RqQruOB+FJd26zW80RX7yFfzFNtHbOHIz2PrWjgHqOtcr0Nkz0L4VSLrPgC1gmwwe3a1kB57FefwpfhXI48GaRBNkSQQ/Z3z6odp/lWH8BrorDrWmsebW8YqP8AZbn+ea6nR7Y6df6ra42ol5LKnush8z+bEfhXpy96N+55k1aTR8u7ItM8ZarFKQixXkiKPUByAAPyrvtFL3UyyXMP2a3VhtdgS7enyjoK53xTbR2fxR8QsUUv9oLKT1Ct83H5112jSgKvzfMzDoeQa5aUkqsL90dj1jc6LRLJElleBJZVz9/5Yx/48f6VvRzxheXgBB5BnDH/AMdzWFoEULeZJMvnPu+9KS5/WugicD7gUfQYr6B7nMXrWduNkDsv94Agf+PEfyrnvirYNc+HINT8rb5MnkHkE7WGe3uAPxrpbGN7mQLzt/iNbXiLSV1TwjqGmxLkvCTHk/xjlf1FZV4e0pSiTz8skz5GtI0ju33g5J5rfi1K00uzmvtQmZbWFctgZPoAPUk8Vzhm82+cDjBxj3pfiTAyfD6RypA+0RDOfrXj0/etF9TeT5U2jhdPiS7srgxyAmbIVnG4rn196gi8MyQx3EktwpjQfwAlmbGQAK52zu5rOUyQNhiMc808392wLNdTfezjeevrXrpW2OFzudR8OvD51XxvZW5G6CzIuLg8cBDnH4tgfjX2r8JmFvoOpXDDPm3ZXggdFH9c18e/Aq0ln8ZvcIG8m2tpGdh0+bCgH88/hX2J4FI/4RK1tcMrvJJNlRkH5j17jpXE3zYy3ZG8VbD+rNDx3o41PwvrA3b5BaSNGSuW3Bcj6cgVjfDu8Sa9nkIkdJreKUopyGyOpHety6S5nP2SBsBFbevnYwCD29K86+H9y1vaeYJWTydLkO5c/wDLMEdv92t6uk4MiGsWil4Gkjk1S61Jwvl3OoXFyAVyCoYhRj6AV6Aly0elMUtJorYPjJj3EZ7gZOBXJfDCwV9C0/8AeGGRLQSh9u75ic8j8a7DUI7s20DebGGk4ZhEQAR6Z61OG1i5d2VV+Kxjzzx+bGquH8wELJuBwfpnNePftLiZfA1glxGpI1GMiVGwG/dy8bfX3r21YYotVR7eya4naMHzWh4Qj3HGa8Y/aht5l8F2U7MWik1NOCoG1vKl4GO3Wugyex8x0UUUzM6/4X2sd14kbzIo5TFA0iBxkBtygH6816w6xeeEvAApO1jjofWvKvhZIIvEU7EZ/wBFbv0+Za9PndGO1AWIPIYfpXv5c7UfmfP5lrW+RZutLt4lZFTcMfKCM59s/rVDXPC+mWvhyHUkkka/vFkliELArFAnDMxHduRjsAfWtzw9qtpZapYTXccdzbxyBJYJuQwzxx64ziuC8R+KppdIvLRrRYGum8pXhASNI1b5gqAYXJ/OssdiZ0/ca0f4/wBdfI1y7DRqe/Fu638vP7tvMwW09bF4pPka7YbhIsgfAPuOmOmPxq/pOoXXh3U7TVbbpFMu9d/31x8w2+471ladOkkYMo4VdiBMDB6jPqK3das4JoVmspWaMhVCSDDk7cscDOAPWvHeru+p7d+W1j6f0q4XVtMju7J1lidBIjKeoIqXSGkt9e01pW/dtIwOfUqcV4V8NfiCvhDSoLW8WWe2kZ4yFG4x85yB+PSvbtJvLbxDpkd5p8ok2ussbe4OcV59SLpy8j11KNandPdHrUT70pw96z9MuPMgV1PBGatz3MUKbnOPQetdcXY8jyJ+MgkAkVFJcAHCcn9KoS3m5QXyqnoo6moXlLjB4H91f6mhy7BYvfbPLPzMg/Go9RWy1bT7iw1GGK5srmMxTRNyGVhgg1j3FxGgKq8KyY4BOTXN+JfFtv4b00X2ouolIxHEvWV+wA/D8qm7voVofNPjO1j8P+JLrRrS5ae006WWCGRiCdu4kA+46fhUfhuyXVb+206WLKTzp5ko+9HH952A/wB0GudvLqe81K9mmlMjzTySlvUsxJIrbuhJ4V1cR3D+bceSrqyMQYmZf/Qlya21JKHxJRB4v1WC1lElskxSFt27bGMBVPoQBgjtiuSlURzDeC8S8ZQ4yMevNeqfEHS/DtjpSmyuJv7Wswgnd1/4+7iTazD2CKccd+vWvKrmRPnZgeM8CqC+h3nwY1rUY9cfSWhivdCuYnbUILlisCQqNzSM38GMcN2OMcmrnxo0GytrObUvDVxcXGiTRREFjkp8y4R/oTwTVTXI7Twz8LtLtbFT/aetzNNc3cb/AOvtE24Qf7Hmg/Ux57isa28RR3Xwv8RaY7TCVWtzGN2VK+apwfyOKV2lZPR9BWTfNbU57wbBp9xHqCajOkRVFkiVxw5G7Iz1HbpT57q6uJIESOFrJflWDflAT1O3tR8OtNn1TXWhikWKJYmeVmQHjpgEg4JzxTPEnh260jxKbS7ikZJTvjeNcB1Pp7joayduYZ0lja65YCZTaRQ28bDznR1W3ZDxnb/F17V1XwXghsGv9Vl0691a9R2tYrGzt/OfAwSzEjCgnAB68GvP9cvVM2mw2Et1dX3krHLFIpJRgcKi8/OcY7elfaXwL8Nr4P8Ah9ZRXlv9k1C6zdXayffDuc4b3AwMdqlSaTT6lKHPaSPnH4l/FJpphZnwgdEvIz829ijFfQrtFeaeHr261TxXHdtvecFpAka53YH3fpjivqP9qyy07U/AEuovDE13ZuhimA+ZQWAK59Dn+VfPfwbtLXVvE1rYxb4b65DRbkBYhB87ngcEgbc1VOcFCTirCqwlCylqdJ8HvC8/ibxjb3s9kLSGG/iZGDnGUcMUC9SeOvQV9sXkW5SSeK4HwrounaJewSwxLb21ugCDy9uSRjJPfvXbTXCuABINjcqw5FTSd1cUim1vGCSX5qS3Co4wwI9RVO6E65KIJB1yDWe9/JDDKzAqVUnntVNqOpK1dkfMv7R1jeeJvGtnHZNETHHIdrvjgvjP6Vy2h6Emk6c+m6hqEMkjSeaVtzkx5GO/0rW+NKao/iyzurGf7NG1psDhsFvmbcfpXN+JVsNM8Ir9mBN7JKuZs/MTg5H0rGDbikXW0m0ivqyyafK8aPvU/dbbg/jWCl09xeJaI2Z5nWNQeASeBz2rNi1S9kYRiR5CTwCc17r8C/hVbawLbxVqt6jQLKwS1hHzb1OOWPAH0yfpWvs+WLlLYjma0OVsvDer+A9aTUrqE3MqfKrp/qUzwcH+I4z6Va1vxMbbXptN8USXFtaTqs1teWI42sMglc4YdRkele5eM9G+xafcS2VqtxblizQs5CsGxkFfXPIIx+FeC/Eq8t7nRdNg0i1njvrZ3BgK+ayRdSCcdA3TPYms4pTZlGrOLtJHT+FNN0+6SZba4g1LTipMr3EeGIx6Hp65rzXxQ3hiO4uLfSbN2mDELPHJiPP45yKwrfXNZ0y2ubdS8MU42SYXHynt+NVfMR1DIh8wnOc/KB/jXRSiqd5Nj5ZTlzMWS4mgiYbJghXClRhd2ep45+lS32ra3qHh2KC7urmXSLeZVjR3JRJCrYC56cbuB61cuLi4utOity4giiG9yM5Yj+QrT1+2u7P4b2A1OTbNdXiXMEBxuEJjfDEep689ivrRKo2tTSMdbF34bXEtvoV09tDE0wuDlivzFdq/Ln0r0/Splu7dJOEbuh5INcJ8HrM3mg3y7owFnYsWcLtGxeea15fEcWkxrDcQW63JbKQWzCaecduF4X8f1rnxOH9tG63R1Uavs9HsdpGcFtx46ir8M4dAG/A1j2MzXUKS4Ko4+633gcdD9KvxDZwDke1eHJPVM9JG58Kbz7F8S9StSflvLdJQPUivWNbxFrTMOPMhRvrgkf0rwXT7s6f8RNBuwcCTMTH15/8Ar17v4j+aWxmH8UTKfwI/xrupyvRRx142nfufOvxQQxfE2+dR/rY4n+vyKP6Vc0W4xLCp4AcZ57VH8aEMfje1kxw9pH0HXDMP8KpadIMZU84rjbcZcy6G8dYo9U8N20QSQyK5G7ruz+ldJHHbLyEY/U1xnhW+8+3bJw/pnrXSx3EMKK1zJ5aNwqgbmc+gHevpk1OKktmcTck7HRWbqCCOOMcVrpeRKjRiT96McZ5H4VzFpO0jDC+VGRgR5yx/3j6+3Styz8tPmZkQepHT/wCvTW5DPlw6S1n4k1G3cHzIrqRTx/tHmuY+NWsxx6fYaJDsZmIuZTnJXGQo/HLH8q9d8bmD/hPNenlURQq4Zs8fKI1yT+HNfLXifVG1rX73UDkLNISikfdQcKPwAFeNhqfNWfaJvWlaHqZiKWPAzjmnyxSRqpZcB13DnPGf/rVGpwas5uPsbKDJ5APzD+HNeurHEzrPCNzLo1po9/Hqd7Zxz6mEmiVsRSRLs3McHtuwcj+Ljoa+0dEleHQ7BGj8gpGANhwW4zk/nXw34RtzeXgjLwW1oB5c884LpEZA0YkIHIA3gZ6A4zxX3hY6cbOC30/7VFcPDAiglxu2hQPxNcsYL2rl1Ojm9xIv6VawTHzAEWc9WHJP1Hb6143FdxaVpGux/aYkltrS8gKeYAxLMwUAHr+FetWaXdlqAcQrcWsrBVKAq6n6E/8A1q+bviXFt8V6rCQflvZW5HpLSxOiUuzKoato92+HkTW9hAsUXmOtrEgXGf4a6DdPfGWWCWYD7kkE6fdPscYrN8JptsZ4PMnhEkcYEseMKQOM9/yq3bzWtmZIbSV7ibdly7HaSPQUYVWoomprNlm3MkUGJECQgff6fmO9eGftZXMc3gLTkjV+NTQljwD+6l6CvdPt5k3b45QMYZl+Yj8+MV4R+1WgHw90wksH/tRBtwMY8qXmt0zNnyrRRRTIOt+GhA16Yk4/0Zu2f4lrvpZyuSQcqc5PNcN8LEEniC4DDI+ysf8Ax5K9H1SNIgGRV2Dup6e9e9l7/c/M8DMP4/3HKzXrNNcLI3X5yd3cH/8AXXpvxJ8AW2n/AAtsNVtcTzXUayYA/wBWrDf1B9K8j1A+VdkspUP68cEda9z8IF/GP7NstnaAzXmi3L7k6narb/1Rz+VYZrHmpxkujOzLfdbXc+dNNaIEBzhgpOG4wwrq/NnhkRoxtdB8qlQQuR0AOR3rntKjgsPElvHeHNsswWRsbsKepx3IBrfeRpYUlRg7n5Sdo5x8o/SvKPSZmWls01xgZIB+7XceDvFl/wCEpXEJM1m2C8JPQ+o96oeE7GFrmeCcRB5IZNryPjy3UZB9s4xz61CVGQRgtyD3pSSkrMcJyhLmifQngb4o6VeXtrbzymGG5O1XkGAkh/hPpnsa7nVdQjTXIIJS2DGSGP3Sc9PrivjSe0R2Ktkr/dycV3Wg+MtegiisZJ/tVuoG37SpYqPZutYqFlY1q1IzfNFWfU99OuMZLx5VCyx5ESE9R2NRz+JoF08YnihOP3hmbZj868E8QeL9acmON44fcZJ/WuVnmu70s17cSTs45LsTihK25lc9Z8U/FXS9Nhkj0sjU77kDYNsSn3bv+FeM6/r+qa7qKahqdw0k652KOFj9lHYU2a2CkkDjNU5lC4UkE1SstgH6ckTXq+YodmOArHALHpk+mcVZ1iZtQ12C2icySeakKYGf4sdT94emaq2CRJcSG6QOgQkBmI6envVa1ujbahHeIuHjO8c/xdiK0T0C2p6N8Vbe20rRtKsLS0jlit7fyWkflVlYl5GXB++TjJ7AYryfULWGLw+t1NM3224uTHFEuAPLVfmZh7llA+hrp7e6/tNtPsNRnkSzRzLNLGAWXdy7D1OOg9a5HxFPFd65ItkH+xRt5Vtv6iNemffufc1TelxeRY1C8vLu3tILiSW4jtrcW9qGORFHkkKvtkt+daWneDry++E+veKMiO00y4ih+bjzWd1DbeOSNy55HBpbGUax/Z2j6fGYry5lW3HmSEjcTjI445JOO3NdF8VPGItfDw8CeH4oxo1ighuWK5ZphIGZ89iWA/I0JdgKvwD8tbnWHkkRWUQ4V2Khh8+ce4rrfi7Yaf8A8IGb+/M/2kTqsBJG5nIOAMDgYGT9K8m8F64ugadq9yEjeVzFEisOTnfnB7DA5q3rXjrWfFNjb6F9mhNtLKgSGJC0jyfdXBJ684AFczg3O43se6/sv+AoYtLTxn4hi8y7bI08TL/qoxwZAD/Exzg+gyOteqeK9f0w2ey6nmTzV3b0kxgEdQRkVx2o3l74dtNL8PPIqWdtYxQq6nG8hAGz+I6V534o1GOys2ghu0EQQiGGTqD2APfmolNN2Z6UaDjBcm5teKtah17Rv7Csbg3UerbrSBnTJ4JG/HfaRn8K7r4ceFdI8GaEsGn2YklQbbm+2AXMrnqOn3PQA8e/Wqvw38PW2maPp1vPbxyT2UI2TMvzI7D5yD2zk5rp5odgzOxB3j96vHmfUe1RNOKt0Oas+dply8nkawVZMg5IAI5A96xI7q/t2IgmlZP7hTIrd1B1yFeUKQANzLx/9asee2mlbK3rSL/dVuP0rZKysJbWHnxDdBcMrKfY5/Sn6VqVzqF29td2+bNlyzfdyc9KbBaqjokm0FjgFjxV3+09Hs28qSZWdPvDcAKmUktDSnhnP3oo5n4jfC2LxvrNlcLrJ06C1txD5EVtvz8xOc5AHXp7VyOqfs3jUraOJPFzIsZJw9jkE/g9ekSeN7S/vxZeHUbUJk/1i2w3hP8AePQfjWu+oXlrbxLO8QuZPvqG4Qenuaz57PQ1+qwa13PI7f8AZ/8AD3hvT47rVbq51Ly8GeVH8lPxUZIT8a7ez1Cz0uyistMhiitYVwkUSACMV0txfPPbzRyKJIypRwRwQeCK+ftY1iXwrrg0q9nZwWP2NmOBLHnAUn+8M4qeeVXRvY5MRhnS99bHrTajHeRSrcyBUYFW39CD6+3tXjy3P2HxpIum3AmhuiYpEkI2+aOw9MjtVq58RrN/x9tuUdIY+h+p71xHiW+urjxPFPbMQr7WjiQABGA59gB3q6Stc4qkea2hxvjq5iuPEF5BpiOtnG5wmOQR1z7A5Aqbw/YXV1NYLpsfmvdkoyHgKw6/pzUeh+JZND1y8mn0+0vvNlYyRyZ5Oex+ua7m0+IuhOryx6W2nTKCzLERt3DG3ZgDHPFdE77JFNOKSSOQvfDbW+syLcXsVzFAwEwjJwr5/wBWM9ccZxXQfEy0Mvg6w1O8ld7+S82k4+VkZCePTGwDHv7Vxi6/M9vdW0CHzLmXerd1JOePc12Hjr7Wnwx0aC9TEkNyiswGQW2SHGfUDFNqzTHzS0Q34caDcap4RvppdTuYNLW6KS20OF3ttU5ZuuORx7V3XhaDSNItpYbS2iS1lG1pVBLgjrubqR7VzHwWUzaNNCZBGrXbZcjIHyL2rtbLw9u1K7NldK9qP+WbKSzN7dgM003c3toZfhqCFZrs6KtzJalyzmfIJ9xmuotWDBWUhh1yDWDr+lajDZIwSKRXIWVfMIAX3Iq1aaha2bRW9tbi3tANoG7OD61x4zDe1XtI/F+Z0UK3L7stg8Vb4jY3MYOYJw270/zgV7092L7SdNlXncMj8VBrw3xGfN0ibuVAcfga9N+H199t8I6W24Ep+6b8Mj/CuGg/daN66vZnnnx1iZfEOjOOC1uRn3D/AP16x7CICFd2M47V1nx9t8f2BcAdDKhP/fBH9a5nT8G3BI5xzWE1dtFQfuo3/DEsaXhjmcxqRuRgcYI5OfbFbukags143nM00nBijT7/AD7fwj6/lXJwId64Gceneui2R2lxDdadJ5KMORGoGD3GfWvVyyspQdJ7r8jKtHW/c7xWEFusuovFZoeVgTBdvb1P1P5Vs6PdPdlHWEwx9FiI5HufeuX0qKz4uI1klZxnzZDk5/Gug067dZQsUYGeCOp+vFektDmseDftJ6pFoPiHW7YSEXuo2sbxoATlWXYzE9AMKwr5kHBBFfR37YEElp4u8M6o0eBcWLwk92MchPT2EgrzTTvhpqmv6Y+oaZFsABYpJwremD259eOa56dONOUmuruTOTlbyPPmwT6GrNhNBFLm6tjcx4IKeYU+hyK19Y8E+JNHsTe6lo91DaKcNLgMq/XBOB7mueRijZHP171qpa3Mmjf8LyHSPFWnNfSfY7aR1ErvEJk8p+DvQnDpg8r3Ge9feXgjS7zSvDdtDd3tpqdxGWWKWBDsSAsTHGpYliFUgBiScY5NfAkUVveWIVGJulwqhm6D2GP15r0/4SfFbVvh1qkem+IJbi60Q/IYtxZrb/d9vVfywaqVP7UQjPoz7GuIJUuHkSN3cjJTO5gMdj6e1fL/AI//AH3iLUZtrKXupDhhg8sOK+kY9Sg8S6FbXegagHs5sSJJbEGN178nkHqCp78Gvnj4lgxeKNRTlgbhuSMHqtceJ+A68P8AEe8aIUkt5IEkWK4KgoWBKnjvikS2R7lINXs9k8J3iaPOH9NxB6UzwvqSWVjM+pOiq7gK0a4IG3gY75xzU0Wq2Op+e1ksqzocNGF+Vvfd0B9qrD/wVYyn8TuTaldSxzQw2NxbKyHc8G3cGX69/pXjH7WdxBL8OtNCRlJjqsZb0/1M33favXbqxsr6ByrtEyYaS4B2eT7MOv4jivF/2sIfK8FaUYmuPIa/j/1vKuRFL8ynuPr61sS9j5ZooooIO3+EkbyeIrryyAVs3bP0ZK6jXLiW0cYZQueV7H6muX+Ev/Iw3Yx1s37dPnSuo8TQkK7kgjrg+le7gNKNzwsbribehx2u32YQVOR1U13f7MPj9PCnjeTTNTm8vSNb2wSMTgRS8+W5PYclT/vZ7V5VcK93e/Z7fLKzDaOnJ/8Ar10E/gu407TNUmv+LuzUEohBVScHk9zjNedjMTzS12PVw1HkjodX8afBU3gzxfPDIh+wO/mWzf8APSMn19R0/CsyxTNp+6UlQvmKCckrjr+FeufCrxFYfGfwVP4M8cB/7X02IPZ6rj5iuQq7j/fBIHP3h7gk+VfEDQNb8E+JjY6zbMkUkYW3mRdscoHG5f6j3rkWmh0PuOubtZJy0ahRnk461NasWyB0zkCsC2uRuwxwoGDW5aSJHEHLgyN/D6VE5WBK5oR27MN20DHb1rc0a3ikuI92Sepx2FctPeEEqvLdwD0q5ZrqNyUFskzkjBESk1G+472NPxFJardvsHB6DOcVm2zRu+FwMipLjQ9UDBpodme8jgGqk2nXMCuzGEkAcLMOOaLBdmp/Z8jAuVynYgVh31sgmK7Ru68Vaj1Sa2g2SxTBf7yNkfmKy729YyYZ88dD1x9aiMWNspXWQxxz2qqo81gvTJqWW4DHZjBJ706CMo6vwCpzzWqdtwfkdBremPongvS9RkiZLrVGleJj/FCAFHH13GuN+zh4lWFi0gXIzx8x611njnxP/wAJHrOmKsfkWdnBHBBb8EIqj9ckEn61y1lLJNHN9mjDy4KkAZ+8Tk1t0IudX8KIF07UtX8QKsd02jWhNsrJlWupPkizn0Zs/wDATXc6/wCENK0X9nrxZdOkV3rn2mAz30hJk3tPHlV4xwGIJB6lgegra8H+Br268L6VpsEJtLOQ/bL29baUUBiVUe4689C3tiqvx2uZR4A1LTNEjgi0CwWCN/n+eRjKh3Y6nnH86ynNRaiVGDlqeJ/DXTI9VXU4JYPPU+V8nl7j/FyPQ/SuxF14b8B/EDRhDBbXNxZzLPcSpyITzwR/eBxx2+tedeGl1iTSdTj0KC7lleSES/ZUZnCYk/u8jnFa+gfDbxjrUskVpoU1uQuZJLseTgevz8/kKSSu3Jiu000e43N0l1BPfXR/tTSro78gbmj78jqMdjXkXjh9Asr2K+0xrh7mKVJY42YsgIOec133jDRdX8P+EvDttBNOdUtI1jvJLOJmVoc4BbjqMgZ68VykfhDXtd1NHaK5m0VJlFzeSRbBgjIAzyenbp3rFJc10z05VFy+91R9L+Db1b7RozMgiumVXZfqM1osTE5JGR3BFctoRVZlVW2qAACO3pXRNcscx3A+df4v71ayRyeQ+a4SRizkBD1z2pFS1APlSW7HuAcGiIRyJnAIPUUg0rT3cuYyrf7LYpA9DO1bS21eJoiyQwIcF2cjBPpjvXPaf8LvCy3Bk8Sapc6kind9nWQxRH/ewct+dTeJbDU71msdD1CSCSUs4i/ve+axo/h5na3inxLOlsvD28L7Xb2Ldh+FYu97s7oRXsly3Oh1Hx1oGiX9t4f8LW0TSE7YtP0yEFvxC8D3JrSltbi3CXmtSxxXUp3C3U5MXsT3P0rj9Z8V+D/hxp6Wvg7To4rq6bYXjUvPO3puOSfzrZmVNM8Iv4x8fTtbOiiSCx37ioP3d395ye1DV2EJqO5peKNfsPCfh6a+1ScJBGOcDLOx6KB3Jr5P8efEKfxNrdvcxWkcNpayF4UcZck92P8AQdPeqfxI8eal441Y3F4fKso2PkWqn5UHqfVveuTWJ2GQuB6k1rTpKGr3OKvXc/dWx1uqeJx/ZqwWUjPczAFpQMbPUD3rL0nVLiCV5AzPNjZmVi2B7Vn21uVlBJUjvio7ZyLhssRu7jvzVqKtZHK32NqW4YQOrRxsSS5PlgtknPBrHisri4lOEK5OS0nFW5IrhnzHL8wOArDFbVq2YVZo1aTbyMcE072M78pX0W3h0q5S52m6vY2DQhBmNWHc5611/j26n1D4X2V5cJiRtVCSMpwpfynJGPxFcpc3l69z9ksITEWwAxHzfh6V1/jA2/8AwpOwgtmDPaayIbghicyGF2yf1H4Vm7uSaKhe95Gn8D9OuLzwnfujxR24vGDO56fImeOvSvRJ2uhfWsNrqlslnaoGkZocGT1H0P8AnNcF8BbGW78MXrRRs228bJzwP3aV6BrHhy/lS3/sya2Jc/vGlBCoMcY9a066HQtjE8XzG/jjTTJp1YH50DBUc4HGao6jo9rZaSs3iScW0YwGSJicn0DevtXZ2/h21tYDNP8A6S8eflchUH0Hf6muY1XVb24lRPKh8qJ9wiePcGwe+aOa24rX2LcttbDSClo6vZzQfuWySNpHqefzrpPgvdCTSbq3B/1M4kxns2M/rmuf8RW51rw+k1rdPaCNt0sauBk45Qmq/wAJbprXWLq1BYb4w2DwSVPf8648RSjGopR6/wDDnRSk5QcX0O3+PFoZPDFhMq58q8AJ9AVYf0Fee6Yqy2oBUMpXBGM7q9g+LVuLn4f3zYz5JimH4MP8a+V77xJfK72Q/cwxMVOw7d2P1rjp0JVatk7WNFUUaep6BqHjLRtH8yN5murpB80MGCV9mboPpyfapvht4/Gvate6NqVpbW63C+bZFMl2dT9wk9Tt56Doa8jvbhmRora3WNXO7JGS3vVzQPDGsWs9rqUUV7CRMrxTtGSAw54NejQw1PDvmjuYzrSlufUej200UxywSM9VDcfXHrXY6M1pGQEvBuPUbfmP49K89F9LbXEDM37qdQwDjG0kZxg10thqM7YEENs56AkEEflXctSHrqXPi94a0/XPDlteX2ni7k06TzU3Dcyoww54/A4HpXlFvrUGigW2mK0uHxl87CfQivZX0+5uNF1BvPeS7lhYRgEhFbHACn+teHeJbyPT7izN/pcqrcfNcSq4wfYe/T8PzrOa1Ie51XhrxCkNzIdRkVLeQEOFiBHTldvdSO2K+dvi/wCGrXTteuNW8PWxi8P3Un7pFVgIHwNyn0BJJUZ6cdq9gj03TZLg6nZ3tw9pKh8pEYMYz33ew9+nc1NPqNnDZyaZrdsklrOpR0ZdySDrjI79/UfrWd3ELJny5BMYpEfGdpz712sutaLq/hT7JdzTw6qr5xOm+HGesbDmNj/EMENgcivS779n+PW7P+0PCepiGOWcExXYPlQxkdBIASSD6jp1Oa881L4NePbAoG8Pz3G4kZtGWYDB7lSRz1reFRxMnC50/wCzb4vufDvxB0/Ro9SEmj6vIYJrdt21JSMI4yMBicDI6g89sdv8WFQeLdSK7gn2hvvdf4etc38BvhR4ms/F+l+J9dsm0rS7GQyIboDfLIAQFCfeXnnLAe2a3/ilOtx4p1J0WRB9oYBX+90Uf/XrkxbvC504bSR7Npggubb7E8fmSygMsf8Ae+h7VUuZ75dSgtbVbSFojslVRtEY7eb/AEI/LFMbzXshDa3HlSyYQRf89PYHsfequm+H3tbiVry4liuTnMAfPyk/xHPz59+KMMrUYkz+JnSrbwSuVIWedV+acEKkWD1jPR/cfnjpXhv7UlzYnwVp9rbTvcTxaihaUk7XBjlzgdBg46cfWvULee7udZXTA1m8HVEDbUXA9P73t/8Arryr9p61K+C7GdljLJqawsykEg+VJwfyrchnzNRRRQQd58G2C+J7rLBf9CfqevzIcV3HiawnktpDy2cjIOe5H07Vw/wbEbeKLnzR8otGPP8AvpX0np3hHwxr/g13TVms9aVGEgmnVYw2DgFf7pA+8OR19q9nB1I06HNJdTxMXTnUxLUOx8fXLPaXsyqxDBs5H517xeTQ3mmyzqS8Wr6SkmwjP7zG0j9a8N8RxvFrFwsi7XDYIzn9e9ez/DW7XUPBGhszfvLG6msGOP4XG9fyzivHxUEpSt3PaoSvFNifsy6Xc3EXjNZkEenvbJbXEzjhCS3A/wBoYzntgV6pp/iOw8S+GE0Lx7arqNvCWtpLjq8Tp8u/1PY7hzz3rkvgSyw3PjXQrof6Pb3qXQHTJkBH6BRWt4ihisvFJEaRRwalB5ioo24lj4PHYlcH8K5ed8zOjlXKrnF+Nfgvqmmwtqng+ca/o5O4LEczJ7Efxfhz7V5hHJcQXTQTxyR3AOGjdSrKfQg179Y6jqOjyC70u4kgcZMkatwfcjoa1bnxF4c11Ebxz4ejupFXIu7NNso+vIP5H8KrmuS42PIdBsrG2CTaq29jz5IP8zXeaPfxXCLHbKYYF4RI+C7ensK2ZvBHgu/tY18J+K4Y71y2YNRYKcE9ACFYEdOc5q7p3w21zS7HzPLguzvwvkSgjGPvHNU1ZEIw/EHh+G6dCBLFIy4JDZwcZzjHNefaroTxKwspDcq5VQy/NkjJPSvVvEOn6/Yskj6dPLEcDZLbsR7nP0PrUd54e1qC/wBOa2Y6XM+ZEnaNgsfHHzYIGfXj0rSNrEvc8V1bTZ9MtbSaZwouE3oUbOPY46H2NZjyQNctBOwkA4WVRg16p4itNdvbi6t7nT7nUbVZGZnitMFsjaGO0YznH5VyWn/DPxPeyR+ToWosxP3miKAfiaHy9wTOQvrJ4FEmfMhP3XHf2qrBcNBJg4ZW5z1r6E8PfBLXZ/LGsPa6bp7KTN5jiRgP90cZ9yao33gz4M+FHB8ReLZdXufMOLSzlDhvRSsQJB9ywpJOS2Hex4zpug6tr2rqmh6bdahcEcRwRFsZ4BY9FHucV694N+Edr4Hs21b4nalZ2IdW8u0jkDuzHtx98gdAvQ854rY1j40waFo40v4eeHrbSbNPuy3Cgt0+95a8buOrMc9xXmHh6PV/G/io6prc13qbp+8mZiWIjB5AHRR2wOKznU5Iblxp8z1R9BprFpf+HbZEtzpmlSI08VuxCyPEv3S56Esedpryb4xWslt8O72KOONWxHPcsxIc75l2gDkHHTg4wK9Pu590VtPMiI12gfyZAE2RKPl+YcHqOPU15X8YJ2tPh9fQnesmoOk7xHIKKJE257EYA6d81zwu5Js2ekdDA/ZovpLafxBBCEDXAt13vnCYMnOR9a+jxKLcmFcmBgA4ClnZv948D8q+aP2dGaI+Ipkh8zy0gOdu4r/rOg7mveDJMJrWPM7sFDSPIcOpI+6FHFaVX7zMY7HUQXMklnGbeLzXDEYbgof61CL6KWzeO6SU3JYxtHIQoz+PGKrW+xTErXMiOw2+Wz8k9fwzTTEZrtrvULONjGuxQW+8QfTufc1m0MqCyisNRKQyCWBhkEdvY1qFg6BGGWH3Ce/tVy2UXcMts9ssMjjepC8fn2rLnVoJGhm4YeldEJcysO49VaPLQ719QBn9KsW81w4wIC/bg4qot+YMebkj+8BVo67pMMJlu7lUK5OelUNanN+JLOee/Ekcr2rohRXifkZrl08NvHKWmklunOCzSEtn86737TYagvmQujo+GXLdqz/EZLaY6ROsbMy7TGeQc5/pUcpqqjXu30Mi38L6F4dvF8UeNJ45Gth/olinOw9c4/iY188fF3xprnjfxJLJfxTW9jGx+y2fZF5wT2LYP4fz9u8Q2rakFm1JnlkJ++x54GB+Fef+IdCtWBzkKOQc0k1F+Zc4e0XuaI8Ve3dB83B9KFCsoLyn6V2OqafHCDt+b61hyWkZz8oH4VspXOWdJrYzJpE8sLESD0PvSTPGYkSMNlTkk96nuLB0G6MZ9qrQHZJggZ96Zi48u5ftjcTMpxsUDjA5NdBpltOJonELupyM44rHtnjwCysp9QaklusyNGXZo9gwAeM59KzlqZW53ZHTyXcFleS3DeXJcGIIoU5VD9R/SnX9rKfgdLqkrsft/iRTjsNtvL19/m/KuTkuJdpaNAcYUlRkius8UWz6f8PLq0JZI31OznERPCk20ykj8h+lC9015VGyR2PwF05r3wXqjNeC1gN4ySMr4Yjy0OK7PxJIlnZ21tot5emK258skAMc5zn0Hp0rg/gbNeSeE7mzsdMNyx1Eu06nDIDGgIz0xxnr3r07X9Iu/stqtjNaNczuEWJ2wQCOuT3q3foaxtbUy01SbWLfzJ3EpZdrRJ8oRvXPf1qxo11bwCS21GNIklztkK8kf3T6+1XbPw9FoyCfVZ99w6hfJiJEWepwev8AKsnxFYrrN/bf2esdnc8LG8jcAZ9OmfSlsx7o5y4sJLe6uZlvZprFyVjjZQFT8PWjwfcG18Z2rGTckpMZz7rx+oFegTabqEkFlazraXMcYBmZo9qsw68f4VwfiOPUYPEsGpPpwtrS0uEjEqcqy7uv5VlWhePoaUpWfqe/+IIRqPgLUogMtLYyAd+QuR+oFfI7eHby9efULaFmgU72YDd+Qr630nULQaIsV5NHEj7o/nbGQR/9evmbTtNu9Gv59PuZZra0R2whJzIQSOvXtWGHg4VHN7NfqEn7vKu50Xg7RoStlqF9pW5F6CSPr7+9etS6vZ2sKwxqkoIDKEBAU9ua4e61LULfw+ss0ExtowqoAApI7Fh19queHYH1uxe5jmgiEQzIHcEg+nt9a7G30MrLqXtYg1O98+6vwkduNrW+F2vtzzkflUukaqY4GZp0WOP73zBcfmck+2KrXfiKKG2k0xYG1G5+7Hvz8v09T9KZbWQaZDKiowbaVYZIPpiqhI2p2asz0jwlOby4W5kmm8r/AJZI5xn3IrzvxxpVoupXdvdlNwlIUP0wTlceldhopxKDE7sq8EnAHvj29TV7xhpWn63YRalcQ7zaAszAfeXHfviqkrodRaXR5Xqmj32m28VuscFrF5Y+e1IIkz6+h/x4NZ2mIxU6dcpLdWa/MUQfNF6HPUD9fr0rvf7XsWUwrZ+XppUeZDHgngdQPT2HPpXA634bv9M1SO78O3EslrfnMex9xAPZ2/unpuOOeOtZrVmHQ3bW+u9BdrKHUfPt7nbtELDy2z/DJ6H6dfTtXe2evLHo0L6dK96VTMsTptMHPb+8oweBnp17VwthGsfmaRcab5moCPMtjGQyup/iBOBtz3OOfetdMy2dvb39ybwRqFi8gbfsJyPknJHI6D5vTle9bWJudHpGuCac+S0SSS5JvLnP2aUY6Af3v8Op6V5N8ULQL4gRoYrgzzpvcuuA3UZTpleODXpBaWW4m0pYobi9EfKxuPKK/U9P93qPpzXHfEd/M1DTInvpLySK3kSQEYeM/wB36/U59658V/CbZrQ+PQ7fSDFPZxyXE2EuAHSUjG9OyYxwe+etRahbQz6oZLKO7QbfmQtmU+4PJx+P+FTeHNPt73w5psMUgW8S2B3StlGXH3R7j9PU037T9km3RSbfLG0uWy4Ppz1H6GqhpBWJe7K6eG7W3EbXdyJbl23RR7vlb6n19+n1ryj9pbSotP8ABdi0dxulfUY/MhBP7v8Ady4+vsT+FeiXs0zxyySSeXG43PJIceZz2/umvLv2hJIJvA9hJAcH7fGHVs7gfKk5OeT9asl7HzzRRRQQdv8ACI48USnkf6M3IH+2lewNcLDOsqxywyxnIKtgj6c9K8a+FjuniOXZ/FbMrfTcteyTguqhSuSAfl6ZFe9l/wDBXzPnsyT9vf0POPiJpltqc/2yzgSK7LHzBFwjD2Xt+fen/CbVFt/7U0zJ8pljulyOQY2wW/X9K2td0yW7hfGUYcepFcX4H83RfiLp6XOViuJGt3LDhlcFf5kVy5phkv3kTuyrE88fZyep7D8LZ3/4XRqos4lltr3SmmZX+UFldQG+oyR+Ndv8QdO8/RzcRxn7fZt9rjO3BIX7wz6Fc/pXMaCdI0vxrFf6l8h+ytFbqMje5IO3jv8ALx9K9E1vVIpfD091bXMJhEYZ5bgYIHQqteBK+jR7a2aOAtpQ8O7g7gMHrlSMg/lVaaJJFcYCsFIOKboEsIjFusiSx24xGy9NpPH+H4VNOFELM3yg5APXFKWg0ZEtg7ZDxpIMfeP4ViXP9paPMZNOvr3TyT1t52UZ+gOK7GxYSEEHgjByOtZfiS33p0yQaqErMmSujFj+Knj2yYpD4muJEB/5bRxyn82U1DP8fPiHbw5OtWsx5BVrCPIx6/KKxJYE+1yghuvpXN+INOLNI0PJHOOldtKtBfGc04SfwnWzftF/EZ1ATVrWLHdLGL+qmsq/+OPxEv8AC3Hii7jTv9niihP5oorhdP0a91C8+zwQsWHLEjhR716fp3w1i0u3jm1V/wB665QEffOOgPbr/wDXrtw+GnX1ikl3/wAjkxOMpYfSTu+x57rOueIPEso/tPUtT1AZyoubh5B+AJwPwqxonhjUje280lviNWDfMce/WvbtK0Kz0+DzIrWMSFTt3KO2Bn881X11xHqLRwNGykld0XQjOMj6/wBa9COW0pO022eZPN6lr0429TiNS0y9uFRFt33SdkO7gDJP5A17J8KrfTNG8P3NsLiJ7y9wsvlyhZY06bR78k//AKq811kTymLyY5Zp2DAAZBBHtVvwxeaLNA9nrFlHaBJRMk0QILYxmNm+9jr0PH5Vy4jJqD1ptr8Ttwua1pR/eJP8D0KKGaz1trCwtbme0uifszXDbSY1GTjPGM5/SuJ+J8yH4fa+8kgWaaWKNIWkwyKkqDG0+p3Hj1rp9MvL+W81OPwvqMWp29vG3k294QSYmxzGTjBGBwfQeuK4D4i61aX/AIFu4RH5c6rEFU4P/LRc4P4V49TAVqEk7cy8unqun9anqUsZSrRa2fn19O5mfAC4igbXzcS+VEEhYkg4JG8Y47817clxKdSskjuYUhUKxnhOc57EV4h+z/Jbrca5He2z3NtJHEGjjGWJ+fGB3717wIrGysVu8y6dIItqqVDOjdB8ozmueovebLi9DRuXMF3OzWsfmAhtxJ2n3xU2i6lOMLdLHDCwx8jEsGz94mqeiG6ljljQu7mMbvPU5PHoe9adhlkdLqFIrVwPnI2nPr71mhluC2mt2kVbnbNN8qvuwMepzTLu0kTT/Ndmcb8l2bcSen5cU65ubGCBpp53igjUKjPyufQdzmuW1HxlFN5FvbW7iNXzJK7EBwf9mrppqVxxi5bItyTlVx2+tUZrGK9VkmVSp6gHrTnnSQrJGQYzkEjtVa7uVgUFnQZB2npk10AtC/bWVvbRhYkI2jA9qssqMACBxyBVCzuFeFHJXJAyA2cHvWhbPE0uQQT9KLDuYXjoi00aCYDrLt/Q/wCFeQ61qpk3AHj0r174yEr4Ms5Yl+7dqDj3Rq8HnVpWyefWspR946acvdMu7keUnAPJqGO13DnIrUFsxPAOTVm306VyBtPNF+guW+pQs9NWVgCM+pNbq+BbXVINwzFKPuuP61s6NoZOPMXFdtpliIUCjpRdlqkpKzR4RrGkz+G5vLv7DKn/AFcoyUb8fX2qO3ksZ3S4vbdiOAI4yRux/wDrr6OuNLtb+1e3voY54HGGRxkGvHfHfwzvtOV77wzJNdWicta5Jlj/AN3+8P1+tK1zlq4WUHzR2OL8TRweYfsyNHbIoyg4Bc84/AV3XxE0bUrf4RaXq2radNYG6voIoElOHaNYZcMy9Rntn0z3qX9nnw5H4t8fWAvmBttKzeTJIM72U/IuO/zbTj2NejftcS3X/CGWEU0TLANTjMbZyD+6l/L6VcdWk+hy09nc5X9nGWeHw1evCjSJ9ubegONw8tO9ei6Fd22t61MbrT2thuxApYgMw6g+/wBK83+Atzp9v4AvPtMrpcHVG4CnbsMcYyT25zXqc1i8sBMUBMQO3zfugN6g/wCFbGy2Ne8hg1OGewSeOWWLGQhB8snoTWLpEFtBfrb3gjllbIUnsw/SnaJoFqlvcNZCb7ZLnc2/C4znH0P40Wmky3AdGj8q3XO+Rl+Uc/r+tS1rca2G63qj297thmiYxjmBCC3pz7Vi3mozyyTPdWsU9qyFWtweD6cnqa66z8LaXFcSyRxma5kUr5pPGehx6Gq8+l6bo6ozsbi6BwFbBGPb/GlrcNCz4aji1Wxs5JkKSwsk6c8qSCCPpjg1k6vpdvJrt24Ie5hlLgMq/KG5+vNanhO7aW+fzEWNn3DavQd6reNbW0kubhbhZxLcw7VdCVAx7/gOK5acnGq4vbUuaTVyrBol1qkZ8+UNYA4dM/IDnngdajn8MQ6GpFnvEUp4k/vexrO8Pqun2i2kU8jRM+5oy2VZz6Cu98PXM95btFPC7xKwWOWQYVT/APWPeulq+hGxn+H9Mvbc3d9a2NuH8raGuPlZuOMdwPrXMabfS3TTm+k8l3YmTbgZHuR0HsK9E1+C3vLCWzuZnkuj8oaI7QO+T2/DmuIutH06z01LW33zXrsGLN95eeRnoBQvdaRdN+8a+jXqXkywRHbaoduegkI/oPT869I0+NWgAQDymGGLfxfQV5X4et4luFLOGCfLlfu/7ij07n1Nej2d5sjUFgMDOM9K2Nmcr4g8ELDeveWs7RWAzI8Sx7mU9eP9n2xmq9oZZLCa3igi0ldo82CTDPdKf4kz0J7ZyexAPNehQ3glPP3SPzrL1fw7a6hMLuGRre9jXEUq87PoDwM9/XvU8ttUZTp31RxV9omnLpXnQyy2cibts0Zbz42xzzyxOOoOfeuT8JWM6yXtudXeznmH7u3VCft4z99uSQx6EKcjPUjivULm21DTLZbuC2il1ZlKzXDtmN1HTIHI9gOncmub8KRXE0N7M1hAIJH/AHt1sAeNs5O0Dqo68YA6jNUnYwasI8X2eBLZrd4ZkGFgjXDrx/Dt9v4gcVzvxNW5FzoovDb5NpIFa37r2zjjP04rT1vWrnQ7oSxs9ySdg1R+UZf7rDofwwPx4rk/GN2t3daZcJHPGZonZjIPvMSOV9j9BWGK/gyNaPxo7LRri4ul06wjs3bFsrLbq38IHMpJ45/Ln1q1Et0dRWWeTE8H3Yyowvs3qfy9q0dJ003Om6ZdKzWsNuig3EZHmAgDI9hng5/LvVHTdERdavbn+1AY5RuaRhg3GO5J4GOmfy4rSHwohvVii1uNR1SaM21uZipJTOIwPUe/6/zrxz9ozTobDwfaqv8Ax8DUkDqTnb+6k4HoK9f1yUtEDoSPCq8hs/xdyh/r3rw/456VfQeBrHULsjZPqIB3Ply3lyEFvyNMT2PBqKKKCDp/h9IItbkZm2r5DZPp8y17Bp2oSTKgUBYjlcnqe/T/ACa8S8KnbqLseixk59PmFelaRqHlgZPPQEDt/Ovoct1oW8z5/M4/vbnSXxXzAIiyDAHXOR/kj0rM1+6mvdFttLxmO2nM8Mm1S6PnICnGVGRnjrVyOQXMWFJJZcgEZ/DH/wBbv1pbjTMosjs2eu1ea7JQjNcszzoVJUnzQ0Ze0zV7XWtb025nQR4mEd1AWGU3ZGQT2yw5r0TWNS02106NbwxzWsmYYbcjLRrjkkewryvRPBureI7xx4ah8y6tk8yVjIqADPHJPPPb/Cr02pWlxEv9tTRR3kjNuBJYoynoeOB7fnXzONwDozbpK67dV/wD6nBY6NeC9po/wfobOqT6dBNp50ryxaxJ5DYUqSpOQxz79/ep1Oe+7DbT71HZXA8SWV5FNp5uLmKIbLiHG2JegJA6Hvjn9Kqae8iWzJMD50Zw2ePp+mK8xtHpKLIZYJheKbZ8c8o3Ao1dd/lseHXg4bjpVy2Ie79CTke9Q65j5+OC4GfwqVJIOVnG3AAvpicjk1l+R9outmDtbK5Azg+9dJDpUl5c3MrzRQRRj5nc/wAR6Ko6sxx09qS2sYVuCIcmMZJL/eb3P6V6uW5e8VLnqfAvxPMzHHLCx5YfG/wLHhPS7awlFxGqtHhgTKSd5xjPGD/kCuufUncf6U8V5GFMatInKZ53D0PHXNc2JBKyRiIqFONw7jAI9qksr77NIjlYbkhdpjnyVG5ThgBjp/OvpnFWslsfLOUpSvJ7nSWSWkunvM15GrHOYipBfnoPX8jXOXy27tbBFIkRvmLZ6b/SprW1uirQ+U6SYBwoO7H0HJrPu55XdHlcnBIDZHABPYe1KEddxS22M7WImM1osUcQBmYNI33SCeAf16YptlpoAW4jj82JIzujcAhvY9vy9Ks3MfnQOwY7FIJ7d/169qjsLmaMPAh+VCQR03DPp+FVJdDenN8qsUtWt7vR7mB5RNbGRRLE4bGU6Agiqni69s73wHqx1JoW1VWjNqyxlGIMoL8jg9+uMe9XdfPnuvLEA4y3IjGBwPQZrn/GhUeF51MZ3/Kd2c4y4P5Vz4iN6Mr72Z1Yef72Nu6NH9nm6ks5tfkhnjSQRxbYnTPmN+8xz2A/rXufh+JZYTPdsWljO51TI/EdzXz98Dhag649w0qzBIlhMbYwTv5x36V7LbancrpcVnHuVUPEzH5yPevkpxvI+nhTlNaHSSahLMszz3awwb8Bj8oPocdSfas+78ReXYJaW+6dkOftE64IP+yvp9awxF5j7slm9TyalFr04z6miNNHUqMY6y1Kk4nupN0jNIx7sc4+npVK8R4Bzycc5rd3LFzwSOormNZ1KFQ5u5ooOOcsBjjnv0qnHoXf7iq3iSbTY8v5rQk8mIZIP+FVLnxWt5bmNizIAeHUgg+tYWmeNdGF7NE9rPfRt8vlCPhh/eBzkGu88KGwuI5J9K0fUgjHynLMpXB7YJqJTcN0c7cJSsnqZXhLxGILn7JMs0iSn5GxwrZ/lXp+lWtxKVeVCi+9RafY6Bpbtt0eTzuCzSRlhn69K3Zddi2KIYkQeoXpWccSn0NHQfUx/iHZG+8KzWoU4ixL9SP8mvF7bSjnCg9e9e66nd+fpt2JCGzG38q88itFWEORgGnCTk22bQhpZHOQaRtYYUACt/TtJXglAfwq7ZW5mb5AMZweK6O3sxGmT/KquaxpmXbWQiAG3gVoQw7QMVPhdx4p3Sgu1hyqFNTxwrOww2Diq+c96kgO3p1oW4S2F0Td4V1a8v7Cyt2e8x9oIQK747hvX615/wDtK6nbap4Et7i1lnG/VozJBI5bY3ky+ten7lni2yenWvGv2iLNYPC9lIAMm+UZ/wC2clapanDWpRacloxP2erGG58J30kylsXzAA9OI4z0717LJq8VjpJjvxczwj5IAi/KeM4J9vc9K8V+AVpf3nhG6hsicSagy8HaM+XGTk/T+XSvZNWGvXd3b6PLFBdJFGjMI4/kY+rE/d78cVqciETUjq9okyKUQgqY0GMfU9xx9KTQ70WF1LbzK89oylhGOiv6Y9PY1dtVQ3QF1bM0cakNFGDlMZ5b24qpq9vEboSJshjlAKRIw5P+fSl5j8hh1HW9Q1K2ttIjiW1jO5o2PAHoxI6fSjxHdX8murBeWMMdpEMK0fJI7HPGfpTobhLJSzTJbBWwpXAz6471I88V6UMJHlSH5c8tn3Hapux2KmjzeXq0TbPLBIwD+RP61f8AHA32UAkcrHI5U4XJ3Ecc9qxEuIjqz22xxJHlUbGMtnnI7D0JqPxUbrS9KleMzXRuH2SNMAwVRyp+o5AP88CublSq3b1LbdtEYelaSumI00cj3HzZI6d+wz1969Fglmh0eM2115sLjeVj6qP5+uelcNoca6lo91cNeW1s0KlSCeUbHG7PQelHgXWdQsba5Amhkhkf5cndtbuc+hArfbcnfY7WG58lUDblLcIg+vr61bm0qz1eykU3Bi1MrmGIcnHrjuD3PQVw2u6+2n2TGMKxZgryOMbCenH5c1q6R4gvdR0SBYbWOx1BCSl/tzu9Dszk5BwQePTthLe4O62EsYbixuWW44mhJQRjovr+Jrp9PunuDlv9Wp2n/aP+FcVp2pavY3d6t7tuJLgYuvOG4SEcBkPqO3bHFbulX62qxh23W7DKN3/GtYyT0NYyvudtDKcA5NaC3O0MW5VOSB/EewrHs7iGXa6uCiLvP9Ku28iGNXZl4OR/vHv+FXYo2Ek4VXxvPUf0rM1a0sEPnzuYRjBSM4EnsR3xWbr+vxaKLSJl8zUL7etpG3CNtA3MzdgMjOOea5qOPU/EGpxSaXcK183yXAcExxqpwSvYAHt3pNpGkaPOuaeiO4/4Q7Tr20jllMksTL5i28hBiBPOduP/AK2ecV41NPdXGpXctukjxI/krj94U2krgnHUYr3m83abpFrp1rdRrdsgjjeUZzgfMcZ5+lfPnivQJbjW782l9LBfSSM06oysjt6jI4P0/GsK0XKNjlpSUZNm/oiXdxbyWKyzGSc8Rq/yyYPRh7dzWhe+HJzpCwRXTvfoSfs/Qf8AAT/U8fSqXgnSNQsdEaBIpJobc5kuT98PnJwOrYz0HSumgYrJ9rjkd52APnE53D37Y9ulaLRJMl6ttHIadq86yCyv49k5O1Sx2knp82eB9a4r9pm0Wy8DWCSyZun1JH2qfkK+VJkgfXHJ55rvZdBv/EWry/aLiPzFyxmPQ+gAH6+lea/tG25tfBljBIHEsd+itvbceI5O/cUyXsfOlFFFBB6f+z/pljrHizU7DVmKWM2mSLKQOQPMixg9jnHNXPFOjXfhrX5tLvN++L5kcjHnRn7rD8OoHfPpXMfCuUw63fMJvLb7EwC4J8w+ZH8vH5/hXuVjpK+LNGFjqjAwoN0FyVBmjb0Vjzt6ZBz04rbDY14So2/he5liMIsTDT4kcZ4VvUuHWN32ADJ75HpW3LcrKTBEucHOc4A64x3PbrXGXum3vhHxHLZ6gBnZuSVc7ZFPQj/Dsa0LbUFaMANgt1weOe3419NCpGrFTg9GfL16UqU3Fo6m41l4/D1vp0FrBaFWMst5GuJ5ueFLcDb0474Fc5qEb3s7zP8ANNId0khOS56s341M14jlo1G75QoJxn1znH+RV1NtxEZQQSvUY5Ynp/LgVcbQ1RlKU56NmFYPeadcGbTLie2mPH7piu76joRV/VNb17U5/OnuFWQqAWjhVcgevFaFvZ75QFID552jjPp0qK7uIBOEt2/cpkvyOQD6/wCc5qKlKjUfNOCb80a0sRXguWEml6mYus6xanOYZNvJMkf+BFF1r+o30JWWSKLeRhYl+bI9znFTSM10ZljVEUHO4jr6D+dVbW3/AH7SON6qPlK9PqPXgGsVgsKnzezV/Q6vruKceVzZq6JpMtwpmuLlYoo1LbpCcb+/uW+lHmAGTGOMgHj0/wDr8U+LzRaxNHHK8xby40UE5OCRgDuSRxUDShlmjUuSrYIB4/EHn/PvXTzdDjlFyd2XN84toUUDcWf5cc8ADOO3/wBap4IIoLxJJYTMqcypuA3cHH5VmpO0dwzxMVzGdmR1+nfNTfa3VmlKq28upZ+gO3+72pdCeR3N3Q9Qe2mW8iLxoFVCUGdqnIPXr0HFTeGtP0y6NzJrLlUNvKyPu24kB4PH9a5+GVnnhiQFmYoib8DJPGCO4561ZikI0tkO7zYZsHyucc4GT3rJxvs7XNLuFm1sUXmS3jlSfaQ5wPl4x16dqxZZUWSVE4Ytjk7gOPXrnNXr/wAyebC7+NxJdwT2qusSFwJchy3UHtjsR17Vt1Ii7R1KMomVSxJYZBz3H4isbxQrHwxPICpUhON3I+cVsZJhCAjacYduMH2NYHimVToUyEAvhcnaM53jvWWJa9jL0Z04a7qx9UanwNGbnVuMnEX/ALPXsEQHpmvmjw9b6i0N5d6VK6yW2wvGjlWdTnpjrjH612Wk6h4o8WsljpN7NFdWybnjZgjEfU9TXyTavqfYU8Qox5ex7bJPBbQtNcOkUagksxxwKrrqkV1YQ3WnRT3sMp2/6Mu9oz23gHK5r588SWWui4W31i8upktySBKTujPfg9DxTfC97q3hjU49R0q7lSMnmSJsqw9HXuPak2re6xSryfwo9eutauk1YQ39i8FsDmVg3zoPpTPHFroOuyxQQ2iNbwrhJRkO5IGTnrV281u18e+Hzd2hhttfsU/eRx8h/wD7E9MHoTXFWetQvGWkQrIvLIvQDuQP6VjztvXc4K3t2tXdG14Z8N6TAotrTMF2W+V5GyJPYnsf0rtfAGpBZr7T9gyjZYdGVhwQRXDRXENzEHt5VZSOoPNdT4R1e1uZX+2ssN2oEcsw/wCWiZ+Vm+h4z7+9Kd7GNHWeu56J4K8VafqN5c6S2BLE58kkf6xO/wCIOfwq9rNoguCsaZPXgYrwfxQb7w5q019Z8zK7SwODgMeu3ivbtB1OPXNFsNUjI+zXkSyIc8gkcqfcHIrOVNaSR62DxEqsXCe6MvUB9n02ZDxuU9ewxXEpLLdyCOL7o6muu8aM0GlTyHJAUjOax/Cdh5tk8y/jWkEd8DX0a1S3i3Pg1NPc5Py9KjfcgCg8VEcH2qjUespPbBNO3jHJqAnmguF5JFArllX446U9GGQQeayry/itoGlmkSOMdWY4FcZq3j103RaVEM8jzpOfyH+NNGNfE06CvUZ6Rd39vZQGW7uI4Ix/E7YFeNfHHxTp+s+HrWysZXlaO7WQvsIXARx1P1rI1C8vdXmZ7mSadz0/ix9B2qt4/tpLbwbZq9rHbr9rTGDl2+R+WNWpanlvHSrPlirI9N/Zp8o/D3UhLdCJv7TcogGWLCKIg8c4+n516vJqcxVHtbY2e1fnC8u2cZGen0PJrwz4B3sNv4Ou08gmddRZ/N3cbfLjGMd/WvaNQa7i0t7y3t3MakfPJgcH+LHUit+gLzL39o3NpaM8O6G3nI3ucO4P972z05zTNHsIL53iuibdMbgzj5yMj19P61maCZ/KWW8t2MTkrDM6kBuOQo7fh1rZilbzY2tcNMh3Bv4R9T+nFIo5fxl5emzR2kltJJuYMJs4LAnHy5BOSK6eM6ellBFpMDxOqjDSqQSSM4bPOfftWpfX9gY7a8l/0i9j5WIKCU7MPb6muCm1y81bWp5P7PLQIMt5APyY6FyeCSMVNugjduZPNjJKphV25Cgcj3HJwRTb+2F1pVwFiADsrkseHyMH+lY2oz3s0cy2IEZmBD9N4Hse34VrhJbnwxLHFv8AtT2xjGCcAj+v61zVtJRZrHZnIeILbw9p3howR+a+oSEMwjO9g4zwe2PaoDpVpb+H7eXw3LNdzghpsnICkfMCB90j05JqTT/CsMFxN9rn86ZcZgJ7ep9T+lZ2sm50SRpdGl8mKc7bhE/iA/iAPAYdPccelb3V7NEWe5aJstPRrjUANZiMZbYiZEWe+3oFbP3jyP5QeGvEaxRsJ0dY1P7oKxf5ewJ7nHc1t+C9IvbeyeWbZBpN03mBmAZl3dW9kb1bOM9Oa07zw5Bb2pjtUCaaWASR+q/TPXnvQ1poCepjXF7c626Q28KptyNo5LKfU+nFX/DGoRafqT22r6e1xhsSAk7l7cL0Iro9O+yxaLBaRWq29yuWE4X5WwfvA9Wz6dP0qC6ubGK8iGxnvz8r45/An88YpJMDO1B7uGWabSIHS0kIQQF9zL6c/U9O1K0/iPQ5Y31PTnNszECRXDgcd8Hitue5tVuEhMqF5mCoeCFB6k1q6zZJbrFG873u5Aiox+4P6D36/WrjKS3K9o0bXhvxNoOqadatMbcTwA4EoDNGx64zyM1e1LxfptjGRahriXskS9a86g8OWjzhI4Q8zHCyKOQPr7U6+tJtMmNvMPMuH/1ewY3jPXPb3p362M+W73LWo3WoapE2r3jj+z2YMqg4ZFHQ+y5/H1rAuY4ZbxJ1KpGvRugH/wBatqwvUsJC7IZZN/NoBkhsdVHr7nj6VJDp9ja3L6tcwo8EgIaBMsI+v3V7nrn07UPUa0Itf8RXdrbWaQ2w0/cn7xgdodR0C/3fr1GfxrNtpxIA8SzR2rgEpn5j6kDt/Wqdz4ntdbu/slx50VsebZWXLOe2T3b0/wAas3kd7pMUJvo8FgQjLznnheM/N7ChgrDNWe7tbMPpj4jH3ZQcuv0rzX9oLVrrU/hno/22yjglTUFHmJwHHlSYIHYH+YruptQn03Vov7Ss28k4dLdx/rR2I/2h6fnXnf7SGqRXmi20FtbvFEt4jfPwS3lvnjt1oQpM+faKKKCCa2uZ7Vy9tNLC5G0tG5UkenFaa+KfECoiLruqhEACqLyTCgdhzxRRRYCve63qt8AL3U764AOQJbh3wemeTUAv7wEEXdwD/wBdD/jRRVKTjomJxT1aHf2nf/8AP9df9/W/xp66xqa/d1G8H0nbv+NFFP2k+7J9nDsiQa9rA6arfj/t4f8AxqE6rqJGDf3ZGMY85v8AGiij2k+4ezj2FXVtRUDbqF4ABgYmbgfnSjWNSXO3UbwZ64nbn9aKKPaS7j5I9iW38Q61bXEdxbavqMU8f3JI7l1ZeMcEHI4qIavqQJYaheBick+e2Sfzooo55dw5I9gGr6krlhqN4GPBInbP86VNa1WNtyanfK2CMrO4OD170UUe0l3Dkj2Gpq+pRusiaheLIvRlmYEfjmnvreqyMzPqd8zN94m4ck/Xmiij2ku4vZx7EY1TUB/y/Xf/AH+b/GlGrajz/wATC756/vm/xooo9pPuw9nDsho1O/GcXt0MjH+tbp+dRS3dzKmyW4mdP7rOSKKKXPJ9RqEVqkFvdXFtu+zTyw7vveW5XP1xT4r+8iuRcRXdwlwOkqyEMPxzmiipsVYlvdY1O+k8y91G8uZMY3TTs5x9SarpdXCAhJ5VB6gORmiilZAPtNQvbO4+0Wl5cQT4x5kUrK2PqDmk+23e8v8AaZ95O4t5hyT60UU7IAjvbqMYjuZ0HT5ZCKkTVNQQkpfXSkjacTMOD260UUrILdSSfW9VuEC3Gp30qjGA9w7Dj6mp7PxPr9lbJbWeuapb26ElYoruRFUk5JABxyaKKLIFpqhbjxR4guEKXGu6rKh6q93Iw/U0kHifXrdCkGt6pEh6ql3Io/Q0UU7IfM+4p8U+ID113VT9buT/ABpP+En1/wD6Dmqf+Bcn+NFFFh80u4f8JPr3/Qb1T/wLk/xpp8S66eutamfrdSf40UUWDmfchuNa1S4A+0aley46b53bH5moft95n/j7uP8Av4f8aKKLENJ6slg1nVIM+RqV7HnrsnYZ/I0l7q2o38KxX2oXdzEp3BJpmcA+uCevJoopWQx2m61quljGmale2Y3b8W87x89M/KRzWg3jXxS0flt4l1sx/wB038uPy3UUUwCbxr4qnQJN4m1yRB0V7+Uj9WpG8aeKGxu8Sa2cDaM38vA9PvUUUAM/4S7xJtC/8JBq+0dB9tk/+Kp8fjLxREhSPxJrSKeoW+lAP/j1FFAEK+KPECuXXXNVDnqwu5Mn9akTxh4mjGE8Rayo64F9KP8A2aiiiyYXGN4q8QvKZX17VmkYbS5vJCSM5xnNRHxFrZlWQ6xqPmKcq32p8g+xzRRQFyT/AISrxD9l+zf27qv2bGPK+2SbPyzipZfGXieWPy5fEetPHx8rX0pHHTjdRRQAS+MvE8qhZfEetOo6Br6Ugf8Aj1RnxT4gJUnXdVJUYB+2ScfrRRQAj+KfEEjZk13VWOMZN5If61L/AMJj4m24/wCEi1nGMY+3S9P++qKKAHJ418Uxrtj8S62q53YF/KBn1+91psvjHxPLOJpfEesvMOA7X0pYfjuoooAQeMPEwk8weItZ8wjbu+3S5x6Z3Uq+MfE6uzr4j1kOwILC+lyf/HqKKAKy+I9bVy66xqQc5ywunyc9e9WZPGHiaQx+Z4i1l/LOU3X0p2n1HzcUUUAJL4v8SzFDN4h1iQodybr2U7T6j5uKpajrOqamipqWpXt4qnIFxO0gB9eSfU0UUAZ9FFFAH//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This series of photographs demonstrates the basic steps in the application of a short leg splint. Positioning the patient prone allows for easier positioning and application.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Richard Derby, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_2_22565=[""].join("\n");
var outline_f22_2_22565=null;
var title_f22_2_22566="Insulin glulisine: Pediatric drug information";
var content_f22_2_22566=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"19\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Insulin glulisine: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?1/9/1176?source=see_link\">",
"    see \"Insulin glulisine: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?0/24/389?source=see_link\">",
"    see \"Insulin glulisine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F2114407\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Apidra&reg;;",
"     </li>",
"     <li>",
"      Apidra&reg; SoloStar&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F2934392\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apidra&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F2984269\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Insulin, Rapid-Acting",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F2984280\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?1/9/1176?source=see_link\">",
"      see \"Insulin glulisine: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Insulin glulisine is a rapid-acting insulin analog which is normally administered SubQ as a premeal component of the insulin regimen or as a continuous SubQ infusion and should be used with an intermediate- or long-acting insulin. Insulin glulisine is equipotent to insulin regular, but has a more rapid onset and shorter duration of activity. In carefully controlled clinical settings with close medical supervision and monitoring of blood glucose and potassium, insulin glulisine may be administered I.V. Insulin requirements vary dramatically between patients and dictate frequent monitoring and close medical supervision. See Insulin Regular for additional information.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      General insulin dosing:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Type 1 diabetes mellitus:",
"     </b>",
"     Children, Adolescents, and Adults:",
"     <b>",
"      Note:",
"     </b>",
"     Multiple daily doses or continuous subcutaneous infusions guided by blood glucose monitoring are utilized. Combinations of insulin formulations are commonly used. The daily doses presented below are expressed as the",
"     <b>",
"      total units/kg/day of all insulin formulations combined",
"     </b>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <b>",
"      Initial dose:",
"     </b>",
"     SubQ: 0.2-0.6 units/kg/day in divided doses. Conservative initial doses of 0.2-0.4 units/kg/day are often recommended to avoid the potential for hypoglycemia. A rapidly acting insulin may be the only insulin formulation used initially.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <b>",
"      Usual maintenance range:",
"     </b>",
"     SubQ: 0.5-1 unit/kg/day in divided doses. An estimate of anticipated needs may be based on body weight and/or activity factors as follows:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Adolescents: May require &le;1.2 units/kg/day during growth spurts",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Nonobese: 0.4-0.6 units/kg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Obese: 0.8-1.2 units/kg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <b>",
"      Adjustment of dose:",
"     </b>",
"     Dosage must be titrated to achieve glucose control and avoid hypoglycemia. Adjust dose to maintain premeal and bedtime glucose in target range. Since combinations of agents are frequently used, dosage adjustment must address the individual component of the insulin regimen which most directly influences the blood glucose value in question, based on the known onset and duration of the insulin component.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <b>",
"      Continuous SubQ insulin infusion (insulin pump):",
"     </b>",
"     A combination of a \"basal\" continuous insulin infusion rate with preprogrammed premeal bolus doses which are patient controlled. When converting from multiple daily SubQ doses of maintenance insulin, it is advisable to reduce the basal rate to less than the equivalent of the total daily units of longer-acting insulin (eg, NPH); divide the total number of units by 24 to get the basal rate in units/hour. Do not include the total units of regular insulin or other rapid-acting insulin formulations in this calculation. The same premeal regular insulin dosage may be used.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Type 2 diabetes mellitus:",
"     </b>",
"     Augmentation therapy (patients for which diet, exercise, weight reduction, and oral hypoglycemic agents have not been adequate): Adults: SubQ: Initial dosage of 0.2 units/kg/day or 10 units/day of an intermediate- or long-acting insulin administered at bedtime has been recommended. As an alternative, regular insulin or rapid-acting insulin (eg, insulin glulisine) formulations administered before meals have also been used. Dosage must be carefully adjusted.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Dosing adjustment in renal impairment:",
"     </b>",
"     Insulin requirements are reduced due to changes in insulin clearance or metabolism.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F2104248\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Apidra&reg;: 100 units/mL (3 mL) [cartridge]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Apidra&reg;: 100 units/mL (10 mL) [vial]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Apidra&reg; SoloStar&reg;: 100 units/mL (3 mL) [prefilled pen]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F2127491\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F2984301\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Parenteral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     SubQ: Administration is usually made into the subcutaneous fat of the thighs, arms, buttocks, or abdomen, with sites rotated; cold injections should be avoided. May be mixed in the same syringe with NPH insulin. When mixing insulin glulisine with NPH insulin, glulisine should be drawn into the syringe first. Administer 15 minutes before meals or within 20 minutes after starting a meal. Can be infused SubQ by external insulin pump; however, when used in an external pump, it is not recommended to be diluted with other insulins.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     I.V.: Dilute with NS to a final concentration of 0.05-1 unit/mL and administer using polyvinyl chloride infusion bags into a dedicated infusion line (the use of other bags and tubing has not been studied).",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F2127501\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Stable in NS;",
"     <b>",
"      incompatible",
"     </b>",
"     with dextrose solution and Ringer's solution",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Compatibility in syringe: Compatible:",
"     </b>",
"     Insulin NPH.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Insulin aspart, insulin detemir, insulin glargine, insulin lispro, insulin regular.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F2984277\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store unopened container in refrigerator; do not freeze; protect from heat and light. Once opened (in use) vials may be stored in refrigerator or at room temperature for up to 28 days.  Cartridges that are in use should be stored at room temperature and used within 28 days; do not refrigerate. Insulin glulisine in reservoir should be replaced every 48 hours. Discard if exposed to temperatures &ge;37&deg;C (98.6&deg;F). May be mixed in the same syringe with NPH insulin.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F2984270\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of type 1 diabetes mellitus (insulin dependent, IDDM); type 2 diabetes mellitus (noninsulin dependent, NIDDM) to control hyperglycemia",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F2127488\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Insulin glulisine may be confused with insulin glargine",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error.",
"       <b>",
"        <i>",
"         Due to the number of insulin preparations, it is essential to identify/clarify the type of insulin to be used.",
"        </i>",
"       </b>",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Other safety concerns:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Cross-contamination may occur if insulin pens are shared among multiple patients. Steps should be taken to prohibit sharing of insulin pens.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F2114420\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Primarily symptoms of hypoglycemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiovascular: Pallor, palpitation, tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Fatigue, headache, hypothermia, loss of consciousness, mental confusion",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Redness, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hypoglycemia, hypokalemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Hunger, nausea, numbness of mouth",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Atrophy or hypertrophy of SubQ fat tissue; edema, itching, pain or warmth at injection site; stinging",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Muscle weakness, paresthesia, tremor",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Transient presbyopia or blurred vision",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Anaphylaxis, diaphoresis, local and/or systemic hypersensitivity reactions",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F2984272\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to insulin glulisine or any component; do not use during episodes of hypoglycemia",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F2984305\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution and adjust dosage in patients with renal impairment; use with caution and monitor closely in patient with hepatic impairment. While regular insulin is the preferred formulation for I.V. administration, both insulin aspart and insulin glulisine have been approved for I.V. use in selected clinical situations with close medical supervision and monitoring of serum potassium.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F2984273\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypoglycemia is the most common adverse effect of insulin. The timing of hypoglycemia differs among various insulin formulations. Any change of insulin should be made cautiously; changing manufacturers, type, and/or method of manufacture may result in the need for a change of dosage. Hypoglycemia may result from increased work or exercise without eating.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F8103884\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F2343861\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antidiabetic Agents (Thiazolidinedione): Insulin may enhance the fluid-retaining effect of Antidiabetic Agents (Thiazolidinedione).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: May enhance the hypoglycemic effect of Insulin.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levobunolol; Metipranolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Orally Inhaled): May diminish the hypoglycemic effect of Antidiabetic Agents. In some instances, corticosteroid-mediated HPA axis suppression has led to episodes of acute adrenal crisis, which may manifest as enhanced hypoglycemia, particularly in the setting of insulin or other antidiabetic agent use.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): May diminish the hypoglycemic effect of Antidiabetic Agents. In some instances, corticosteroid-mediated HPA axis suppression has led to episodes of acute adrenal crisis, which may manifest as enhanced hypoglycemia, particularly in the setting of insulin or other antidiabetic agent use.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Edetate CALCIUM Disodium: May enhance the hypoglycemic effect of Insulin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Edetate Disodium: May enhance the hypoglycemic effect of Insulin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypoglycemic Properties): May enhance the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypoglycemic Agents: May enhance the adverse/toxic effect of other Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: May diminish the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Luteinizing Hormone-Releasing Hormone Analogs: May diminish the therapeutic effect of Antidiabetic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pegvisomant: May enhance the hypoglycemic effect of Antidiabetic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinolone Antibiotics: Insulin may enhance the hyperglycemic effect of Quinolone Antibiotics. Insulin may enhance the hypoglycemic effect of Quinolone Antibiotics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: May enhance the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: May enhance the hypoglycemic effect of Hypoglycemic Agents. Selective Serotonin Reuptake Inhibitors may increase the serum concentration of Hypoglycemic Agents. Management: Consider increased monitoring of glycemic control with concomitant use of a hypoglycemic agent and an SSRI. Dosage adjustments of the hypoglycemic agent may be necessary upon SSRI initiation or discontinuation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Somatropin: May diminish the hypoglycemic effect of Antidiabetic Agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: May diminish the therapeutic effect of Antidiabetic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F2984276\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Use caution with chromium, garlic, gymnema (may increase hypoglycemia).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F2127493\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F2127494\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were observed in some animal reproduction studies. Maternal hyperglycemia can be associated with adverse effects in the fetus, including macrosomia, neonatal hyperglycemia, and hyperbilirubinemia; the risk of congenital malformations is increased when the Hb A",
"     <sub>",
"      1c",
"     </sub>",
"     is &gt;1% above the normal range.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Insulin requirements tend to fall during the first trimester of pregnancy and increase in the later trimesters, peaking at 28-32 weeks of gestation. Following delivery, insulin requirements decrease rapidly. Diabetes can also be associated with adverse effects in the mother. Poorly-treated diabetes may cause end-organ damage that may in turn negatively affect obstetric outcomes. Physiologic glucose levels should be maintained prior to and during pregnancy to decrease the risk of adverse events in the fetus and mother. Insulin is the drug of choice for the control of diabetes mellitus during pregnancy. Due to lack of clinical studies with insulin glulisine in pregnant women, the manufacturer recommends use during pregnancy only if the potential benefit to the mother justifies any potential risk to the fetus.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F2984302\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Urine sugar and acetone, serum glucose, electrolytes, Hb A",
"     <sub>",
"      1c",
"     </sub>",
"     , lipid profile",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F2984303\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Glucose, fasting:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Newborns: 30-90 mg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: 70-110 mg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Recommendations for glycemic control with type 1 diabetes:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hb A",
"     <sub>",
"      1c",
"     </sub>",
"     :",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &lt;6 years: &le;8.5% and &ge;7.5%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     6-12 years: &lt;8%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     13-19 years: &lt;7.5%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Adults: &lt;7%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Plasma glucose*:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Preprandial:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     &lt;6 years: 90-130 mg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     6-12 years: 90-180 mg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     13 years to Adults: 90-130 mg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Bedtime and overnight:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     &lt;6 years: 110-200 mg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     6-12 years: 100-180 mg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     13-19 years: 90-150 mg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Peak postprandial** : Adults: &lt;180 mg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     *Plasma glucose concentrations are generally 10% to 15% higher than those in whole blood",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     **Peak postprandial plasma glucose is measured 1-2 hours after a meal",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Criteria for diagnosis of DKA:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Serum glucose:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children: &gt;200 mg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Adults: &gt;250 mg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Arterial pH:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children: &lt;7.3",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Adults: &lt;7-7.24",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Bicarbonate:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children: &lt;15 mEq/L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Adults: &lt;10-15 mEq/L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Moderate ketonuria or ketonemia",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F2984278\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Insulin acts via specific membrane-bound receptors on target tissues to regulate metabolism of carbohydrate, protein, and fats. Insulin facilitates entry of glucose into muscle, adipose, and other tissues via hexose transporters, including GLUT4. Insulin stimulates the cellular uptake of amino acids and increases cellular permeability to several ions, including potassium, magnesium, and phosphate. By activating sodium-potassium ATPases, insulin promotes the intracellular movement of potassium.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Target organs for insulin include the liver, skeletal muscle, and adipose tissue. Within the liver, insulin stimulates hepatic glycogen synthesis through the activation of the enzymes hexokinase, phosphofructokinase, and glycogen synthase as well as the inhibition of glucose-6 phosphatase. Insulin promotes hepatic synthesis of fatty acids, which are released into the circulation as lipoproteins. Skeletal muscle effects of insulin include increased protein synthesis and increased glycogen synthesis. Within adipose tissue, insulin stimulates the processing of circulating lipoproteins to provide free fatty acids, facilitating triglyceride synthesis and storage by adipocytes. Insulin also directly inhibits the hydrolysis of triglycerides.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Normally secreted by the pancreas, insulin products are manufactured for pharmacologic use through recombinant DNA technology using either",
"     <i>",
"      E. coli",
"     </i>",
"     or",
"     <i>",
"      Saccharomyces cerevisiae",
"     </i>",
"     . Insulins are categorized based on promptness and duration of effect, including rapid-, short-, intermediate-, and long-acting insulins. Insulin glulisine is a rapid-acting insulin analog.",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F2984306\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Onset and duration of hypoglycemic effects depend upon the route of administration (adsorption and onset of action are more rapid after deeper I.M. injections than after SubQ), site of injection (onset and duration are progressively slower with SubQ injection into the abdomen, arm, buttock, or thigh respectively), volume and concentration of injection, and the preparation administered; local heat and massage also increase the rate of absorption.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: 5-15 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Maximum effect: 45-75 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: 2-4 hours",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F2984279\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     :  Adults: 13 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bioavailability: SubQ: ~70%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     SubQ: 42 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     I.V.: 13 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Time to peak serum concentration: SubQ: 60 minutes (range: 40-120 minutes)",
"    </p>",
"    <p style=\"text-indent:-4em;margin-left:4em;\">",
"     Elimination: Urine",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F2984304\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?0/24/389?source=see_link\">",
"      see \"Insulin glulisine: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Do not take any new medication during therapy unless approved by healthcare provider. This medication is used to control diabetes; it is not a cure. It is imperative to follow other components of prescribed treatment (eg, diet and exercise regimen). Take exactly as directed. Do not change dose or discontinue unless advised by healthcare provider. With insulin glulisine (Apidra&reg;), you must administer 15 minutes before or within 20 minutes after starting a meal. If you experience hypoglycemic reaction, contact healthcare provider immediately. Always carry quick source of sugar with you. Monitor glucose levels as directed by healthcare provider. Report adverse side effects, including chest pain or palpitations; persistent fatigue, confusion, headache; skin rash or redness; numbness of mouth, lips, or tongue; muscle weakness or tremors; vision changes; respiratory difficulty; or nausea, vomiting, or flu-like symptoms.",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F14455338\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Division of daily insulin requirement (\"conventional therapy\"):",
"     </b>",
"     Generally, 50% to 75% of the daily insulin dose is given as an intermediate- or long-acting form of insulin (in 1-2 daily injections). The remaining portion of the 24-hour insulin requirement is divided and administered as either regular insulin or a rapid-acting (eg, insulin glulisine) form of insulin at the same time before breakfast and dinner.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Division of daily insulin requirement (\"intensive therapy\"):",
"     </b>",
"     Basal insulin delivery with 1 or 2 doses of intermediate- or long-acting insulin formulations superimposed with doses of rapid- or very rapid-acting insulin (eg, insulin glulisine) formulations 3 or more times daily.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12641 Version 31.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-220.255.2.117-317DDF55DB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_2_22566=[""].join("\n");
var outline_f22_2_22566=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2114407\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2934392\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2984269\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2984280\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2104248\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2127491\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2984301\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2127501\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2984277\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2984270\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2127488\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2114420\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2984272\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2984305\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2984273\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8103884\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2343861\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2984276\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2127493\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2127494\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2984302\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2984303\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2984278\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2984306\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2984279\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2984304\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14455338\">",
"      Additional Information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12641\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12641|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?1/9/1176?source=related_link\">",
"      Insulin glulisine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?0/24/389?source=related_link\">",
"      Insulin glulisine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_2_22567="Treatment of stage I seminoma";
var content_f22_2_22567=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of stage I seminoma",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/2/22567/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/2/22567/contributors\">",
"     Clair J Beard, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/2/22567/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/2/22567/contributors\">",
"     William K Oh, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/2/22567/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/2/22567/contributors\">",
"     Don S Dizon, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?22/2/22567/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 29, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Testicular germ cell tumors (GCTs) can consist of one histologic pattern or represent a mix of multiple histologic types. Testicular GCTs are divided into two groups: pure seminoma and nonseminomatous GCTs (NSGCTs) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/2/22567/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Men with stage I seminoma have an excellent prognosis following orchiectomy. Therefore, treatment can be tailored to individual patient preferences. &nbsp;",
"   </p>",
"   <p>",
"    The treatment approach for men with stage I seminoma is reviewed here. An overview of the management of testicular GCTs, the epidemiology, clinical manifestations, diagnosis, and staging of testicular germ cell tumors, and the approach to patients with stage II and stage III seminoma are presented separately.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/47/41720?source=see_link\">",
"       \"Clinical manifestations, diagnosis, and staging of testicular germ cell tumors\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/25/2457?source=see_link\">",
"       \"Epidemiology of and risk factors for testicular germ cell tumors\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/7/13432?source=see_link\">",
"       \"Overview of the treatment of testicular germ cell tumors\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/58/38822?source=see_link\">",
"       \"Serum tumor markers in testicular germ cell tumors\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/40/5770?source=see_link\">",
"       \"Anatomy and pathology of testicular tumors\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/45/22230?source=see_link\">",
"       \"Treatment of stage II seminoma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/17/24852?source=see_link\">",
"       \"Risk stratification of metastatic testicular germ cell tumors\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of stage I seminoma is based upon:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Histologic diagnosis of pure seminoma (without any evidence of nonseminomatous elements) on final pathologic analysis of the orchiectomy specimen",
"     </li>",
"     <li>",
"      No evidence of lymph node involvement or distant metastases based on staging computerized tomography (CT) of the abdomen and pelvis and chest imaging (x-ray or CT)",
"     </li>",
"     <li>",
"      Normal tumor marker studies following orchiectomy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Men with seminoma do not require surgical staging of the retroperitoneal nodes. Hence, they are classified as &ldquo;clinical&rdquo; stage I seminoma using American Joint Committee on Cancer (AJCC) terminology (",
"    <a class=\"graphic graphic_table graphicRef82117 \" href=\"UTD.htm?35/13/36061\">",
"     table 1",
"    </a>",
"    ). Men with findings of lymphadenopathy by imaging (defined as any adenopathy that measures at least 10 mm on the short axis of cross-sectional imaging) and men who undergo a retroperitoneal node dissection for clinical stage I seminoma and are diagnosed with pathologically involved nodes do not have stage I seminoma; instead, they have more advanced disease.",
"   </p>",
"   <p>",
"    The management of men with seminoma and radiologically suspicious or pathologically involved lymph nodes is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/45/22230?source=see_link\">",
"     \"Treatment of stage II seminoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/63/24568?source=see_link&amp;anchor=H547494364#H547494364\">",
"     \"Initial risk-stratified treatment for advanced testicular germ cell tumors\", section on 'Seminomas'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23177522\">",
"    <span class=\"h1\">",
"     APPROACH TO TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;More than 80 percent of patients with stage I seminoma are cured with orchiectomy, and there is no uniform postsurgical (or adjuvant) treatment. Following orchiectomy, men with stage I seminoma may be managed with one of the following strategies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Active surveillance (See",
"      <a class=\"local\" href=\"#H77783068\">",
"       'Active surveillance'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Adjuvant single agent",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"       carboplatin",
"      </a>",
"      (See",
"      <a class=\"local\" href=\"#H77783389\">",
"       'Adjuvant chemotherapy'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Adjuvant radiation therapy (RT) (See",
"      <a class=\"local\" href=\"#H261198349\">",
"       'Adjuvant radiation therapy'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Given the high likelihood of cure, however, we recommend active surveillance. There is no evidence that a specific approach is superior to the others [",
"    <a class=\"abstract\" href=\"UTD.htm?22/2/22567/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. However, the approach depends on whether or not men are willing to comply with follow-up",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    whether or not they desire a more aggressive treatment approach (despite their already excellent prognosis).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H77783068\">",
"    <span class=\"h2\">",
"     Active surveillance",
"    </span>",
"    &nbsp;&mdash;&nbsp;For men who are willing and able to comply with follow-up, we prefer active surveillance because their prognosis is excellent. Should these men recur, treatment in the setting of recurrent disease can be administered with the intent of a high probability of cure.",
"   </p>",
"   <p>",
"    Active surveillance is a form of treatment for men with stage I seminoma. The main benefit of surveillance is the avoidance of unnecessary treatment in the 85 percent of patients who will never relapse following orchiectomy and the associated treatment-related adverse effects [",
"    <a class=\"abstract\" href=\"UTD.htm?22/2/22567/abstract/1\">",
"     1",
"    </a>",
"    ]. Men contemplating active surveillance should be informed that their chance of survival with this approach is excellent without or with the administration of adjuvant therapy. Although there may be concerns about noncompliance, there is no clear impact of noncompliance on survival outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?22/2/22567/abstract/5,6\">",
"     5,6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The outcome using active surveillance is illustrated in a systematic review of the literature, which identified 14 studies with 2060 patients who were managed with active surveillance [",
"    <a class=\"abstract\" href=\"UTD.htm?22/2/22567/abstract/1\">",
"     1",
"    </a>",
"    ]. Relapse occurred in 356 patients (17 percent). Of these, late relapses (variably defined, but at least two years) were reported in 23 cases (2 percent of all men in these studies and 9 percent of those who relapsed). There were six deaths (0.3 percent) due to seminoma.",
"   </p>",
"   <p>",
"    In a separate prospective study of 512 men with diagnosed between 2000 and 2006, with at least four years of follow-up, 65 patients (14 percent) relapsed at a median of 1.4 years after diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/2/22567/abstract/4\">",
"     4",
"    </a>",
"    ]. Relapse after five years occurred in only two cases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23176390\">",
"    <span class=\"h3\">",
"     Is there an optimal surveillance protocol?",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients undergoing active surveillance, serial radiologic imaging is required to ensure early detection of any recurrence. However, the use of serum tumors adds little advantage as they are rarely increased in the absence of radiologic evidence of disease [",
"    <a class=\"abstract\" href=\"UTD.htm?22/2/22567/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/16/3334?source=see_link\">",
"     \"Active surveillance following orchiectomy for stage I testicular germ cell tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H77783102\">",
"    <span class=\"h4\">",
"     CT imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;The traditional approach has been to use regular CT scans, although this is expensive and exposes the patient to radiation and its potential risks. However, less frequent testing may delay the diagnosis of a relapse until more advanced disease is present, thus necessitating more intensive treatment. A number of different surveillance recommendations are used or recommended for patients with clinical stage I seminoma [",
"    <a class=\"abstract\" href=\"UTD.htm?22/2/22567/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. Our practice is consistent with National Comprehensive Cancer Network (NCCN) guidelines. We perform CT scans (of the chest, abdomen, and pelvis) every six months for the first two years, every 6 to 12 months for year 3, then annually for years 4 to 5 [",
"    <a class=\"abstract\" href=\"UTD.htm?22/2/22567/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An even less intensive approach to imaging men with clinical stage I seminoma is currently being evaluated by the Medical Research Council (MRC) in the",
"    <a class=\"external\" href=\"file://clinicaltrials.gov/ct2/show/NCT00589537\">",
"     TE24 Trial of Imaging and Schedule in Seminoma Testis",
"    </a>",
"    (TRSST). In this trial, patients are randomly assigned to imaging with either CT (with either three studies over 36 months or seven studies over 60 months) or MRI (using the same two schedules).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H77783127\">",
"    <span class=\"h4\">",
"     Tumor markers",
"    </span>",
"    &nbsp;&mdash;&nbsp;In contrast to men with NSGCT, serum tumor markers have very low utility in the follow-up of men with stage I seminoma. Therefore, we do not follow them as part of a surveillance protocol [",
"    <a class=\"abstract\" href=\"UTD.htm?22/2/22567/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. This was demonstrated in a study involving 527 men managed by surveillance in one institution [",
"    <a class=\"abstract\" href=\"UTD.htm?22/2/22567/abstract/7\">",
"     7",
"    </a>",
"    ]. At a median of 72 months, relapse occurred in 75 men (14 percent). Only 11 of these men (15 percent) had an elevated marker at the time of relapse. Elevated tumor markers (before the documentation of clinical or radiologic progression) were detected in only one man (1.3 percent). These findings support the guidelines from the American Society of Clinical Oncology (ASCO) and suggest not using markers to monitor for relapse in men with stage I seminoma [",
"    <a class=\"abstract\" href=\"UTD.htm?22/2/22567/abstract/8\">",
"     8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/58/38822?source=see_link\">",
"     \"Serum tumor markers in testicular germ cell tumors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/16/3334?source=see_link&amp;anchor=H900676917#H900676917\">",
"     \"Active surveillance following orchiectomy for stage I testicular germ cell tumors\", section on 'Active surveillance protocols'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H77783835\">",
"    <span class=\"h2\">",
"     Men who decline active surveillance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Men who choose to undergo adjuvant treatment rather than surveillance should be informed that while adjuvant therapy reduces their risk of recurrence, it will not improve their chance of survival (which is already excellent following orchiectomy).",
"   </p>",
"   <p>",
"    For men who are willing to accept the risks of treatment, adjuvant treatment options include chemotherapy and RT. We prefer chemotherapy because it is associated with less long term toxicity risks than adjuvant RT. In addition, given their excellent prognosis, single agent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    is used rather than a multiagent cisplatin-based regimen. This reduces the risks of treatment-related and long-term complications from chemotherapy even further.",
"   </p>",
"   <p>",
"    For men who decline active surveillance, a baseline semen analysis should be performed, particularly in men who desire to father their own children in the future. At our institution, fertility experts strongly prefer to bank sperm on everyone, but in particular, recommend it for those men with poor quality semen analysis. Semen cryopreservation should be made available to all men diagnosed with testicular cancer prior to instituting therapy if they wish to preserve fertility. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/47/41720?source=see_link&amp;anchor=H18#H18\">",
"     \"Clinical manifestations, diagnosis, and staging of testicular germ cell tumors\", section on 'Cryopreservation of sperm'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The evidence to support these recommendations is discussed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H77783389\">",
"    <span class=\"h3\">",
"     Adjuvant chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cisplatin-based combination chemotherapy is the standard treatment for advanced testicular GCTs, including both seminomas and NSGCTs. This led to the evaluation of chemotherapy as an adjuvant option in men with stage I seminoma. Single-agent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    , rather than a cisplatin-based combination, has been used because it is associated with less toxicity than cisplatin-based regimens.",
"   </p>",
"   <p>",
"    The efficacy of adjuvant",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    was demonstrated in a phase III trial conducted by the European Organization for Research and Treatment of Cancer (EORTC) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/2/22567/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. In this trial, 1477 men with stage I seminoma were randomly assigned to adjuvant RT or a single course of carboplatin (dosed at an area under the concentration x time curve [AUC] of 7). At a median follow-up of 6.5 years, relapse-free rates were similar with carboplatin and RT (94.7 and 96.0 percent, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/2/22567/abstract/12\">",
"     12",
"    </a>",
"    ]. There were no deaths due to seminoma. In addition, contralateral germ cell tumors were less frequent in those treated with carboplatin (2 [0.3 percent] versus 15 [1.7 percent] with RT).",
"   </p>",
"   <p>",
"    Multiple studies have looked at the relapse rate with either one or two cycles of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?22/2/22567/abstract/13-19\">",
"     13-19",
"    </a>",
"    ]. A review of this literature found that the relapse rate was higher among patients who had received only one cycle of carboplatin compared to those who had received two cycles (36 of 799 [4.5 percent] versus 11 of 611 [1.8 percent]) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/2/22567/abstract/11\">",
"     11",
"    </a>",
"    ]. However, no deaths due to germ cell tumors were reported in any of these studies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H261198349\">",
"    <span class=\"h3\">",
"     Adjuvant radiation therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radiation therapy (RT) prevents relapse in approximately 96 percent or more of patients with clinical stage I seminoma [",
"    <a class=\"abstract\" href=\"UTD.htm?22/2/22567/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. Although adjuvant RT is associated with an increased risk of long-term toxicities (eg, an increased risk for second malignancies), contemporary clinical trials have identified meaningful reductions in the size of the treatment field and the dose delivered, which have resulted in a reduction in long-term risks. (See",
"    <a class=\"local\" href=\"#H77784158\">",
"     'Treatment-related toxicity'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The favorable outcome in patients with clinical stage I seminoma who received adjuvant RT is illustrated by a combined analysis of 1893 patients treated between 1989 and 2001 in one of three randomized phase III trials [",
"    <a class=\"abstract\" href=\"UTD.htm?22/2/22567/abstract/3\">",
"     3",
"    </a>",
"    ]. Although relapses were seen in 4 percent of patients, there were only four deaths from seminoma, with the remaining patients successfully treated with chemotherapy administered at the time of recurrence.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H261198371\">",
"    <span class=\"h4\">",
"     Technique",
"    </span>",
"    &nbsp;&mdash;&nbsp;In men with clinical stage I seminoma who choose adjuvant para-aortic radiotherapy, patients should undergo simulation in the supine position [",
"    <a class=\"abstract\" href=\"UTD.htm?22/2/22567/abstract/20\">",
"     20",
"    </a>",
"    ]. A clamshell shield should be used to protect the remaining testis to reduce the dose of RT it is exposed to. Tattoos should be placed at the level of the isocenter anteriorly and laterally.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H101307361\">",
"    <span class=\"h5\">",
"     Treatment field",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of a \"hockey stick\" or \"dog leg\" field, which includes the bilateral paraaortic nodes and pelvic lymph nodes, is associated with an excellent cure rate (",
"    <a class=\"graphic graphic_figure graphicRef81832 \" href=\"UTD.htm?2/30/2531\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/2/22567/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. This approach included all of the regional lymph nodes of the involved testicle that are at risk for micrometastatic disease [",
"    <a class=\"abstract\" href=\"UTD.htm?22/2/22567/abstract/23\">",
"     23",
"    </a>",
"    ]. The role of RT to the inguinal orchiectomy scar and ipsilateral scrotal contents is uncertain if scrotal violation occurred during surgery.",
"   </p>",
"   <p>",
"    Because the paraaortic lymph nodes are the initial nodal group to be involved in the majority of patients who experience tumor spread, PA-strip RT protocols were introduced in an effort to decrease treatment-related morbidity (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef76077 \" href=\"UTD.htm?34/46/35552\">",
"     image 1",
"    </a>",
"    ). Using this approach, several centers found overall recurrence and survival rates identical on the PR trial to those obtained with hockey-stick or large field RT [",
"    <a class=\"abstract\" href=\"UTD.htm?22/2/22567/abstract/24-28\">",
"     24-28",
"    </a>",
"    ]. Clinicians who prescribe RT should tailor the RT fields by lowering the superior border from the top of T11 to the bottom of T12 and by ensuring the RT field is contoured to the ventricles to ensure the heart receives no direct RT.",
"   </p>",
"   <p>",
"    The Medical Research Council Testicular Tumor Working Group TE10 trial randomly assigned 478 men with stage I seminoma to PA strip or paraaortic plus ipsilateral iliac lymph node RT following inguinal orchiectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?22/2/22567/abstract/29\">",
"     29",
"    </a>",
"    ]. The short-term side effects of RT were decreased, and the incidence of azoospermia was significantly decreased using PA strip RT compared with a more extensive RT field (11 versus 35 percent). With a median follow-up of 4.5 years, there were nine relapses in each group (4 percent). There was only one death due to seminoma in the trial.",
"   </p>",
"   <p>",
"    Adjuvant mediastinal RT is not necessary to minimize the risk of relapse and leads to an unacceptably high long-term risk of cardiopulmonary disease [",
"    <a class=\"abstract\" href=\"UTD.htm?22/2/22567/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H101307368\">",
"    <span class=\"h5\">",
"     Dose",
"    </span>",
"    &nbsp;&mdash;&nbsp;Due to the radiosensitivity of seminoma, a low therapeutic dose is required to effectively treat seminoma with recommended doses ranging from 20 to 25 Gy [",
"    <a class=\"abstract\" href=\"UTD.htm?22/2/22567/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. A scrotal shield should be used even with PA strip radiation to minimize radiation to the remaining testicle [",
"    <a class=\"abstract\" href=\"UTD.htm?22/2/22567/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The effect of dose was studied in the Medical Research Council TE18 trial, in which 625 men with seminoma were randomly assigned to 20 Gy in 10 fractions or 30 Gy in 15 fractions [",
"    <a class=\"abstract\" href=\"UTD.htm?22/2/22567/abstract/31\">",
"     31",
"    </a>",
"    ]. With a median follow-up of five years, the disease-free survival rates were 98 and 97 percent for the 30 and 20 Gy groups, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?22/2/22567/abstract/31\">",
"     31",
"    </a>",
"    ]. While men receiving the higher dose had significantly more lethargy (20 versus 5 percent) and inability to work (46 versus 28 percent) at four weeks, these differences disappeared by 12 weeks. However, six new primary cancers were diagnosed, all in men treated with 30 Gy. Nine new germ cell primary cancers were diagnosed, six in the 20 Gy group, and three in the 30 Gy group.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H77784158\">",
"    <span class=\"h3\">",
"     Treatment-related toxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Whether single agent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    or adjuvant RT is used, adjuvant treatment is associated with a risk for both acute and long-term side effects.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acute side effects of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"       carboplatin",
"      </a>",
"      include:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Thrombocytopenia",
"     </li>",
"     <li>",
"      Nausea and vomiting",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acute side effects of RT observed during or shortly after treatment including the following:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Fatigue",
"     </li>",
"     <li>",
"      Gastrointestinal effects, including nausea and vomiting (if antiemetics are not used)",
"     </li>",
"     <li>",
"      Myelosuppression, which is typically mild",
"     </li>",
"     <li>",
"      Mild, self-limited tanning of the treated skin",
"     </li>",
"     <li>",
"      Impaired fertility (although this is not an issue with modern RT techniques including testicular shielding)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A discussion of acute and late treatment-related toxicities is covered separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/49/20250?source=see_link\">",
"     \"Treatment-related toxicity in men with testicular germ cell tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    While single agent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    is unlikely to be associated with long-term complications, adjuvant RT may be associated with late effects including an increased risk of secondary malignancies and a possible increased risk for cardiovascular disease. A more detailed discussion of long-term complications is covered separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/41/16025?source=see_link&amp;anchor=H2639185#H2639185\">",
"     \"Approach to the care of long-term testicular cancer survivors\", section on 'Organ-specific effects of treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The overall prognosis of men with stage I testicular seminoma is excellent following orchiectomy. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For men with stage I testicular seminoma, we recommend active surveillance rather than adjuvant treatment (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H77783068\">",
"       'Active surveillance'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For men who want to minimize any risk of relapse and who understand the risk of adverse late effects, we suggest adjuvant treatment (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ); we suggest chemotherapy rather than RT (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Our preferred agent is",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"       carboplatin",
"      </a>",
"      in this setting. (See",
"      <a class=\"local\" href=\"#H77783389\">",
"       'Adjuvant chemotherapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For men in whom active surveillance is not an option (eg, due to compliance issues) and who refuse chemotherapy, we suggest adjuvant RT (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). If administered, we recommend RT to the paraaortic lymph nodes (a so-called \"PA-strip\"), rather than the older, more extensive \"hockey stick\" field (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H261198349\">",
"       'Adjuvant radiation therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22567/abstract/1\">",
"      Groll RJ, Warde P, Jewett MA. A comprehensive systematic review of testicular germ cell tumor surveillance. Crit Rev Oncol Hematol 2007; 64:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22567/abstract/2\">",
"      Warde P, Gospodarowicz M. Evolving concepts in stage I seminoma. BJU Int 2009; 104:1357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22567/abstract/3\">",
"      Mead GM, Fossa SD, Oliver RT, et al. Randomized trials in 2466 patients with stage I seminoma: patterns of relapse and follow-up. J Natl Cancer Inst 2011; 103:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22567/abstract/4\">",
"      Tandstad T, Smaaland R, Solberg A, et al. Management of seminomatous testicular cancer: a binational prospective population-based study from the Swedish norwegian testicular cancer study group. J Clin Oncol 2011; 29:719.",
"     </a>",
"    </li>",
"    <li>",
"     Arvold ND, Catalano PJ, Sweeney C, et al. Physician and patient factors influencing management recommendations in stage I testicular seminoma: A survey among radiation oncologists in the United States (abstract 225). J Clin Oncol 2011; 29 Suppl 7:225.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22567/abstract/6\">",
"      Yu HY, Madison RA, Setodji CM, Saigal CS. Quality of surveillance for stage I testis cancer in the community. J Clin Oncol 2009; 27:4327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22567/abstract/7\">",
"      Vesprini D, Chung P, Tolan S, et al. Utility of serum tumor markers during surveillance for stage I seminoma. Cancer 2012; 118:5245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22567/abstract/8\">",
"      Gilligan TD, Seidenfeld J, Basch EM, et al. American Society of Clinical Oncology Clinical Practice Guideline on uses of serum tumor markers in adult males with germ cell tumors. J Clin Oncol 2010; 28:3388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22567/abstract/9\">",
"      Schmoll HJ, Jordan K, Huddart R, et al. Testicular seminoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010; 21 Suppl 5:v140.",
"     </a>",
"    </li>",
"    <li>",
"     NCCN Clinical Practice Guidelines in Oncology. Testicular Cancer. Version 1.2012. file://www.nccn.org/professionals/physician_gls/pdf/testicular.pdf (Accessed on June 22, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22567/abstract/11\">",
"      Oliver RT, Mason MD, Mead GM, et al. Radiotherapy versus single-dose carboplatin in adjuvant treatment of stage I seminoma: a randomised trial. Lancet 2005; 366:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22567/abstract/12\">",
"      Oliver RT, Mead GM, Rustin GJ, et al. Randomized trial of carboplatin versus radiotherapy for stage I seminoma: mature results on relapse and contralateral testis cancer rates in MRC TE19/EORTC 30982 study (ISRCTN27163214). J Clin Oncol 2011; 29:957.",
"     </a>",
"    </li>",
"    <li>",
"     Oliver T, Dieckmann KP, Steiner H, et al. Pooled analyisis of phase 2 reports of 2 v 1 course of carboplatin as adjuvant for stage I seminoma (abstract). J Clin Oncol 2005; 23:395s.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22567/abstract/14\">",
"      Dieckmann KP, Br&uuml;ggeboes B, Pichlmeier U, et al. Adjuvant treatment of clinical stage I seminoma: is a single course of carboplatin sufficient? Urology 2000; 55:102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22567/abstract/15\">",
"      Oliver R, Boublikova L, Ong J. Fifteen year follow-up of the Anglican germ cell cancer group adjuvant studies of carboplatin as an alternative to radiation or surveilance for stage 1 seminoma. Proc Am Soc Clin Oncol 2001; 20:196a.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22567/abstract/16\">",
"      Reiter WJ, Brodowicz T, Alavi S, et al. Twelve-year experience with two courses of adjuvant single-agent carboplatin therapy for clinical stage I seminoma. J Clin Oncol 2001; 19:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22567/abstract/17\">",
"      Steiner H, H&ouml;ltl L, Wirtenberger W, et al. Long-term experience with carboplatin monotherapy for clinical stage I seminoma: a retrospective single-center study. Urology 2002; 60:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22567/abstract/18\">",
"      Aparicio J, Germ&agrave; JR, Garc&iacute;a del Muro X, et al. Risk-adapted management for patients with clinical stage I seminoma: the Second Spanish Germ Cell Cancer Cooperative Group study. J Clin Oncol 2005; 23:8717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22567/abstract/19\">",
"      Aparicio J, Garc&iacute;a del Muro X, Maroto P, et al. Multicenter study evaluating a dual policy of postorchiectomy surveillance and selective adjuvant single-agent carboplatin for patients with clinical stage I seminoma. Ann Oncol 2003; 14:867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22567/abstract/20\">",
"      Wilder RB, Buyyounouski MK, Efstathiou JA, Beard CJ. Radiotherapy treatment planning for testicular seminoma. Int J Radiat Oncol Biol Phys 2012; 83:e445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22567/abstract/21\">",
"      Dosoretz DE, Shipley WU, Blitzer PH, et al. Megavoltage irradiation for pure testicular seminoma: results and patterns of failure. Cancer 1981; 48:2184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22567/abstract/22\">",
"      Foss&aring; SD, Aass N, Kaalhus O. Radiotherapy for testicular seminoma stage I: treatment results and long-term post-irradiation morbidity in 365 patients. Int J Radiat Oncol Biol Phys 1989; 16:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22567/abstract/23\">",
"      Zagars GK, Babaian RJ. Stage I testicular seminoma: rationale for postorchiectomy radiation therapy. Int J Radiat Oncol Biol Phys 1987; 13:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22567/abstract/24\">",
"      Bamberg M, Schmidberger H, Meisner C, et al. Radiotherapy for stages I and IIA/B testicular seminoma. Int J Cancer 1999; 83:823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22567/abstract/25\">",
"      Willan BD, McGowan DG. Seminoma of the testis: a 22-year experience with radiation therapy. Int J Radiat Oncol Biol Phys 1985; 11:1769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22567/abstract/26\">",
"      Niazi TM, Souhami L, Sultanem K, et al. Long-term results of para-aortic irradiation for patients with stage I seminoma of the testis. Int J Radiat Oncol Biol Phys 2005; 61:741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22567/abstract/27\">",
"      Kiricuta IC, Sauer J, Bohndorf W. Omission of the pelvic irradiation in stage I testicular seminoma: a study of postorchiectomy paraaortic radiotherapy. Int J Radiat Oncol Biol Phys 1996; 35:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22567/abstract/28\">",
"      Classen J, Schmidberger H, Meisner C, et al. Para-aortic irradiation for stage I testicular seminoma: results of a prospective study in 675 patients. A trial of the German testicular cancer study group (GTCSG). Br J Cancer 2004; 90:2305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22567/abstract/29\">",
"      Foss&aring; SD, Horwich A, Russell JM, et al. Optimal planning target volume for stage I testicular seminoma: A Medical Research Council randomized trial. Medical Research Council Testicular Tumor Working Group. J Clin Oncol 1999; 17:1146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22567/abstract/30\">",
"      Hanks GE, Peters T, Owen J. Seminoma of the testis: long-term beneficial and deleterious results of radiation. Int J Radiat Oncol Biol Phys 1992; 24:913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22567/abstract/31\">",
"      Jones WG, Fossa SD, Mead GM, et al. Randomized trial of 30 versus 20 Gy in the adjuvant treatment of stage I Testicular Seminoma: a report on Medical Research Council Trial TE18, European Organisation for the Research and Treatment of Cancer Trial 30942 (ISRCTN18525328). J Clin Oncol 2005; 23:1200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22567/abstract/32\">",
"      Krege S, Souchon R, Schmoll HJ, German Testicular Cancer Study Group. Interdisciplinary consensus on diagnosis and treatment of testicular germ cell tumors: result of an update conference on evidence-based medicine (EBM). Eur Urol 2001; 40:372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22567/abstract/33\">",
"      Bieri S, Rouzaud M, Miralbell R. Seminoma of the testis: is scrotal shielding necessary when radiotherapy is limited to the para-aortic nodes? Radiother Oncol 1999; 50:349.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2993 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.55.141.10-629A639819-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_2_22567=[""].join("\n");
var outline_f22_2_22567=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H27\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23177522\">",
"      APPROACH TO TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H77783068\">",
"      Active surveillance",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23176390\">",
"      - Is there an optimal surveillance protocol?",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H77783102\">",
"      CT imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H77783127\">",
"      Tumor markers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H77783835\">",
"      Men who decline active surveillance",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H77783389\">",
"      - Adjuvant chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H261198349\">",
"      - Adjuvant radiation therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H261198371\">",
"      Technique",
"     </a>",
"    </li>",
"    <li class=\"dashItem2\">",
"     <a class=\"outlineLink\" href=\"#H101307361\">",
"      - Treatment field",
"     </a>",
"    </li>",
"    <li class=\"dashItem2\">",
"     <a class=\"outlineLink\" href=\"#H101307368\">",
"      - Dose",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H77784158\">",
"      - Treatment-related toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/2993\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/2993|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?34/46/35552\" title=\"diagnostic image 1\">",
"      Small field RT portal seminoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/2993|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?2/30/2531\" title=\"figure 1\">",
"      Large field RT portal seminoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/2993|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?35/13/36061\" title=\"table 1\">",
"      TNM staging testicular CA",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/16/3334?source=related_link\">",
"      Active surveillance following orchiectomy for stage I testicular germ cell tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/40/5770?source=related_link\">",
"      Anatomy and pathology of testicular tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/41/16025?source=related_link\">",
"      Approach to the care of long-term testicular cancer survivors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/47/41720?source=related_link\">",
"      Clinical manifestations, diagnosis, and staging of testicular germ cell tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/25/2457?source=related_link\">",
"      Epidemiology of and risk factors for testicular germ cell tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/63/24568?source=related_link\">",
"      Initial risk-stratified treatment for advanced testicular germ cell tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/7/13432?source=related_link\">",
"      Overview of the treatment of testicular germ cell tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/17/24852?source=related_link\">",
"      Risk stratification of metastatic testicular germ cell tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/58/38822?source=related_link\">",
"      Serum tumor markers in testicular germ cell tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/45/22230?source=related_link\">",
"      Treatment of stage II seminoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/49/20250?source=related_link\">",
"      Treatment-related toxicity in men with testicular germ cell tumors",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_2_22568="Salivary gland stones";
var content_f22_2_22568=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Salivary gland stones",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/2/22568/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/2/22568/contributors\">",
"     Sara B Fazio, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/2/22568/contributors\">",
"     Kevin Emerick, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/2/22568/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/2/22568/contributors\">",
"     Daniel G Deschler, MD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/2/22568/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/2/22568/contributors\">",
"     Fenny H Lin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?22/2/22568/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 3, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sialolithiasis, the presence of stones or calculi in the salivary glands or ducts, is a relatively common condition. Although a 1 percent incidence is noted in autopsy studies [",
"    <a class=\"abstract\" href=\"UTD.htm?22/2/22568/abstract/1\">",
"     1",
"    </a>",
"    ], clinically symptomatic stones are much less frequently noted. A review of 15 health regions in England from 1991 to 1995 revealed an incidence of symptomatic sialolithiasis of 27 to 59 cases per million population per year [",
"    <a class=\"abstract\" href=\"UTD.htm?22/2/22568/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The presentation, evaluation, and treatment of salivary gland stones will be reviewed here.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ANATOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The three major salivary glands (parotid, submandibular, and sublingual), and occasionally the minor salivary glands, are subject to the development of stones. The anatomy of the glands and ducts affects where stones are likely to lodge and also affects the choice of therapies. (See",
"    <a class=\"local\" href=\"#H30\">",
"     'Treatment'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Parotid glands and Stensen's duct",
"    </span>",
"    &nbsp;&mdash;&nbsp;The parotid glands are located on the sides of the face anterior to the external auditory canal, superior to the angle of the mandible, and inferior to the zygomatic arch. Most of the parotid gland is superficial to the masseter muscle. Stensen's duct arises from the anterior border of the parotid gland and is 4 to 7 cm long, narrows to 1.2 mm at an isthmus, and the os is 0.5 mm and is opposite the upper second molar (",
"    <a class=\"graphic graphic_figure graphicRef62744 \" href=\"UTD.htm?6/19/6449\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Submandibular glands and Wharton's duct",
"    </span>",
"    &nbsp;&mdash;&nbsp;The submandibular glands lie beneath the floor of the mouth. Wharton's duct arises from the medial surface and is 5 cm long and 1.5 mm in diameter. The os is 0.5 mm in diameter and located on the floor of the mouth near the frenulum of the tongue (",
"    <a class=\"graphic graphic_figure graphicRef62744 \" href=\"UTD.htm?6/19/6449\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Sublingual glands",
"    </span>",
"    &nbsp;&mdash;&nbsp;The sublingual glands are located below the mucous membrane of the floor of the mouth. They are drained by multiple small ducts that empty either into Wharton's duct or directly into the floor of the mouth (",
"    <a class=\"graphic graphic_figure graphicRef62744 \" href=\"UTD.htm?6/19/6449\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Minor salivary glands",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is salivary gland tissue in multiple locations throughout the oral mucosa (including buccal, labial, lingual, and palatal locations) that drains directly into the mouth.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Eighty to 92 percent of stones arise from the submandibular glands with approximately 6 to 20 percent from the parotid glands, and 1 to 2 percent from the sublingual as well as minor salivary glands [",
"    <a class=\"abstract\" href=\"UTD.htm?22/2/22568/abstract/1,3\">",
"     1,3",
"    </a>",
"    ]. Men develop more stones than women, and the majority of cases occur in individuals between the ages of 30 and 60 years. Stones rarely occur in children. Seventy-five percent of salivary stones are single and approximately 3 percent are bilateral [",
"    <a class=\"abstract\" href=\"UTD.htm?22/2/22568/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. Stones occur equally on the right and left sides. Submandibular stones tend to be the largest and are most often located in the duct. Parotid stones tend to be smaller and are more often multiple, and 50 percent of the time they are located within the gland itself.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The exact cause of stone formation is not known, but it is felt to be secondary to the relative stagnation of saliva that is rich in calcium, in a setting of partial obstruction. Salivary stones are composed largely of calcium phosphate and hydroxyapatite with smaller amounts of magnesium, potassium, and ammonium [",
"    <a class=\"abstract\" href=\"UTD.htm?22/2/22568/abstract/1\">",
"     1",
"    </a>",
"    ]. Inflammation of the gland, or sialadenitis, is often a contributing factor, as is localized injury or ductal inflammation. The submandibular gland may be more prone to stone formation because the duct is long and large, the flow of saliva is slow and against gravity, and the saliva is more alkaline with a high mucin and calcium content [",
"    <a class=\"abstract\" href=\"UTD.htm?22/2/22568/abstract/6\">",
"     6",
"    </a>",
"    ]. There are several risk factors thought to be associated with salivary gland stones [",
"    <a class=\"abstract\" href=\"UTD.htm?22/2/22568/abstract/1,7\">",
"     1,7",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Dehydration",
"     </li>",
"     <li>",
"      Diuretics",
"     </li>",
"     <li>",
"      Anti-cholinergic medications",
"     </li>",
"     <li>",
"      Trauma",
"     </li>",
"     <li>",
"      Gout",
"     </li>",
"     <li>",
"      Smoking",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    While it has been suggested that hypercalcemia can also lead to salivary stone formation, the association, if present, does not appear to be strong [",
"    <a class=\"abstract\" href=\"UTD.htm?22/2/22568/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sialolithiasis typically presents with pain and swelling in the involved gland; these are usually aggravated by eating or with anticipation of eating. Stones can present as painless swelling or may be noted incidentally on physical exam or on radiographs (such as dental x-rays). Approximately 30 percent of the time submandibular sialolithiasis will present with painless swelling and 12 percent of the time with pain alone [",
"    <a class=\"abstract\" href=\"UTD.htm?22/2/22568/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients may have waxing and waning symptoms of episodic swelling and discomfort, or may have more persistent symptoms. If sialadenitis develops, pain and erythema typically worsen. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Sialadenitis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Patients with stones that intermittently obstruct will usually have symptomatic episodes separated by days to weeks.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Attention should be paid to the flow of saliva from the respective duct, allowing the recognition of complete or intermittent obstruction. Normally, clear saliva should be seen flowing from the duct when the respective gland is compressed. Small stones may be visible at the duct orifice and may be seen to be intermittently obstructing the duct or moving in and out of view with compression of the gland (",
"    <a class=\"graphic graphic_picture graphicRef71787 \" href=\"UTD.htm?38/56/39823\">",
"     picture 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef50735 \" href=\"UTD.htm?23/61/24528\">",
"     picture 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    In patients with a suspected submandibular stone, palpation of the floor of the mouth in a posterior to anterior direction is recommended to find a stone impacted in Wharton's duct. Having the patient close his or her mouth slightly to relax the musculature on the floor of the mouth will facilitate this examination [",
"    <a class=\"abstract\" href=\"UTD.htm?22/2/22568/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For the parotid gland, palpation of the buccal mucosa around the orifice of Stensen's duct may reveal a stone. Also palpate the face along the duct's route, by starting at the attachment of the earlobe and palpating forward in the direction of the jaw-line with one hand on the outside and one hand inside the mouth.",
"   </p>",
"   <p>",
"    Palpation of the gland is important as well. A functioning gland should be spongy and elastic and in this setting may be quite tender, particularly in the presence of associated infection.",
"   </p>",
"   <p>",
"    Stones are typically rock hard and small; they may be smooth or irregular. They are most commonly felt within the ductal system, in contrast to salivary gland tumors that are palpable in the parenchyma of the gland.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Sialadenitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute sialadenitis in the setting of sialolithiasis typically presents with pain, swelling, and erythema in the area of the gland, and with pus draining from the respective duct. Patients with sialadenitis may have systemic symptoms including fevers and chills.",
"   </p>",
"   <p>",
"    Sialadenitis will usually resolve in 7 to 10 days when treated with antibiotics and conservative measures (see",
"    <a class=\"local\" href=\"#H30\">",
"     'Treatment'",
"    </a>",
"    below). Lack of improvement",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    focal worsening within the gland suggests the possibility of abscess formation, which can be seen on high resolution CT. Stones usually remain after acute sialadenitis resolves.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Chronic obstruction",
"    </span>",
"    &nbsp;&mdash;&nbsp;When salivary gland outflow is completely obstructed, the gland will initially be persistently swollen, but this will regress over a period of many weeks as the obstruction results in the gland ceasing to produce saliva. The gland will then feel firm and can be mistaken for a focal mass. Fine needle aspiration will show chronic inflammation, and stones may be found on physical examination or radiographic studies. Patients are usually asymptomatic at this point, and in the absence of symptoms no intervention is required.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Imaging studies are most useful when the stone or suspected stone is not palpable or readily noted on physical examination.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Computerized tomography",
"    </span>",
"    &nbsp;&mdash;&nbsp;High resolution noncontrast CT scanning is currently the imaging modality of choice for the evaluation of salivary stones [",
"    <a class=\"abstract\" href=\"UTD.htm?22/2/22568/abstract/10\">",
"     10",
"    </a>",
"    ]. Most stones contain enough calcium to be visible with noncontrast imaging. Fine cuts must be requested so that the stone or stones are not missed.",
"   </p>",
"   <p>",
"    CT scans have a 10-fold greater sensitivity in detecting stones when compared with plain films. Excellent assessment of the entire gland is available and sensitivity for the identification of parotid tumors approaches 100 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?22/2/22568/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Plain films",
"    </span>",
"    &nbsp;&mdash;&nbsp;Plain films are effective in detecting radiopaque stones. Submandibular calculi tend to be radiopaque in 80 to 95 percent of cases, whereas parotid calculi are radiopaque in 60 percent of cases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Ultrasound",
"    </span>",
"    &nbsp;&mdash;&nbsp;More than 90 percent of stones 2 mm in diameter or larger can be detected by ultrasound [",
"    <a class=\"abstract\" href=\"UTD.htm?22/2/22568/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. Ultrasound may better assess periglandular structures than sialography [",
"    <a class=\"abstract\" href=\"UTD.htm?22/2/22568/abstract/14\">",
"     14",
"    </a>",
"    ]. In addition, ultrasound is less invasive than sialography and may be able to detect radiolucent stones or radiopaque stones that are superimposed on bone and thus undetectable on conventional x-rays [",
"    <a class=\"abstract\" href=\"UTD.htm?22/2/22568/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Sialography",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the past, sialography was often performed to evaluate sialolithiasis. The duct is cannulated and a radiopaque dye is injected, followed by plain films. Because of the invasive and technically demanding nature of the procedure, sialography for the diagnosis of sialolithiasis has been largely supplanted by high-resolution CT scanning or ultrasound [",
"    <a class=\"abstract\" href=\"UTD.htm?22/2/22568/abstract/10\">",
"     10",
"    </a>",
"    ]. Sialography is contraindicated in patients with acute sialadenitis or contrast allergy.",
"   </p>",
"   <p>",
"    Sialography is still utilized by some clinicians. In particular it may help facilitate a diagnosis other than sialolithiasis such as stricture, sialectasis, and cystic degeneration of the duct and gland [",
"    <a class=\"abstract\" href=\"UTD.htm?22/2/22568/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Magnetic resonance imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Standard MRI will not visualize stones [",
"    <a class=\"abstract\" href=\"UTD.htm?22/2/22568/abstract/1\">",
"     1",
"    </a>",
"    ]. There is ongoing investigation regarding the use of MRI to visualize the ducts as an alternative to conventional sialography [",
"    <a class=\"abstract\" href=\"UTD.htm?22/2/22568/abstract/16\">",
"     16",
"    </a>",
"    ]; no intraductal contrast is required for MR sialography. Studies of MR sialography suggest that it may have superior sensitivity compared with ultrasound [",
"    <a class=\"abstract\" href=\"UTD.htm?22/2/22568/abstract/17\">",
"     17",
"    </a>",
"    ] and have a lower procedural failure rate than standard sialography [",
"    <a class=\"abstract\" href=\"UTD.htm?22/2/22568/abstract/18\">",
"     18",
"    </a>",
"    ]. However, the procedure is time-consuming and is not yet widely used.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of other disease processes may affect the salivary glands and must be distinguished from sialolithiasis. These include infections, inflammatory conditions, and neoplastic and non-neoplastic masses.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Viral sialadenitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Viral parotitis due to mumps virus is characterized by acute pain and swelling of one or both parotid glands. It is the most common cause of parotid gland swelling [",
"    <a class=\"abstract\" href=\"UTD.htm?22/2/22568/abstract/4\">",
"     4",
"    </a>",
"    ]. Infection is frequently accompanied by a nonspecific prodrome consisting of low grade fever, malaise, headache, myalgias, and anorexia. These symptoms are generally followed within 48 hours by the development of parotitis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/61/8154?source=see_link\">",
"     \"Epidemiology, clinical manifestations, diagnosis and management of mumps\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other less common viral etiologies of sialadenitis include coxsackie viruses A and B, echovirus, parainfluenzavirus, influenza A, and Epstein-Barr virus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Acute bacterial sialadenitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute bacterial sialadenitis (suppurative sialadenitis) in the absence of sialolithiasis is a condition that typically affects elderly, malnourished, or postoperative patients [",
"    <a class=\"abstract\" href=\"UTD.htm?22/2/22568/abstract/19\">",
"     19",
"    </a>",
"    ]. The parotid gland is most commonly involved. It is characterized by sudden onset of a very firm and tender swelling over the involved gland. Fever and chills are usually present, generally with fairly marked systemic toxicity. Purulent drainage can often be expressed from the effected duct orifice.",
"   </p>",
"   <p>",
"    Staphylococcus aureus is the most frequent microbiologic isolate, but Streptococcus pneumonia, Streptococcus viridans, Haemophilus influenzae, and Bacteroides species have also been isolated. Broad-spectrum therapy should be initiated. Prompt surgical drainage and decompression is required if an abscess develops. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/14/22758?source=see_link\">",
"     \"Suppurative parotitis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Sialography has been reported to trigger episodes of sialadenitis and is contraindicated in the setting of acute salivary gland infection [",
"    <a class=\"abstract\" href=\"UTD.htm?22/2/22568/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Chronic bacterial sialadenitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic bacterial sialadenitis is a low grade chronic infection that can eventually lead to destruction of the salivary gland. It may occur more commonly in patients with decreased salivary secretion and increased mucus content in their saliva [",
"    <a class=\"abstract\" href=\"UTD.htm?22/2/22568/abstract/4\">",
"     4",
"    </a>",
"    ]. Other predisposing factors include stones, strictures, and trauma. Patients with chronic bacterial sialadenitis generally have intermittent exacerbations of acute sialadenitis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Human immunodeficiency virus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with HIV infection are prone to the development of lymphoepithelial cysts within the parotid gland; cysts can also occur in other major salivary glands [",
"    <a class=\"abstract\" href=\"UTD.htm?22/2/22568/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. These may become superinfected. Parotid swelling in HIV infection is typically diffuse and symmetric. While some asymmetric swelling can occur, a significant degree of asymmetry with diffuse parotid enlargement, or any focal parotid mass, raises a concern for neoplasm; evaluation should follow that of any parotid mass and include appropriate imaging with high resolution noncontrast CT. Cystic lesions on imaging are consistent with the diagnosis of lymphoepithelial cysts, but solid lesions are concerning for lymphoma or other parotid malignancy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Sj&ouml;gren's syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sj&ouml;gren's syndrome is a chronic inflammatory disorder characterized primarily by diminished lacrimal and salivary gland secretions resulting in symptoms of dry eyes and dry mouth, the so-called \"sicca complex\" (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/1/11287?source=see_link\">",
"     \"Clinical manifestations of Sj&ouml;gren's syndrome: Exocrine gland disease\"",
"    </a>",
"    ). Sj&ouml;gren's syndrome may present with a gradual swelling of the parotid or submandibular glands, typically bilaterally. Autoimmune sialadenitis eventually causes parenchymal destruction and dilation of the intraglandular ducts [",
"    <a class=\"abstract\" href=\"UTD.htm?22/2/22568/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Sarcoidosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Extrapulmonary sarcoidosis affects the parotid glands in 1 to 6 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?22/2/22568/abstract/23\">",
"     23",
"    </a>",
"    ] and may be associated with uveitis and facial paralysis (Heerfordt's syndrome) (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/25/21914?source=see_link\">",
"     \"Clinical manifestations and diagnosis of sarcoidosis\"",
"    </a>",
"    ). The presentation is characterized by bilateral painless parotid enlargement due to granulomatous infiltration.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Radiation sialadenitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Low-dose radiation to a salivary gland causes acute, tender, painful swelling [",
"    <a class=\"abstract\" href=\"UTD.htm?22/2/22568/abstract/5\">",
"     5",
"    </a>",
"    ]. Patients tend to complain of a burning, dry mouth with diminished ability to taste.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Malnutrition",
"    </span>",
"    &nbsp;&mdash;&nbsp;Malnutrition is commonly associated with sialadenosis, which is a noninflammatory, non-neoplastic enlargement of a salivary gland, typically the parotid [",
"    <a class=\"abstract\" href=\"UTD.htm?22/2/22568/abstract/5\">",
"     5",
"    </a>",
"    ]. Associated conditions include anorexia nervosa, bulimia, beriberi, pellagra, diabetes, and alcoholic cirrhosis. Histologic evaluation reveals acinar hypertrophy without an inflammatory infiltrate.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Salivary gland tumors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Salivary gland masses require a disciplined and thorough evaluation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/44/9927?source=see_link\">",
"     \"Salivary gland tumors: Epidemiology, diagnosis, evaluation, and staging\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A possible salivary gland etiology should be considered for all noncentral upper neck masses. Evaluation requires a thorough physical examination and assessment of symptoms concerning for malignancy such as pain, facial nerve dysfunction, or a firm and fixed position. Evaluation should include imaging with CT or MRI. Fine needle aspiration is a safe and useful modality to assess tissue type prior to definitive resection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/24/7558?source=see_link\">",
"     \"Evaluation of a neck mass\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As a general rule, the smaller the salivary gland in adults, the higher the probability that a neoplasm arising in such a gland is malignant [",
"    <a class=\"abstract\" href=\"UTD.htm?22/2/22568/abstract/24\">",
"     24",
"    </a>",
"    ]. As examples, malignancy is present in 15 to 25 percent of all parotid tumors, 37 to 43 percent of submandibular gland tumors, and over 80 percent of the minor salivary gland tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?22/2/22568/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/44/9927?source=see_link\">",
"     \"Salivary gland tumors: Epidemiology, diagnosis, evaluation, and staging\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     General approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;Conservative management is the mainstay of treatment in the majority of patients presenting to a primary care clinician. Patients should be instructed to keep well hydrated, apply moist heat to the involved area, massage the gland, and \"milk\" the duct.",
"   </p>",
"   <p>",
"    Sialogogues, which promote ductal secretions, are often helpful (examples include tart hard candies such as lemon drops). These should be used throughout the day as often as tolerated by the patient.",
"   </p>",
"   <p>",
"    If possible, patients should discontinue medications with anticholinergic effects that reduce salivary flow, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/2/33824?source=see_link\">",
"     diphenhydramine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/30/27112?source=see_link\">",
"     amitriptyline",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Moderate pain can generally be controlled with NSAIDs such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/38/15978?source=see_link\">",
"     ibuprofen",
"    </a>",
"    ; NSAIDs may also help reduce inflammation. Patients with more severe pain may require opioid analgesics.",
"   </p>",
"   <p>",
"    If superinfection is suspected because of increasing pain, fever, or purulent drainage from the duct, antistaphylococcal antibiotics such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/11/3253?source=see_link\">",
"     dicloxacillin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/37/37462?source=see_link\">",
"     cephalexin",
"    </a>",
"    500 mg four times a day should be administered for 7 to 10 days. When possible, surgical intervention is typically avoided during acute infection.",
"   </p>",
"   <p>",
"    Patients without evidence of infection but who have persistent symptoms",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    obstruction lasting more than a few days should be referred for specialist management; this can be done on a non-urgent basis if symptoms permit. Patients with frequently recurrent symptoms or recurrent episodes of sialadenitis should also be referred for specialist management.",
"   </p>",
"   <p>",
"    Patients with severe persistent symptoms may require more rapid referral, and patients with infection that worsens or does not improve over a 7 to 10 day period with antibiotic therapy require urgent referral as they are at risk for the development of salivary gland abscess. Additionally, inflammation from the submandibular region can spread to the floor of the mouth, ultimately leading to airway compromise in the most severe setting.",
"   </p>",
"   <p>",
"    Generally speaking, stones less than 2 mm in diameter can often be treated without a surgical approach as smaller stones can typically pass with the assistance of ductal dilatation alone. The ductal anatomy (see",
"    <a class=\"local\" href=\"#H2\">",
"     'Anatomy'",
"    </a>",
"    above), stone size, and location of the stone determine the type of treatment.",
"   </p>",
"   <p>",
"    For salivary stones that do not resolve with medical management, minimally-invasive approaches are highly successful. One multicenter, observational study in Europe of 4691 patients with symptomatic stones found that 80 percent of stones were successfully removed with one or more minimally-invasive approaches (extracorporeal lithotripsy, fluoroscopic- or endoscopic-guided wire basket retrieval, intraoral stone removal) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/2/22568/abstract/27\">",
"     27",
"    </a>",
"    ]. Partial removal without further significant symptoms was possible in up to 16 percent of the patients. Only 3 percent ultimately required gland removal for a persistent stone. With increasing experience, these have become the first-line treatment for symptomatic sialolithiasis refractory to non-interventional management.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Lithotripsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients in whom a simple transoral approach is not possible (typically stones in the proximal ducts or in the salivary glands themselves) or fails, extracorporeal lithotripsy appears to be effective for stones that are intraductal and less than 7 mm. In one prospective study, 76 patients with sonographically detected parotid stones were treated with extracorporeal shock wave therapy after failure of conservative treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?22/2/22568/abstract/28\">",
"     28",
"    </a>",
"    ]. Fifty percent were free of stones after a follow-up period of 48 months. Twenty-six percent had residual stone fragments detected but were asymptomatic.",
"   </p>",
"   <p>",
"    Laser lithotripsy is an alternative to extracorporeal lithotripsy, and can be performed via an endoscope (see",
"    <a class=\"local\" href=\"#H35\">",
"     'Sialoendoscopy'",
"    </a>",
"    below). This technique is becoming more popular with increasing availability of endoscopy. A preliminary report of clinical use in 17 patients indicated successful treatment of 21 stones with full fragmentation of 5, and partial fragmentation for forceps retrieval or loosening of the remainder [",
"    <a class=\"abstract\" href=\"UTD.htm?22/2/22568/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Wire basket retrieval",
"    </span>",
"    &nbsp;&mdash;&nbsp;Removal of stones with a wire basket extractor under fluoroscopic guidance is an alternative to invasive surgery and sialadenectomy in some cases [",
"    <a class=\"abstract\" href=\"UTD.htm?22/2/22568/abstract/30\">",
"     30",
"    </a>",
"    ]. This technique is becoming less frequently used with the availability of other minimally invasive techniques.",
"   </p>",
"   <p>",
"    In a study of 83 patients with 86 cases of salivary gland stones treated with wire basket extraction, stones were completely removed in 64 percent of the cases [",
"    <a class=\"abstract\" href=\"UTD.htm?22/2/22568/abstract/31\">",
"     31",
"    </a>",
"    ]. The most common reason for failure was fixation of the stone within the duct. Complications included localized pain and swelling; 16 percent of patients developed sialadenitis and required antibiotic therapy. Optimal conditions for this procedure include a stone or fragment that is mobile and located in the extraglandular portion of the parotid or submandibular duct.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Sialoendoscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endoscopy may be utilized to visualize the ductal anatomy as well as to remove small stones that are beyond the reach of traditional transoral surgical procedures. Endoscopy may also find stones that have gone undetected by other imaging techniques [",
"    <a class=\"abstract\" href=\"UTD.htm?22/2/22568/abstract/32\">",
"     32",
"    </a>",
"    ]. In a series of 154 patients with known or suspected salivary gland obstruction (96 submandibular, 57 parotid, 1 sublingual) who underwent endoscopy, 112 were found to have obstructions and 33 had sialadenitis alone [",
"    <a class=\"abstract\" href=\"UTD.htm?22/2/22568/abstract/32\">",
"     32",
"    </a>",
"    ]. The success rate for removal of calculi in patients with stones was 82 percent. Another study reported success rates of 86 percent for parotid stones and 89 percent for submandibular stones [",
"    <a class=\"abstract\" href=\"UTD.htm?22/2/22568/abstract/33\">",
"     33",
"    </a>",
"    ]. In a systematic review, the overall success rate of sialoendoscopy (for a variety of indications, including obstructive stones, stenosis, and sialadenitis) was 86 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?22/2/22568/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Good prognostic factors for removal of salivary stones via sialoendoscopy include small size, mobility, roundness, and distal location in the main salivary duct [",
"    <a class=\"abstract\" href=\"UTD.htm?22/2/22568/abstract/35\">",
"     35",
"    </a>",
"    ]. Size is the most important predictor of success with this technique; stones less than 3 mm in the parotid and 4 mm in the submandibular gland are easily removed without fragmentation, while removal of stones larger than this is technically more difficult [",
"    <a class=\"abstract\" href=\"UTD.htm?22/2/22568/abstract/36\">",
"     36",
"    </a>",
"    ]. However, an open intraoral approach assisted by sialoendoscopy allows retrieval of proximal stones larger than 10 mm in over 80 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?22/2/22568/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. Some authors recommend performing laser lithotripsy through a sialoendoscope to allow fragmentation of the stone prior to endoscopic removal [",
"    <a class=\"abstract\" href=\"UTD.htm?22/2/22568/abstract/39\">",
"     39",
"    </a>",
"    ]. The application of different laser systems to the endoscope enhances the ability to fragment larger stones and facilitate removal.",
"   </p>",
"   <p>",
"    Endoscopy may be used after traditional transoral calculus removal to check for the presence of residual stone fragments. It may also be used diagnostically, particularly in the case of relatively small stones, as well as to aid in differentiating a stone from a polyp or mucous plug.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H577252247\">",
"    <span class=\"h2\">",
"     Surgical intervention",
"    </span>",
"    &nbsp;&mdash;&nbsp;Submandibular stones can be removed via a transoral approach approximately 50 percent of the time [",
"    <a class=\"abstract\" href=\"UTD.htm?22/2/22568/abstract/9\">",
"     9",
"    </a>",
"    ]. Stones that are palpable within the mouth are generally amenable to this procedure. Care must be taken to avoid excess trauma to the duct and associated sublingual glands as this can lead to ranula formation; a ranula is a retention cyst on the floor of the mouth.",
"   </p>",
"   <p>",
"    Proximal stones are more challenging to remove transorally, although technically achievable [",
"    <a class=\"abstract\" href=\"UTD.htm?22/2/22568/abstract/27\">",
"     27",
"    </a>",
"    ]. The increased dissection required through a limited exposure may lead to a greater risk of trauma to surrounding nerves. Additionally, multiple procedures may be required when the initial attempt is unsuccessful. Growing experience with combining endoscopic and open intraoral techniques has led to improved success rates in removing proximal stones [",
"    <a class=\"abstract\" href=\"UTD.htm?22/2/22568/abstract/37,38\">",
"     37,38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Transcervical excision is typically reserved for cases where transoral or minimally invasive approaches have been unsuccessful or for a patient who would not tolerate a potential second procedure. Transcervical excision is a more difficult procedure and risks injury to the lingual and hypoglossal nerves [",
"    <a class=\"abstract\" href=\"UTD.htm?22/2/22568/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Parotid stones are far less likely to be approachable transorally. Thus, other minimally invasive or open approaches are usually used to remove stones that are not near the distal aspect of the orifice of Stensen's duct. Parotidectomy is typically a last resort, reserved for patients who have failed less invasive approaches and whose symptoms warrant the additional risk to the auriculotemporal nerve (a branch of cranial nerve V) and facial nerve during dissection [",
"    <a class=\"abstract\" href=\"UTD.htm?22/2/22568/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Evidence from series of patients with sialadenectomy for chronic sialadenitis suggests that facial nerve injuries are common. As an example, one series found that facial nerve injury occurred in 29 percent of parotidectomies and 12 percent of submandibular gland excisions performed for chronic sialadenitis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/2/22568/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sialolithiasis can lead to secondary infection as a result of ductal obstruction and stasis; this is a particular problem in older adult patients [",
"    <a class=\"abstract\" href=\"UTD.htm?22/2/22568/abstract/19\">",
"     19",
"    </a>",
"    ]. While these infections are often minor and respond rapidly to antibiotics, a small number progress to extensive cellulitis and abscess formation with the potential to compromise the airway.",
"   </p>",
"   <p>",
"    In patients with chronic sialadenitis, the involved gland may become dysfunctional. This can result in a significant drop in measured basal salivary flow rates, if a submandibular gland is involved, since the submandibular glands contribute 70 percent of the oral salivary flow [",
"    <a class=\"abstract\" href=\"UTD.htm?22/2/22568/abstract/43\">",
"     43",
"    </a>",
"    ]. The drop in salivary flow rarely has any clinical consequences, however. Glands that have been compromised can still have return of function up to 75 percent of the time after removal of a stone, as long as the gland and duct are left intact [",
"    <a class=\"abstract\" href=\"UTD.htm?22/2/22568/abstract/44\">",
"     44",
"    </a>",
"    ]. However, once a gland has regressed from chronic obstruction it will never recover significant function. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Chronic obstruction'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    In patients who have undergone transoral surgical stone removal, recurrence has been reported in 18 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?22/2/22568/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?5/14/5346?source=see_link\">",
"       \"Patient information: Parotitis (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Salivary gland stones primarily are found in the three major salivary glands: parotid, submandibular, and sublingual. Eighty to 90 percent of stones arise from the submandibular glands, most often occurring as single stones within Wharton's duct. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Anatomy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Dehydration, anticholinergic medications, and trauma are felt to predispose to the formation of stones. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Etiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Sialolithiasis typically presents with pain and swelling, though painless swelling may occur. Symptoms may be intermittent. For the submandibular gland, palpation of the floor of the mouth in a posterior to anterior direction, with mouth slightly closed for relaxation, may find a stone impacted in Wharton's duct. For the parotid gland, the buccal mucosa around the Stensen's duct orifice, and the path of the duct from the earlobe attachment to the jaw line should be palpated bimanually. Pain, swelling, erythema, and purulent drainage are seen with acute sialadenitis, which may cause systemic symptoms. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      High-resolution noncontrast CT scan is helpful when stones are suspected but not palpable; sialography is rarely performed. Ultrasonography is an alternative diagnostic test when CT is not available. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The differential diagnosis of salivary gland stones includes infection (viral or bacterial sialadenitis, HIV), Sj&ouml;gren's syndrome, sarcoidosis, and malnutrition. Malignant tumors of the salivary gland should be considered when there is failure of swelling to respond to treatment, involvement of minor salivary gland tumors, facial nerve dysfunction, or a firm fixed mass. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Conservative management is the initial mainstay of treatment in primary care; patients should be instructed to keep well hydrated, apply moist heat to the involved area, massage the gland, \"milk\" the duct, and suck on tart hard candies to promote salivary flow. Pain should be managed with NSAIDs or occasionally opioid analgesics. Anticholinergic medications should be discontinued when possible. Patients with symptoms persisting for more than a few days should be referred for specialist management.",
"      <br/>",
"      <br/>",
"      Suspected sialadenitis should be treated with an antistaphylococcal antibiotic (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?3/11/3253?source=see_link\">",
"       dicloxacillin",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/37/37462?source=see_link\">",
"       cephalexin",
"      </a>",
"      500 mg four times a day for 7 to 10 days). Infection that worsens or does not respond to antibiotic therapy within 7 to 10 days requires urgent referral. (See",
"      <a class=\"local\" href=\"#H31\">",
"       'General approach'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Intervention is usually avoided during acute infection. Stones less than 2 mm will often pass without intervention. Interventional procedures include endoscopy, lithotripsy, wire basket extraction under fluoroscopy, and surgery via a transoral approach. Sialadenectomy remains an important modality of treatment but is usually reserved for patients with recurrent stones or failed minimally invasive procedures. Sialadenectomy has the potential for damage to lingual, hypoglossal, and facial nerves. (See",
"      <a class=\"local\" href=\"#H30\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22568/abstract/1\">",
"      Williams MF. Sialolithiasis. Otolaryngol Clin North Am 1999; 32:819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22568/abstract/2\">",
"      Escudier MP, McGurk M. Symptomatic sialoadenitis and sialolithiasis in the English population, an estimate of the cost of hospital treatment. Br Dent J 1999; 186:463.",
"     </a>",
"    </li>",
"    <li>",
"     Pfaff J, Moore GP. Otolaryngology. In: Rosen's Emergency Medicine: Concepts and Clinical Practice, Marx J (Ed), Mosby Inc, St. Louis 2002. p.935.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22568/abstract/4\">",
"      McKenna JP, Bostock DJ, McMenamin PG. Sialolithiasis. Am Fam Physician 1987; 36:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22568/abstract/5\">",
"      Rice DH. Noninflammatory, non-neoplastic disorders of the salivary glands. Otolaryngol Clin North Am 1999; 32:835.",
"     </a>",
"    </li>",
"    <li>",
"     Work WP, Hecht, DW. Inflammatory Diseases of the Major Salivary Glands. In: Otolaryngology, Papparella MM, Shumrick DF (Eds), WB Saunders, Philadelphia 1980. p.2235.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22568/abstract/7\">",
"      Huoh KC, Eisele DW. Etiologic factors in sialolithiasis. Otolaryngol Head Neck Surg 2011; 145:935.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22568/abstract/8\">",
"      Paterson JR, Murphy MJ. Bones, groans, moans... and salivary stones? J Clin Pathol 2001; 54:412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22568/abstract/9\">",
"      Ellies M, Laskawi R, Arglebe C, Schott A. Surgical management of nonneoplastic diseases of the submandibular gland. A follow-up study. Int J Oral Maxillofac Surg 1996; 25:285.",
"     </a>",
"    </li>",
"    <li>",
"     Salivary gland anatomy and physiology. In: Head and Neck Imaging, Som PM, Curtain HD (Eds), Mosby, St. Louis 2003.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22568/abstract/11\">",
"      Bryan RN, Miller RH, Ferreyro RI, Sessions RB. Computed tomography of the major salivary glands. AJR Am J Roentgenol 1982; 139:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22568/abstract/12\">",
"      van den Akker HP. Diagnostic imaging in salivary gland disease. Oral Surg Oral Med Oral Pathol 1988; 66:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22568/abstract/13\">",
"      Alyas F, Lewis K, Williams M, et al. Diseases of the submandibular gland as demonstrated using high resolution ultrasound. Br J Radiol 2005; 78:362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22568/abstract/14\">",
"      Zbaren P, Ducommun JC. Diagnosis of salivary gland disease using ultrasound and sialography: a comparison. Clin Otolaryngol Allied Sci 1989; 14:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22568/abstract/15\">",
"      Hasson O. Modern sialography for screening of salivary gland obstruction. J Oral Maxillofac Surg 2010; 68:276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22568/abstract/16\">",
"      Fischbach R, Kugel H, Ernst S, et al. MR sialography: initial experience using a T2-weighted fast SE sequence. J Comput Assist Tomogr 1997; 21:826.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22568/abstract/17\">",
"      J&auml;ger L, Menauer F, Holzknecht N, et al. Sialolithiasis: MR sialography of the submandibular duct--an alternative to conventional sialography and US? Radiology 2000; 216:665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22568/abstract/18\">",
"      Kalinowski M, Heverhagen JT, Rehberg E, et al. Comparative study of MR sialography and digital subtraction sialography for benign salivary gland disorders. AJNR Am J Neuroradiol 2002; 23:1485.",
"     </a>",
"    </li>",
"    <li>",
"     Chow A. Infections of the Oral Cavity, Neck, and Head. In: Principles and Practice of Infectious Diseases, Mandell G, Bennett JE, Dolin R (Eds), Churchill Livingstone, Inc., Philadelphia 2000. p.699.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22568/abstract/20\">",
"      McQuone SJ. Acute viral and bacterial infections of the salivary glands. Otolaryngol Clin North Am 1999; 32:793.",
"     </a>",
"    </li>",
"    <li>",
"     Diaz D. Oral Cavity and Salivary Gland Disease. In: Textbook of Primary Care Medicine, Noble J (Ed), Mosby, Inc, St. Louis 2001.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22568/abstract/22\">",
"      Gottesman RI, Som PM, Mester J, Silvers A. Observations on two cases of apparent submandibular gland cysts in HIV positive patients: MR and CT findings. J Comput Assist Tomogr 1996; 20:444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22568/abstract/23\">",
"      Koischwitz D, Gritzmann N. Ultrasound of the neck. Radiol Clin North Am 2000; 38:1029.",
"     </a>",
"    </li>",
"    <li>",
"     Ward MJ, Levine PA. Salivary gland tumors. In: Essentials of Head and Neck Oncology, 1st ed, Close LG, Larson DL, Shah JP (Eds), Thieme, New York 1998.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22568/abstract/25\">",
"      Spiro RH. Salivary neoplasms: overview of a 35-year experience with 2,807 patients. Head Neck Surg 1986; 8:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22568/abstract/26\">",
"      Eveson JW, Cawson RA. Salivary gland tumours. A review of 2410 cases with particular reference to histological types, site, age and sex distribution. J Pathol 1985; 146:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22568/abstract/27\">",
"      Iro H, Zenk J, Escudier MP, et al. Outcome of minimally invasive management of salivary calculi in 4,691 patients. Laryngoscope 2009; 119:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22568/abstract/28\">",
"      Iro H, Zenk J, Waldfahrer F, et al. Extracorporeal shock wave lithotripsy of parotid stones. Results of a prospective clinical trial. Ann Otol Rhinol Laryngol 1998; 107:860.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22568/abstract/29\">",
"      Raif J, Vardi M, Nahlieli O, Gannot I. An Er:YAG laser endoscopic fiber delivery system for lithotripsy of salivary stones. Lasers Surg Med 2006; 38:580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22568/abstract/30\">",
"      Drage NA, Brown JE, Escudier MP, McGurk M. Interventional radiology in the removal of salivary calculi. Radiology 2000; 214:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22568/abstract/31\">",
"      Brown JE, Drage NA, Escudier MP, et al. Minimally invasive radiologically guided intervention for the treatment of salivary calculi. Cardiovasc Intervent Radiol 2002; 25:352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22568/abstract/32\">",
"      Nahlieli O, Baruchin AM. Endoscopic technique for the diagnosis and treatment of obstructive salivary gland diseases. J Oral Maxillofac Surg 1999; 57:1394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22568/abstract/33\">",
"      Nahlieli O, Nakar LH, Nazarian Y, Turner MD. Sialoendoscopy: A new approach to salivary gland obstructive pathology. J Am Dent Assoc 2006; 137:1394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22568/abstract/34\">",
"      Strychowsky JE, Sommer DD, Gupta MK, et al. Sialendoscopy for the management of obstructive salivary gland disease: a systematic review and meta-analysis. Arch Otolaryngol Head Neck Surg 2012; 138:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22568/abstract/35\">",
"      Luers JC, Grosheva M, Stenner M, Beutner D. Sialoendoscopy: prognostic factors for endoscopic removal of salivary stones. Arch Otolaryngol Head Neck Surg 2011; 137:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22568/abstract/36\">",
"      Marchal F, Dulguerov P, Becker M, et al. Specificity of parotid sialendoscopy. Laryngoscope 2001; 111:264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22568/abstract/37\">",
"      Zhang L, Escudier M, Brown J, et al. Long-term outcome after intraoral removal of large submandibular gland calculi. Laryngoscope 2010; 120:964.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22568/abstract/38\">",
"      Wallace E, Tauzin M, Hagan J, et al. Management of giant sialoliths: review of the literature and preliminary experience with interventional sialendoscopy. Laryngoscope 2010; 120:1974.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22568/abstract/39\">",
"      Marchal F, Dulguerov P. Sialolithiasis management: the state of the art. Arch Otolaryngol Head Neck Surg 2003; 129:951.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22568/abstract/40\">",
"      Zenk J, Constantinidis J, Al-Kadah B, Iro H. Transoral removal of submandibular stones. Arch Otolaryngol Head Neck Surg 2001; 127:432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22568/abstract/41\">",
"      Sinha UK, Ng M. Surgery of the salivary glands. Otolaryngol Clin North Am 1999; 32:887.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22568/abstract/42\">",
"      Bates D, O'Brien CJ, Tikaram K, Painter DM. Parotid and submandibular sialadenitis treated by salivary gland excision. Aust N Z J Surg 1998; 68:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22568/abstract/43\">",
"      Jacob RF, Weber RS, King GE. Whole salivary flow rates following submandibular gland resection. Head Neck 1996; 18:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22568/abstract/44\">",
"      Briffa NP, Callum KG. Use of an embolectomy catheter to remove a submandibular duct stone. Br J Surg 1989; 76:814.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6854 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-89.32.226.102-36135ECCB4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_2_22568=[""].join("\n");
var outline_f22_2_22568=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H37\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ANATOMY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Parotid glands and Stensen's duct",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Submandibular glands and Wharton's duct",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Sublingual glands",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Minor salivary glands",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Sialadenitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Chronic obstruction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Computerized tomography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Plain films",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Ultrasound",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Sialography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Magnetic resonance imaging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Viral sialadenitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Acute bacterial sialadenitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Chronic bacterial sialadenitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Human immunodeficiency virus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Sj&ouml;gren's syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Sarcoidosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Radiation sialadenitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Malnutrition",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Salivary gland tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      General approach",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Lithotripsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Wire basket retrieval",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Sialoendoscopy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H577252247\">",
"      Surgical intervention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PC/6854\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/6854|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?6/19/6449\" title=\"figure 1\">",
"      Salivary gland anatomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/6854|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?38/56/39823\" title=\"picture 1\">",
"      Sialolith",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?23/61/24528\" title=\"picture 2\">",
"      Sialolith constrict frenulum",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/25/21914?source=related_link\">",
"      Clinical manifestations and diagnosis of sarcoidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/1/11287?source=related_link\">",
"      Clinical manifestations of Sj&ouml;gren's syndrome: Exocrine gland disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/61/8154?source=related_link\">",
"      Epidemiology, clinical manifestations, diagnosis and management of mumps",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/24/7558?source=related_link\">",
"      Evaluation of a neck mass",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?5/14/5346?source=related_link\">",
"      Patient information: Parotitis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/44/9927?source=related_link\">",
"      Salivary gland tumors: Epidemiology, diagnosis, evaluation, and staging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/14/22758?source=related_link\">",
"      Suppurative parotitis in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_2_22569="Trauma in pregnancy";
var content_f22_2_22569=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Trauma in pregnancy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/2/22569/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/2/22569/contributors\">",
"     Sarah J Kilpatrick, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/2/22569/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/2/22569/contributors\">",
"     Charles J Lockwood, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/2/22569/contributors\">",
"     Scott Manaker, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/2/22569/contributors\">",
"     Maria E Moreira, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/2/22569/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/2/22569/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?22/2/22569/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 22, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evaluation of the pregnant trauma patient presents unique challenges since the presence of a fetus means that there are two patients potentially at risk, both of whom require evaluation and management. Knowledge of pregnancy-related anatomic and physiologic changes is also important in the evaluation and management of these women.",
"   </p>",
"   <p>",
"    Issues specific to the pregnant trauma patient will be discussed here. Issues related to management of trauma in the nonpregnant population are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/11/35002?source=see_link\">",
"     \"Initial management of trauma in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INCIDENCE AND ETIOLOGY OF TRAUMA IN PREGNANT WOMEN",
"    </span>",
"    &nbsp;&mdash;&nbsp;Trauma is a major contributor to maternal mortality, and is the leading cause of pregnancy-associated maternal deaths in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?22/2/22569/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. In 2002, there were 4.1 injury-related hospitalizations of pregnant women per 1000 deliveries in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?22/2/22569/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Motor vehicle crashes are responsible for approximately two-thirds of maternal trauma cases in developed countries, while domestic violence, other assaults, falls, burns, and suicide account for the majority of the remainder [",
"    <a class=\"abstract\" href=\"UTD.htm?22/2/22569/abstract/3-7\">",
"     3-7",
"    </a>",
"    ]. In fact, pregnancy appears to be a risk factor for being assaulted. Between 1993 and 1998, homicide was the leading cause of death among pregnant or recently pregnant women in Maryland and accounted for 20 percent of these deaths, but it was only the fifth leading cause of death among nonpregnant women [",
"    <a class=\"abstract\" href=\"UTD.htm?22/2/22569/abstract/8\">",
"     8",
"    </a>",
"    ]. In another American series, 5 percent of female homicide victims were murdered while pregnant [",
"    <a class=\"abstract\" href=\"UTD.htm?22/2/22569/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/16/18696?source=see_link\">",
"     \"Community violence\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/41/5784?source=see_link&amp;anchor=H86601695#H86601695\">",
"     \"Intimate partner violence: Epidemiology and health consequences\", section on 'Pregnancy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PREGNANCY-RELATED CONSIDERATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Changes in major organ systems",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pertinent changes in major organ systems are summarized below. An in-depth review of each topic can be found separately.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Cardiovascular system",
"      </strong>",
"      &mdash; Cardiac output progressively increases beginning in the first trimester; most of the increase occurs by 20 weeks of gestation (",
"      <a class=\"graphic graphic_figure graphicRef54685 graphicRef61948 graphicRef55985 \" href=\"UTD.htm?20/30/20963\">",
"       figure 1A-C",
"      </a>",
"      ). Heart rate increases by approximately 15 beats per minute beginning in the first trimester, while systolic and diastolic blood pressure decrease by a mean of 10 mmHg due to reduced systemic vascular resistance. The blood pressure nadir occurs at about 28 weeks of gestation, after which blood pressure slowly rises back to its prepregnancy baseline. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/40/20105?source=see_link\">",
"       \"Maternal cardiovascular and hemodynamic adaptations to pregnancy\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      The heart is rotated toward the left, resulting in a 15 to 20&ordm; left axis deviation. Other findings, which can be normal, include transient ST segment and T wave changes, the presence of a Q wave and inverted T waves in lead III, an attenuated Q wave in lead AVF, and inverted T waves in leads V1, V2 and, occasionally, V3.",
"     </li>",
"     <li>",
"      <strong>",
"       Pulmonary&nbsp;system",
"      </strong>",
"      &mdash; Lung volume changes occur by 20 weeks of gestation and include a decrease in functional residual capacity and an increase in tidal volume. There is no change in FEV1 or in respiratory rate. Respiratory alkalosis due to physiologic hyperventilation with a compensatory metabolic acidosis also occurs during pregnancy. This results in low arterial carbon dioxide tension (PaCO2), elevated arterial oxygen tension (PaO2), and low bicarbonate concentration (",
"      <a class=\"graphic graphic_table graphicRef78192 \" href=\"UTD.htm?2/22/2411\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/37/32340?source=see_link\">",
"       \"Respiratory tract changes during pregnancy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Hematological system",
"      </strong>",
"      &mdash; The plasma volume of pregnant women increases by 45 percent over that of nonpregnant women beginning at six to eight weeks of gestation. A dilutional (physiologic) anemia of pregnancy results from a greater rise in plasma volume compared to red cell volume. Hemoglobin levels as low as 10.5",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      are considered normal in pregnant women and not suggestive of",
"      <span class=\"nowrap\">",
"       anemia/hemorrhage.",
"      </span>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/12/21703?source=see_link\">",
"       \"Hematologic changes in pregnancy\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      The normal pregnant woman's white blood cell count ranges from 6000 to 16,000",
"      <span class=\"nowrap\">",
"       cell/mm3",
"      </span>",
"      in the first and second trimesters, and may rise as high as 20,000 to 30,000",
"      <span class=\"nowrap\">",
"       cells/mm3",
"      </span>",
"      during labor. Thus, leukocytosis can be a normal finding in pregnant women. A normal fibrinogen concentration in pregnancy is greater than 200",
"      <span class=\"nowrap\">",
"       mg/dL.",
"      </span>",
"      <br/>",
"      <br/>",
"      A fibrinogen &lt;200",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      and thrombocytopenia suggest disseminated intravascular coagulation (DIC), a complication of severe abruption. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Abruptio placentae'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      <strong>",
"       Gastrointestinal system",
"      </strong>",
"      &mdash; Pregnant women are predisposed to gastric aspiration due to increased intraabdominal pressure and relaxation of the lower esophageal sphincter. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/60/9160?source=see_link\">",
"       \"Maternal gastrointestinal tract adaptation to pregnancy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Renal system",
"      </strong>",
"      &mdash; The glomerular hyperfiltration results in a normal reduction in the plasma creatinine concentration to about 0.4 to 0.5",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (35 to 44",
"      <span class=\"nowrap\">",
"       micromol/L);",
"      </span>",
"      thus, a \"normal\" level of 0.8",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (70",
"      <span class=\"nowrap\">",
"       micromol/L)",
"      </span>",
"      during pregnancy represents a mild decline in renal function. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/32/24072?source=see_link\">",
"       \"Renal and urinary tract physiology in normal pregnancy\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Increased risk of IVC compression",
"    </span>",
"    &nbsp;&mdash;&nbsp;The uterus reaches the level of the maternal umbilicus by approximately 20 weeks of gestation, at which point, it is large enough to compress the inferior vena cava (IVC) when the woman is supine and result in up to a 30 percent reduction in cardiac output [",
"    <a class=\"abstract\" href=\"UTD.htm?22/2/22569/abstract/10\">",
"     10",
"    </a>",
"    ]. The subsequent reduction in preload results in a significant fall in stroke volume. Healthy women compensate for this phenomenon by increasing systemic vascular resistance and heart rate, but many become hypotensive, diaphoretic, lightheaded, and nauseous. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/40/20105?source=see_link\">",
"     \"Maternal cardiovascular and hemodynamic adaptations to pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Displacing the uterus to the left, off the vena cava, is critical to restoring cardiac output. This is best accomplished by placing the woman on her left side, but putting a wedge or rolled towel under her right side, or adjusting her platform to a 30&ordm; left lateral tilt is also useful. Left-sided tilt should be utilized whenever possible for all women after 20 weeks of gestation during trauma evaluation or during surgery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Cardiopulmonary resuscitation (CPR)",
"    </span>",
"    &nbsp;&mdash;&nbsp;External chest compression is more difficult during pregnancy because of reduced chest compliance in pregnant women [",
"    <a class=\"abstract\" href=\"UTD.htm?22/2/22569/abstract/11\">",
"     11",
"    </a>",
"    ]. Although the abdominal contents push the diaphragm and, in turn, the heart, more cephalad, there are no guidelines for hand position on the sternum specific for pregnant women.",
"   </p>",
"   <p>",
"    External chest compression for cardiac arrest may not be effective in the late second and third trimesters because aortocaval compression in the supine position significantly reduces cardiac output (see above) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/2/22569/abstract/12\">",
"     12",
"    </a>",
"    ]. In some instances, emptying the uterus by performing a cesarean delivery is required to perform effective CPR and save the mother's life [",
"    <a class=\"abstract\" href=\"UTD.htm?22/2/22569/abstract/13\">",
"     13",
"    </a>",
"    ]. Several studies have suggested that the best fetal and maternal outcomes are achieved if a cesarean delivery is performed within four to five minutes of a cardiac arrest if maternal resuscitation has not been successful [",
"    <a class=\"abstract\" href=\"UTD.htm?22/2/22569/abstract/12-15\">",
"     12-15",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Cesarean delivery'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Increased vascularity and blood flow",
"    </span>",
"    &nbsp;&mdash;&nbsp;The dilated pelvic vasculature increases the risk of retroperitoneal hemorrhage from abdominal or pelvic injury [",
"    <a class=\"abstract\" href=\"UTD.htm?22/2/22569/abstract/16\">",
"     16",
"    </a>",
"    ]. Rapid exsanguination can occur since blood flow to the uterus is as high as 600",
"    <span class=\"nowrap\">",
"     mL/min.",
"    </span>",
"   </p>",
"   <p>",
"    Fetal",
"    oxygenation is dependent, in part, upon uterine blood flow. Uterine blood flow is not autoregulated, thus a decrease in maternal systolic blood pressure can cause a significant fall in uterine blood flow, and in turn, fetal oxygenation. Uterine blood flow can also be reduced from vasoconstriction related to drugs or maternal hypercarbia or hypocarbia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Changes in the abdomen",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pregnancy alters the pattern of maternal injury such that pregnant women are more likely than nonpregnant women to sustain abdominal trauma [",
"    <a class=\"abstract\" href=\"UTD.htm?22/2/22569/abstract/17\">",
"     17",
"    </a>",
"    ]. The enlarged uterus reduces the risk of visceral injury after lower abdominal penetrating injuries by displacing the bowel cephalad and laterally. However, penetrating injuries above the uterine fundus are likely to damage the bowel for the same reason [",
"    <a class=\"abstract\" href=\"UTD.htm?22/2/22569/abstract/18\">",
"     18",
"    </a>",
"    ]. The enlarged uterus also shields retroperitoneal structures from penetrating abdominal trauma.",
"   </p>",
"   <p>",
"    Rebound tenderness and guarding may be less prominent than in nonpregnant women because the gravid uterus lifts and stretches the anterior abdominal wall, potentially impeding contact between areas of inflammation and parietal peritoneum.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     EVALUATION AND MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Optimal care of the pregnant trauma patient requires good communication among a multidisciplinary group of physicians. The obstetrical service should be consulted to help with the evaluation and to determine whether emergent cesarean delivery is indicated. Any treatment required to save the mother's life or treat her critical status should be undertaken, even if such intervention is potentially disadvantageous to the fetus. Short- and long-term morbidity in surviving fetuses are usually related to the direct and indirect consequences of maternal trauma (eg, hypotension, hypoxemia, abruptio placentae, preterm birth), but direct fetal injury sometimes occurs [",
"    <a class=\"abstract\" href=\"UTD.htm?22/2/22569/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Assessment/stabilization",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial evaluation is focused upon establishing maternal cardiopulmonary stability: airway, breathing, and circulation [",
"    <a class=\"abstract\" href=\"UTD.htm?22/2/22569/abstract/20\">",
"     20",
"    </a>",
"    ]. Displacement of a large uterus off the IVC is an important component of this process (see",
"    <a class=\"local\" href=\"#H5\">",
"     'Increased risk of IVC compression'",
"    </a>",
"    above). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/25/36248?source=see_link\">",
"     \"Basic life support (BLS) in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/33/13850?source=see_link\">",
"     \"Advanced cardiac life support (ACLS) in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/22/20840?source=see_link\">",
"     \"Management of cardiopulmonary arrest in pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    After, or simultaneous with, stabilizing the gravida, the uterine size, gestational age, and fetal viability should be determined by physical examination and ultrasound. This information is crucial when making decisions about management of both the mother and baby. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/47/34553?source=see_link\">",
"     \"Prenatal assessment of gestational age\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The provider should administer antenatal glucocorticoids to women at risk of preterm birth, according to standard guidelines. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/55/31610?source=see_link\">",
"     \"Antenatal corticosteroid therapy for reduction of neonatal morbidity and mortality from preterm delivery\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Fetal monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;Maternal trauma can compromise the fetus as a result of maternal hypotension or hypoxemia, placental abruption, uterine rupture, or fetal trauma. We suggest continuous fetal monitoring of fetuses who have reached viability. The fetal heart rate pattern should be monitored by a physician or nurse experienced in fetal heart rate interpretation. It is important to compare the maternal and fetal heart rates to make sure that the fetal heart rate, not the maternal heart rate, is being monitored. The minimum duration of post-trauma fetal monitoring has not been validated; we suggest a minimum of four hours (see",
"    <a class=\"local\" href=\"#H20\">",
"     'Abruptio placentae'",
"    </a>",
"    below); others have suggested two to six hours [",
"    <a class=\"abstract\" href=\"UTD.htm?22/2/22569/abstract/5,21-23\">",
"     5,21-23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The importance of prompt fetal evaluation and appropriate intervention after maternal trauma was illustrated by a study of 441 pregnant trauma patients in whom fetal and maternal survival were 45 and 72 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?22/2/22569/abstract/14\">",
"     14",
"    </a>",
"    ]. Major findings of this analysis were:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      No fetus with absent fetal heart tones survived emergency delivery, while 75 percent of those with fetal heart tones and gestational age &ge;26 weeks survived.",
"     </li>",
"     <li>",
"      Five infant deaths resulted from delayed recognition of nonreassuring fetal heart rate patterns; three of the five mothers of these infants had only mild or moderate injuries; therefore, these deaths were considered potentially preventable, had fetal monitoring been performed and operative intervention promptly initiated.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Diagnostic imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diagnostic imaging should be undertaken, as needed. Ultrasound is the preferred modality, when appropriate, because of its safety in pregnancy. In some cases, magnetic resonance imaging is the preferred diagnostic modality because it provides better images than ultrasonography, while avoiding the ionizing radiation of computed tomography. When techniques involving ionizing radiation are required, the information obtained nearly always outweighs the radiation risk to the fetus since fetal radiation exposure from diagnostic studies is small [",
"    <a class=\"abstract\" href=\"UTD.htm?22/2/22569/abstract/24\">",
"     24",
"    </a>",
"    ]. The levels of radiation and the risks associated with diagnostic imaging procedures in pregnant women are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/29/28120?source=see_link\">",
"     \"Diagnostic imaging procedures during pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If computed tomography of the abdomen or pelvis is necessary to evaluate the maternal condition, intrauterine pathology (eg, fetal fracture, abruptio placenta) may be diagnosed as well.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Respiratory support",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oxygen supplementation should be used liberally, as anoxia develops more quickly in pregnant women. Maternal oxygen saturation (SaO2) should be maintained at greater than 95 percent during pregnancy, which is in excess of the oxygen delivery needs of the mother. If SaO2 falls below 95 percent, an arterial blood gas is obtained to measure PaO2. Maternal PaO2 greater than 70 mmHg is desirable to maintain a favorable oxygen diffusion gradient from the maternal to the fetal side of the placenta. Early intubation after preoxygenation is recommended if adequate maternal oxygenation has not been achieved. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/18/41256?source=see_link&amp;anchor=H22#H22\">",
"     \"Placental development and physiology\", section on 'Respiratory gas exchange'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Airway edema is more common in pregnant women and can contribute to difficult intubation. Difficulty securing the airway, along with the decreased lower esophageal tone, are the primary factors that increase the risk of aspiration. We suggest applying cricoid pressure to prevent aspiration of gastric contents until the airway has been protected with a cuffed endotracheal tube. The value of cricoid pressure has been questioned in nonpregnant individuals because of some evidence that it may impair gas exchange and ventilation; however, there are no randomized trials that have assessed the efficacy of cricoid pressure in pregnant women. Modifying or releasing cricoid pressure should be considered if there are any problems with ventilation or intubation.",
"   </p>",
"   <p>",
"    If a chest tube is placed, the physician should keep in mind that the diaphragm is elevated in pregnancy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Volume replacement",
"    </span>",
"    &nbsp;&mdash;&nbsp;We place one or two large bore (eg, 14 or 16 gauge) intravenous lines in women who may have been seriously injured. Volume replacement is preferable to vasopressors for blood pressure support since vasopressors can reduce uterine blood flow [",
"    <a class=\"abstract\" href=\"UTD.htm?22/2/22569/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Cesarean delivery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Urgent cesarean delivery may be appropriate in the setting of: imminent maternal death, cardiopulmonary resuscitation that has not been effective within four minutes, or a stable mother with a nonreassuring fetal heart rate tracing [",
"    <a class=\"abstract\" href=\"UTD.htm?22/2/22569/abstract/11\">",
"     11",
"    </a>",
"    ]. A cesarean delivery may also be necessary during laparotomy for repair of maternal injuries if the gravid uterus prevents adequate surgical exposure.",
"   </p>",
"   <p>",
"    Reviews of perimortem cesarean delivery suggest optimum infant and maternal survival are obtained when cesarean delivery is initiated within",
"    <strong>",
"     four minutes",
"    </strong>",
"    of maternal cardiac arrest and the fetus is delivered within five minutes of unsuccessful resuscitation attempts [",
"    <a class=\"abstract\" href=\"UTD.htm?22/2/22569/abstract/12-15\">",
"     12-15",
"    </a>",
"    ]. The principle of cesarean delivery if maternal resuscitative efforts have not been successful after four minutes (the &ldquo;five minute rule&rdquo;) has been adopted by the American Heart Association. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/22/20840?source=see_link&amp;anchor=H2349341435#H2349341435\">",
"     \"Management of cardiopulmonary arrest in pregnancy\", section on '\"Five minute rule\"'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The rationale for this approach is that [",
"    <a class=\"abstract\" href=\"UTD.htm?22/2/22569/abstract/26-28\">",
"     26-28",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Irreversible brain damage can occur in nonpregnant individuals after four to six minutes of anoxia.",
"     </li>",
"     <li>",
"      Pregnant women become anoxic sooner than nonpregnant women because of decreased functional residual capacity.",
"     </li>",
"     <li>",
"      If the uterine fundus &ge;4 fingerbreadths above the umbilicus [",
"      <a class=\"abstract\" href=\"UTD.htm?22/2/22569/abstract/12\">",
"       12",
"      </a>",
"      ], ineffective resuscitation efforts may become effective when the uterus is no longer gravid and potentially causing aortocaval compression.",
"     </li>",
"     <li>",
"      Intact fetal survival diminishes as the time between maternal death and delivery lengthen.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Cesarean delivery for fetal indications is generally avoided before fetal viability. However, deciding upon a threshold of viability is challenging, as it remains uncertain which extremely preterm infants, particularly those born at 23 and 24 weeks of gestation, have a reasonable chance of survival without severe deficits. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/1/27672?source=see_link\">",
"     \"Limit of viability\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Cesarean delivery after maternal cardiopulmonary arrest is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/22/20840?source=see_link&amp;anchor=H9057240#H9057240\">",
"     \"Management of cardiopulmonary arrest in pregnancy\", section on 'Delivery as part of the resuscitation process'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Blunt abdominal trauma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ultrasound examination to look for free fluid in the",
"    <span class=\"nowrap\">",
"     pelvis/abdomen",
"    </span>",
"    appears to be useful in determining whether blunt trauma caused intraabdominal bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?22/2/22569/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/5/19545?source=see_link\">",
"     \"Initial evaluation and management of blunt abdominal trauma in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Obstetrical issues",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once catastrophic trauma has been excluded, the physician must determine whether the patient has any obstetrical complications and attend to treatment of minor or moderate traumatic injuries. The likelihood of obstetrical complications is related, in part, to the gestational age and the severity and type of trauma. The majority of women who develop adverse obstetrical outcomes have symptoms such as contractions, vaginal bleeding, and abdominal pain upon initial presentation [",
"    <a class=\"abstract\" href=\"UTD.htm?22/2/22569/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Uterine rupture",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sharp or blunt abdominal trauma can lead to uterine rupture [",
"    <a class=\"abstract\" href=\"UTD.htm?22/2/22569/abstract/18,32-37\">",
"     18,32-37",
"    </a>",
"    ]. Signs and symptoms include shock, nonreassuring fetal heart rate tracing or fetal death, uterine tenderness, peritoneal irritation, and vaginal bleeding. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/10/5290?source=see_link&amp;anchor=H15065397#H15065397\">",
"     \"Choosing the route of delivery after cesarean birth\", section on 'Uterine rupture'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Penetrating abdominal trauma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gunshot wounds are more common than stab wounds in pregnancy and, interestingly, death from gunshot or stab wounds is less common in the pregnant than nonpregnant victim [",
"    <a class=\"abstract\" href=\"UTD.htm?22/2/22569/abstract/10\">",
"     10",
"    </a>",
"    ]. The decreased risk of death is likely related to anatomic changes: the enlarged uterus displaces visceral organs superiorly. As a result, upper abdominal penetrating trauma is more likely to injure maternal bowel, while lower abdominal penetrating trauma is more likely to injure the uterus and or fetus. In contrast to nonpregnant victims of abdominal penetrating trauma where immediate surgical exploration is the most common management approach [",
"    <a class=\"abstract\" href=\"UTD.htm?22/2/22569/abstract/10\">",
"     10",
"    </a>",
"    ], in pregnancy, the decision to proceed immediately to surgical exploration is based on location of the injury (upper or lower abdomen) and the uterine size, in addition to maternal and fetal vital signs. If the injury is in the upper abdomen, then surgical exploration is generally the best approach [",
"    <a class=\"abstract\" href=\"UTD.htm?22/2/22569/abstract/18\">",
"     18",
"    </a>",
"    ]. If the injury is in the lower abdomen and mother and fetus are stable, then a more conservative approach, including observation, laparoscopy, and wound exploration, is reasonable [",
"    <a class=\"abstract\" href=\"UTD.htm?22/2/22569/abstract/10,18\">",
"     10,18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Abruptio placentae",
"    </span>",
"    &nbsp;&mdash;&nbsp;The reported incidence of abruptio placentae after trauma varies, but is consistently higher than the rate in the general obstetrical population (0.4 to 1.3 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/2/22569/abstract/5,38-41\">",
"     5,38-41",
"    </a>",
"    ]. In one large series, the frequency of abruption after a motor vehicle accident with severe injury, nonsevere injury, or no injury was 13, 7.4, and 8.5 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?22/2/22569/abstract/41\">",
"     41",
"    </a>",
"    ]. However, the rate can be much higher (40 to 66 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?22/2/22569/abstract/42\">",
"     42",
"    </a>",
"    ]) in women who sustain severe trauma to the abdomen.",
"   </p>",
"   <p>",
"    Significant direct abdominal trauma, abdominal or uterine tenderness, or vaginal bleeding are suggestive of an abruption and warrant fetal and uterine monitoring and laboratory assessment. It is important to remember that abruption leading to nonreassuring fetal heart rate patterns and fetal death can occur despite relatively mild maternal trauma or discomfort [",
"    <a class=\"abstract\" href=\"UTD.htm?22/2/22569/abstract/40\">",
"     40",
"    </a>",
"    ]. More than one-half of fetal losses are related to minor trauma since most maternal traumatic events are not serious.",
"   </p>",
"   <p>",
"    The diagnosis of abruption is based upon the presence of characteristic clinical features; however, a significant abruption can be asymptomatic or associated with minimal maternal symptoms. Sonographic and laboratory assessments (eg, platelet count, fibrinogen concentration) support the diagnosis if abnormal, but may be normal despite mild to moderate pathology. Ultrasound is of limited usefulness in diagnosing abruption; an abruption is likely if a subchorionic hematoma is observed, but many abruptions are not visualized sonographically [",
"    <a class=\"abstract\" href=\"UTD.htm?22/2/22569/abstract/43\">",
"     43",
"    </a>",
"    ]. Computed tomography (CT) is never used clinically for evaluation of the placenta, but if performed as part of a maternal trauma evaluation, it may show findings consistent with abruption [",
"    <a class=\"abstract\" href=\"UTD.htm?22/2/22569/abstract/44\">",
"     44",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/46/29417?source=see_link\">",
"     \"Placental abruption: Clinical features and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For pregnancies that have been subjected to abdominal trauma and have reached the stage of fetal viability, we suggest continuous fetal and uterine monitoring with an external fetal heart rate and tocodynamometer to assess for preterm labor and abruption. The importance of fetal heart rate and uterine contraction monitoring lies in its negative predictive value for abruptio placentae. As an example, one study reported no adverse outcomes directly related to trauma when monitoring was normal and early warning symptoms (bleeding, abdominal pain) were absent (negative predictive value 100 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/2/22569/abstract/5\">",
"     5",
"    </a>",
"    ]. In contrast, the presence of vaginal bleeding, uterine contractions, abnormal fetal heart rate monitoring,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    abdominal pain or uterine tenderness was not predictive of either preterm delivery or adverse pregnancy outcome (sensitivity and specificity 52 and 48 percent, respectively).",
"   </p>",
"   <p>",
"    The amount of time the woman should be monitored is controversial, with recommendations ranging from 4 to 48 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?22/2/22569/abstract/5,21-23\">",
"     5,21-23",
"    </a>",
"    ]. The rationale for a prolonged period of monitoring is concern about delayed abruption, which has been reported up to six days after a traumatic event [",
"    <a class=\"abstract\" href=\"UTD.htm?22/2/22569/abstract/22,45\">",
"     22,45",
"    </a>",
"    ]. However, the risk of a delayed abruption is extremely low. In the study described above [",
"    <a class=\"abstract\" href=\"UTD.htm?22/2/22569/abstract/5\">",
"     5",
"    </a>",
"    ], repetitive monitoring over several days did not uncover any patients whose fetal heart rate tracings evolved from normal to abnormal.",
"   </p>",
"   <p>",
"    We suggest discontinuing continuous monitoring after four hours if",
"    <strong>",
"     all",
"    </strong>",
"    of the following criteria are met [",
"    <a class=\"abstract\" href=\"UTD.htm?22/2/22569/abstract/5,31,46\">",
"     5,31,46",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Uterine contractions less frequent than 1 in 10 minutes,",
"     </li>",
"     <li>",
"      Absence of vaginal bleeding,",
"     </li>",
"     <li>",
"      Absence of abdominal pain, and",
"     </li>",
"     <li>",
"      Reassuring fetal heart rate tracing",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The woman may be discharged if there are no maternal conditions requiring attention.",
"   </p>",
"   <p>",
"    We suggest a minimum 24-hour period of monitoring for women with any of the following: abdominal bruising or other obvious injury, regular contractions, vaginal bleeding, a nonreassuring fetal heart rate tracing,",
"    <span class=\"nowrap\">",
"     abdominal/uterine",
"    </span>",
"    pain, or suspicion of coagulopathy (eg, low platelets or fibrinogen &lt; 200",
"    <span class=\"nowrap\">",
"     mg/dL).",
"    </span>",
"    These patients should not be discharged until the clinician is reasonably sure that they do not have an abruption or preterm labor.",
"   </p>",
"   <p>",
"    Abruption is managed according to usual obstetrical protocols. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/46/29417?source=see_link\">",
"     \"Placental abruption: Clinical features and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/54/34663?source=see_link\">",
"     \"Placental abruption: Management\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Fetomaternal hemorrhage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fetomaternal hemorrhage has been reported in 2.6 to 30 percent of pregnant trauma patients [",
"    <a class=\"abstract\" href=\"UTD.htm?22/2/22569/abstract/47\">",
"     47",
"    </a>",
"    ]. It is more common in women with an anterior placenta or tender uterus [",
"    <a class=\"abstract\" href=\"UTD.htm?22/2/22569/abstract/21,48\">",
"     21,48",
"    </a>",
"    ]. Complications associated with fetomaternal hemorrhage include fetal anemia, fetal death, and maternal isoimmunization [",
"    <a class=\"abstract\" href=\"UTD.htm?22/2/22569/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The presence of fetomaternal hemorrhage can be evaluated by a Kleihauer-Betke test, which measures the percent of red blood cells containing fetal hemoglobin in maternal blood. Some experts recommend that this test be ordered routinely after abdominal trauma and report fetomaternal hemorrhage rates as high as 47 percent in women with an anterior placenta [",
"    <a class=\"abstract\" href=\"UTD.htm?22/2/22569/abstract/21\">",
"     21",
"    </a>",
"    ]. Others have not found the Kleihauer-Betke test to be useful, except in Rh(D)-negative women, and do not recommend it [",
"    <a class=\"abstract\" href=\"UTD.htm?22/2/22569/abstract/5,31,49,50\">",
"     5,31,49,50",
"    </a>",
"    ]. Most experts suggest a Kleihauer-Betke test be performed in all women with significant abdominal trauma [",
"    <a class=\"abstract\" href=\"UTD.htm?22/2/22569/abstract/23\">",
"     23",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/45/3800?source=see_link\">",
"     \"Diagnosis and management of massive fetomaternal hemorrhage\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Administration of a standard dose of anti-D immune globulin (ie, Rho (D) immune globulin) is recommended for all Rh(D)-negative pregnant women who have experienced abdominal trauma (and are not already alloimmunized) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/2/22569/abstract/51\">",
"     51",
"    </a>",
"    ]; additional doses may be required on rare occasions if a large fetomaternal hemorrhage is suspected and confirmed by Kleihauer-Betke. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/44/40648?source=see_link\">",
"     \"Prevention of Rh(D) alloimmunization\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Preterm labor and premature rupture of membranes",
"    </span>",
"    &nbsp;&mdash;&nbsp;The possibility of preterm labor or premature rupture of membranes should also be considered in the evaluation of these patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/30/5608?source=see_link\">",
"     \"Overview of preterm labor and birth\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/31/15866?source=see_link\">",
"     \"Preterm premature rupture of membranes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     OUTCOME",
"    </span>",
"    &nbsp;&mdash;&nbsp;Potential consequences of trauma during pregnancy include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Maternal injury or death",
"     </li>",
"     <li>",
"      Fetal injury or death",
"     </li>",
"     <li>",
"      Pregnancy complications",
"     </li>",
"     <li>",
"      Any of the complications of trauma in the nonpregnant woman",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Maternal mortality as a result of trauma is not increased by pregnancy, in fact it appears to be decreased compared to nonpregnant women of similar age with equivalent injuries [",
"    <a class=\"abstract\" href=\"UTD.htm?22/2/22569/abstract/17,52\">",
"     17,52",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Influence of gestational age",
"    </span>",
"    &nbsp;&mdash;&nbsp;Trauma in the first trimester does not usually cause pregnancy loss because the uterus is protected by the maternal pelvis. Exceptions are cases complicated by (1) profound maternal hypotension, which leads to reduced uteroplacental blood flow [",
"    <a class=\"abstract\" href=\"UTD.htm?22/2/22569/abstract/53\">",
"     53",
"    </a>",
"    ], or (2) serious maternal pelvic injuries (eg, gunshot wounds, pelvic fracture), which can directly injure the fetus, fetal membranes, uterus, placenta, or uterine vessels. The pregnancy outcome after traumatic events later in pregnancy is difficult to predict.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Influence of trauma severity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Severity of injury is the major factor predictive of maternal death [",
"    <a class=\"abstract\" href=\"UTD.htm?22/2/22569/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Factors predictive of poor fetal outcome are maternal hypotension, nonreassuring fetal heart rate, direct injury to the",
"    <span class=\"nowrap\">",
"     uterus/fetus,",
"    </span>",
"    maternal death, and a high Injury Severity Score (ISS) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/2/22569/abstract/17,53,55-57\">",
"     17,53,55-57",
"    </a>",
"    ]. The highest risk of fetal loss (40 to 50 percent) is among women who sustain life-threatening trauma (eg, with hypovolemic shock, coma, or necessitating emergency laparotomy) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/2/22569/abstract/53\">",
"     53",
"    </a>",
"    ]. Pregnancy loss after minor trauma occurs in fewer than 5 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?22/2/22569/abstract/4\">",
"     4",
"    </a>",
"    ]. However, severe abruption with fetal death can occur after relatively minor maternal abdominal trauma and in the absence of obvious injury [",
"    <a class=\"abstract\" href=\"UTD.htm?22/2/22569/abstract/56\">",
"     56",
"    </a>",
"    ]&nbsp;(see",
"    <a class=\"local\" href=\"#H20\">",
"     'Abruptio placentae'",
"    </a>",
"    above).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Overall outcome",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a population-based study, one in four pregnant women admitted for trauma during the third trimester were delivered [",
"    <a class=\"abstract\" href=\"UTD.htm?22/2/22569/abstract/38\">",
"     38",
"    </a>",
"    ]. Immediate and delayed outcomes after maternal trauma have been evaluated in several large series [",
"    <a class=\"abstract\" href=\"UTD.htm?22/2/22569/abstract/38,39,41,58\">",
"     38,39,41,58",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One retrospective cohort study used an obstetric database in California to obtain a population-based estimate of pregnancy outcomes in over 10,000 women hospitalized due to trauma (",
"      <a class=\"graphic graphic_table graphicRef52506 \" href=\"UTD.htm?22/8/22668\">",
"       table 2",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef72426 \" href=\"UTD.htm?25/36/26188\">",
"       table 3",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?22/2/22569/abstract/38,39,57\">",
"       38,39,57",
"      </a>",
"      ]. Motor vehicle accidents were the most common mechanism of injury, followed by falls and assaults.",
"      <br/>",
"      <br/>",
"      One-quarter of these patients delivered during the hospitalization for the traumatic event; the remainder were discharged and delivered during a subsequent hospitalization. Women who delivered remote from their trauma episode still had significantly increased rates of preterm birth, low birth weight and abruption [",
"      <a class=\"abstract\" href=\"UTD.htm?22/2/22569/abstract/38,39\">",
"       38,39",
"      </a>",
"      ]. The authors hypothesized that late morbidity might have resulted from subclinical chronic abruption.",
"     </li>",
"     <li>",
"      Another retrospective cohort study evaluated the risk of adverse pregnancy outcome following motor vehicle collisions (n = 582) during pregnancy in Washington State from 1989 to 2001 [",
"      <a class=\"abstract\" href=\"UTD.htm?22/2/22569/abstract/41\">",
"       41",
"      </a>",
"      ]. The authors compared 84 severely injured (ISS 9), 309 nonseverely injured (ISS 1&ndash;8), and 189 uninjured (ISS 0) pregnant women to pregnant women who had not been hospitalized for a motor vehicle collision (n = 17,274). Two-thirds of the women were in their third trimester.",
"      <br/>",
"      <br/>",
"      Although 83 percent of the women were hospitalized and discharged without delivering, they still bore a high risk of adverse pregnancy outcomes compared to the women who were not in accidents. Women with severe injuries were more likely to have had fractures, dislocations, sprains, intracranial injuries, open wounds, and internal injuries, but ISS was a poor predictor of adverse pregnancy outcomes (",
"      <a class=\"graphic graphic_table graphicRef78058 \" href=\"UTD.htm?20/38/21099\">",
"       table 4",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Similarly, a third retrospective cohort study from a Texas trauma center reported that women who had experienced traumatic injury, but were discharged from the hospital undelivered, had a significant increase in risk of preterm delivery and low birth weight compared to women who experienced no injury from their trauma [",
"      <a class=\"abstract\" href=\"UTD.htm?22/2/22569/abstract/58\">",
"       58",
"      </a>",
"      ]. By comparison, a population-based cohort study from Australia reported no increase in adverse pregnancy outcome among women admitted to the hospital following a motor vehicle accident but who remained undelivered compared with women not involved in motor vehicle accidents [",
"      <a class=\"abstract\" href=\"UTD.htm?22/2/22569/abstract/59\">",
"       59",
"      </a>",
"      ]. These differences may be due to chance or to differences between studies in the severity of maternal trauma.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prenatal care should incorporate education about correct seat belt use in pregnancy and evaluation for the presence of domestic violence, since the majority of maternal trauma is related to these two entities. Impact severity and use of seat belts were the best predictors of fetal outcome, with severe crash and no seat belt use associated with 100 percent adverse outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?22/2/22569/abstract/60\">",
"     60",
"    </a>",
"    ]. In pregnancy, the lap belt should be placed under the uterus and the shoulder belt should be positioned between the breasts, lateral to the uterus, and over the middle portion of the clavicle [",
"    <a class=\"abstract\" href=\"UTD.htm?22/2/22569/abstract/53\">",
"     53",
"    </a>",
"    ]. This placement is associated with significantly decreased force transmission through the uterus in car crash simulation tests with pregnant dummies [",
"    <a class=\"abstract\" href=\"UTD.htm?22/2/22569/abstract/61\">",
"     61",
"    </a>",
"    ]. Routine instruction on correct seat belt use and its importance in preventing injury and death should decrease these morbidities in pregnant women. In one study, only 68 percent of pregnant women surveyed used seat belts appropriately, but there was a significant increase in proper use with prenatal education [",
"    <a class=\"abstract\" href=\"UTD.htm?22/2/22569/abstract/62\">",
"     62",
"    </a>",
"    ]. Finally, a state-wide study including over 3000 car crashes found that women in vehicles equipped with an airbag did not have a significantly higher frequency of abruption than women in vehicles without an airbag [",
"    <a class=\"abstract\" href=\"UTD.htm?22/2/22569/abstract/63\">",
"     63",
"    </a>",
"    ]. There were four abruptions among the 198 women whose airbag deployed. The pregnant woman's sternum should be at least 10 inches away from a dashboard or steering wheel containing an airbag.",
"   </p>",
"   <p>",
"    Intimate partner violence often begins or, if already present, increases during pregnancy and the postpartum period and may involve homicide [",
"    <a class=\"abstract\" href=\"UTD.htm?22/2/22569/abstract/64-66\">",
"     64-66",
"    </a>",
"    ]. Homicide accounts for a significant proportion of injury-related deaths of pregnant and postpartum women, with the majority of deaths caused by firearms [",
"    <a class=\"abstract\" href=\"UTD.htm?22/2/22569/abstract/1\">",
"     1",
"    </a>",
"    ]. Multiple effective tools are available to detect the presence of intimate partner violence and substance abuse, and one of these tools should be used as part of the initial obstetric prenatal visit [",
"    <a class=\"abstract\" href=\"UTD.htm?22/2/22569/abstract/67\">",
"     67",
"    </a>",
"    ]. These tools are described in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/41/5784?source=see_link&amp;anchor=H86601695#H86601695\">",
"     \"Intimate partner violence: Epidemiology and health consequences\", section on 'Pregnancy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/15/6393?source=see_link\">",
"     \"Intimate partner violence: Diagnosis and screening\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Additional risk factors for trauma during pregnancy include young age and drug or alcohol use; the latter should also be assessed [",
"    <a class=\"abstract\" href=\"UTD.htm?22/2/22569/abstract/47\">",
"     47",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/12/6346?source=see_link\">",
"     \"Overview of illicit drug use in pregnant women\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/38/41575?source=see_link\">",
"     \"Alcohol intake and pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Anatomic and physiologic changes related to pregnancy impact the evaluation and management of pregnant trauma patients. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Changes in major organ systems'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The initial evaluation of the pregnant trauma patient should focus on establishing maternal cardiopulmonary stability. Any treatment required to save the mother's life or treat her critical status should be undertaken, regardless of her pregnancy, including any diagnostic imaging deemed necessary. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Evaluation and management'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H10\">",
"       'Assessment/stabilization'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Displacing the uterus about 30 degrees to the left, off of the vena cava, is critical to maximize effectiveness of cardiopulmonary resuscitation in the second half of pregnancy. In some instances, emptying the uterus by performing a cesarean delivery is required to save the mother's life. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Increased risk of IVC compression'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H6\">",
"       'Cardiopulmonary resuscitation (CPR)'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H15\">",
"       'Cesarean delivery'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Once catastrophic trauma has been excluded, the physician should determine whether the patient has any obstetric complications (eg, abruption, uterine rupture, fetomaternal hemorrhage, preterm labor, premature rupture of membranes). The majority of women who develop adverse obstetrical outcomes have symptoms such as contractions, vaginal bleeding, or abdominal pain upon initial presentation, but some may have minimal symptoms. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Obstetrical issues'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Abruption leading to nonreassuring fetal heart rate patterns and death can occur despite relatively mild maternal trauma or discomfort. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Abruptio placentae'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In pregnancies that have reached the stage of fetal viability, we suggest continuous rather than intermittent fetal and uterine monitoring (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). We monitor patients for at least four hours after even mild abdominal trauma to look for signs of preterm labor and abruption. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Fetal monitoring'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H20\">",
"       'Abruptio placentae'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We discontinue monitoring after a minimum of four hours in women with uterine contractions less frequent than 1 in 10 minutes, absence of vaginal bleeding, absence of abdominal pain, and a normal fetal heart rate tracing. Women with regular contractions, vaginal bleeding, a nonreassuring fetal heart rate tracing,",
"      <span class=\"nowrap\">",
"       abdominal/uterine",
"      </span>",
"      pain, or suspicion of coagulopathy (eg, low platelets or fibrinogen &lt;200",
"      <span class=\"nowrap\">",
"       mg/dL)",
"      </span>",
"      are monitored for at least 24 hours. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Abruptio placentae'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Anti-D immune globulin is administered to unsensitized Rh(D)-negative women who experience abdominal trauma to prevent alloimmunization from fetomaternal hemorrhage. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Fetomaternal hemorrhage'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22569/abstract/1\">",
"      Chang J, Berg CJ, Saltzman LE, Herndon J. Homicide: a leading cause of injury deaths among pregnant and postpartum women in the United States, 1991-1999. Am J Public Health 2005; 95:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22569/abstract/2\">",
"      Fildes J, Reed L, Jones N, et al. Trauma: the leading cause of maternal death. J Trauma 1992; 32:643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22569/abstract/3\">",
"      Kuo C, Jamieson DJ, McPheeters ML, et al. Injury hospitalizations of pregnant women in the United States, 2002. Am J Obstet Gynecol 2007; 196:161.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22569/abstract/4\">",
"      Pak LL, Reece EA, Chan L. Is adverse pregnancy outcome predictable after blunt abdominal trauma? Am J Obstet Gynecol 1998; 179:1140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22569/abstract/5\">",
"      Connolly AM, Katz VL, Bash KL, et al. Trauma and pregnancy. Am J Perinatol 1997; 14:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22569/abstract/6\">",
"      Weiss HB, Songer TJ, Fabio A. Fetal deaths related to maternal injury. JAMA 2001; 286:1863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22569/abstract/7\">",
"      Schiff MA. Pregnancy outcomes following hospitalisation for a fall in Washington State from 1987 to 2004. BJOG 2008; 115:1648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22569/abstract/8\">",
"      Horon IL, Cheng D. Enhanced surveillance for pregnancy-associated mortality--Maryland, 1993-1998. JAMA 2001; 285:1455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22569/abstract/9\">",
"      McFarlane J, Campbell JC, Sharps P, Watson K. Abuse during pregnancy and femicide: urgent implications for women's health. Obstet Gynecol 2002; 100:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22569/abstract/10\">",
"      Muench MV, Canterino JC. Trauma in pregnancy. Obstet Gynecol Clin North Am 2007; 34:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22569/abstract/11\">",
"      Morris S, Stacey M. Resuscitation in pregnancy. BMJ 2003; 327:1277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22569/abstract/12\">",
"      Katz V, Balderston K, DeFreest M. Perimortem cesarean delivery: were our assumptions correct? Am J Obstet Gynecol 2005; 192:1916.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22569/abstract/13\">",
"      Katz VL, Dotters DJ, Droegemueller W. Perimortem cesarean delivery. Obstet Gynecol 1986; 68:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22569/abstract/14\">",
"      Morris JA Jr, Rosenbower TJ, Jurkovich GJ, et al. Infant survival after cesarean section for trauma. Ann Surg 1996; 223:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22569/abstract/15\">",
"      Weber CE. Postmortem cesarean section: review of the literature and case reports. Am J Obstet Gynecol 1971; 110:158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22569/abstract/16\">",
"      Stone IK. Trauma in the obstetric patient. Obstet Gynecol Clin North Am 1999; 26:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22569/abstract/17\">",
"      Shah KH, Simons RK, Holbrook T, et al. Trauma in pregnancy: maternal and fetal outcomes. J Trauma 1998; 45:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22569/abstract/18\">",
"      Awwad JT, Azar GB, Seoud MA, et al. High-velocity penetrating wounds of the gravid uterus: review of 16 years of civil war. Obstet Gynecol 1994; 83:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22569/abstract/19\">",
"      Pearlman MD, Tintinalli JE, Lorenz RP. Blunt trauma during pregnancy. N Engl J Med 1990; 323:1609.",
"     </a>",
"    </li>",
"    <li>",
"     Committee on Trauma of the American College of Surgeons. Advanced Trauma Life Support: Course for Physicians, 5th ed, American College of Surgeons, Chicago, 1993, p. 17.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22569/abstract/21\">",
"      Pearlman MD, Tintinallli JE, Lorenz RP. A prospective controlled study of outcome after trauma during pregnancy. Am J Obstet Gynecol 1990; 162:1502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22569/abstract/22\">",
"      Higgins SD, Garite TJ. Late abruptio placenta in trauma patients: implications for monitoring. Obstet Gynecol 1984; 63:10S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22569/abstract/23\">",
"      Barraco RD, Chiu WC, Clancy TV, et al. Practice management guidelines for the diagnosis and management of injury in the pregnant patient: the EAST Practice Management Guidelines Work Group. J Trauma 2010; 69:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22569/abstract/24\">",
"      Mann FA, Nathens A, Langer SG, et al. Communicating with the family: the risks of medical radiation to conceptuses in victims of major blunt-force torso trauma. J Trauma 2000; 48:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22569/abstract/25\">",
"      Sperry JL, Minei JP, Frankel HL, et al. Early use of vasopressors after injury: caution before constriction. J Trauma 2008; 64:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22569/abstract/26\">",
"      O'Connor RL, Sevarino FB. Cardiopulmonary arrest in the pregnant patient: a report of a successful resuscitation. J Clin Anesth 1994; 6:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22569/abstract/27\">",
"      Cordero DR, Toffle RC, McCauley CS. Cardiopulmonary arrest in pregnancy: the role of caesarean section in the resuscitative protocol. W V Med J 1992; 88:402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22569/abstract/28\">",
"      DePace NL, Betesh JS, Kotler MN. 'Postmortem' cesarean section with recovery of both mother and offspring. JAMA 1982; 248:971.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22569/abstract/29\">",
"      Ormsby EL, Geng J, McGahan JP, Richards JR. Pelvic free fluid: clinical importance for reproductive age women with blunt abdominal trauma. Ultrasound Obstet Gynecol 2005; 26:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22569/abstract/30\">",
"      Brown MA, Sirlin CB, Farahmand N, et al. Screening sonography in pregnant patients with blunt abdominal trauma. J Ultrasound Med 2005; 24:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22569/abstract/31\">",
"      Goodwin TM, Breen MT. Pregnancy outcome and fetomaternal hemorrhage after noncatastrophic trauma. Am J Obstet Gynecol 1990; 162:665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22569/abstract/32\">",
"      Muzumdar D, Higgins MJ, Ventureyra EC. Intrauterine penetrating direct fetal head trauma following gunshot injury: a case report and review of the literature. Childs Nerv Syst 2006; 22:398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22569/abstract/33\">",
"      Vaysse C, Mignot F, Benezech JP, Parant O. [Traumatic uterine rupture: a rare complication of motor vehicle accidents during pregnancy. A case report]. J Gynecol Obstet Biol Reprod (Paris) 2007; 36:611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22569/abstract/34\">",
"      Franger AL, Buchsbaum HJ, Peaceman AM. Abdominal gunshot wounds in pregnancy. Am J Obstet Gynecol 1989; 160:1124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22569/abstract/35\">",
"      Sakala EP, Kort DD. Management of stab wounds to the pregnant uterus: a case report and a review of the literature. Obstet Gynecol Surv 1988; 43:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22569/abstract/36\">",
"      McNabney WK, Smith EI. Penetrating wounds of the gravid uterus. J Trauma 1972; 12:1024.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22569/abstract/37\">",
"      Grubb DK. Nonsurgical management of penetrating uterine trauma in pregnancy: a case report. Am J Obstet Gynecol 1992; 166:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22569/abstract/38\">",
"      El-Kady D, Gilbert WM, Anderson J, et al. Trauma during pregnancy: an analysis of maternal and fetal outcomes in a large population. Am J Obstet Gynecol 2004; 190:1661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22569/abstract/39\">",
"      El Kady D, Gilbert WM, Xing G, Smith LH. Maternal and neonatal outcomes of assaults during pregnancy. Obstet Gynecol 2005; 105:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22569/abstract/40\">",
"      Rogers FB, Rozycki GS, Osler TM, et al. A multi-institutional study of factors associated with fetal death in injured pregnant patients. Arch Surg 1999; 134:1274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22569/abstract/41\">",
"      Schiff MA, Holt VL. Pregnancy outcomes following hospitalization for motor vehicle crashes in Washington State from 1989 to 2001. Am J Epidemiol 2005; 161:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22569/abstract/42\">",
"      Esposito TJ. Trauma during pregnancy. Emerg Med Clin North Am 1994; 12:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22569/abstract/43\">",
"      Kuhlmann RS, Warsof S. Ultrasound of the placenta. Clin Obstet Gynecol 1996; 39:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22569/abstract/44\">",
"      Manriquez M, Srinivas G, Bollepalli S, et al. Is computed tomography a reliable diagnostic modality in detecting placental injuries in the setting of acute trauma? Am J Obstet Gynecol 2010; 202:611.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22569/abstract/45\">",
"      Lavin JP Jr, Miodovnik M. Delayed abruption after maternal trauma as a result of an automobile accident. J Reprod Med 1981; 26:621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22569/abstract/46\">",
"      Dahmus MA, Sibai BM. Blunt abdominal trauma: are there any predictive factors for abruptio placentae or maternal-fetal distress? Am J Obstet Gynecol 1993; 169:1054.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22569/abstract/47\">",
"      Chames MC, Pearlman MD. Trauma during pregnancy: outcomes and clinical management. Clin Obstet Gynecol 2008; 51:398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22569/abstract/48\">",
"      Rose PG, Strohm PL, Zuspan FP. Fetomaternal hemorrhage following trauma. Am J Obstet Gynecol 1985; 153:844.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22569/abstract/49\">",
"      Dhanraj D, Lambers D. The incidences of positive Kleihauer-Betke test in low-risk pregnancies and maternal trauma patients. Am J Obstet Gynecol 2004; 190:1461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22569/abstract/50\">",
"      Cahill AG, Bastek JA, Stamilio DM, et al. Minor trauma in pregnancy--is the evaluation unwarranted? Am J Obstet Gynecol 2008; 198:208.e1.",
"     </a>",
"    </li>",
"    <li>",
"     American College of Obstetricians and Gynecologists. Obstetric aspects of trauma management. ACOG educational bulletin #251. September 1998.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22569/abstract/52\">",
"      John PR, Shiozawa A, Haut ER, et al. An assessment of the impact of pregnancy on trauma mortality. Surgery 2011; 149:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22569/abstract/53\">",
"      ACOG. Obstetric aspects of trauma management. ACOG educational bulletin 1998; 251:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22569/abstract/54\">",
"      Drost TF, Rosemurgy AS, Sherman HF, et al. Major trauma in pregnant women: maternal/fetal outcome. J Trauma 1990; 30:574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22569/abstract/55\">",
"      Baerga-Varela Y, Zietlow SP, Bannon MP, et al. Trauma in pregnancy. Mayo Clin Proc 2000; 75:1243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22569/abstract/56\">",
"      Theodorou DA, Velmahos GC, Souter I, et al. Fetal death after trauma in pregnancy. Am Surg 2000; 66:809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22569/abstract/57\">",
"      Aboutanos MB, Aboutanos SZ, Dompkowski D, et al. Significance of motor vehicle crashes and pelvic injury on fetal mortality: a five-year institutional review. J Trauma 2008; 65:616.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22569/abstract/58\">",
"      Sperry JL, Casey BM, McIntire DD, et al. Long-term fetal outcomes in pregnant trauma patients. Am J Surg 2006; 192:715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22569/abstract/59\">",
"      Vivian-Taylor J, Roberts CL, Chen JS, Ford JB. Motor vehicle accidents during pregnancy: a population-based study. BJOG 2012; 119:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22569/abstract/60\">",
"      Pearlman MD, Klinich KD, Schneider LW, et al. A comprehensive program to improve safety for pregnant women and fetuses in motor vehicle crashes: a preliminary report. Am J Obstet Gynecol 2000; 182:1554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22569/abstract/61\">",
"      Pearlman MD, Viano D. Automobile crash simulation with the first pregnant crash test dummy. Am J Obstet Gynecol 1996; 175:977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22569/abstract/62\">",
"      Pearlman MD, Phillips ME. Safety belt use during pregnancy. Obstet Gynecol 1996; 88:1026.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22569/abstract/63\">",
"      Schiff MA, Mack CD, Kaufman RP, et al. The effect of air bags on pregnancy outcomes in Washington State: 2002-2005. Obstet Gynecol 2010; 115:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22569/abstract/64\">",
"      Stewart DE. Incidence of postpartum abuse in women with a history of abuse during pregnancy. CMAJ 1994; 151:1601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22569/abstract/65\">",
"      Gazmararian JA, Lazorick S, Spitz AM, et al. Prevalence of violence against pregnant women. JAMA 1996; 275:1915.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22569/abstract/66\">",
"      Hillard PJ. Physical abuse in pregnancy. Obstet Gynecol 1985; 66:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22569/abstract/67\">",
"      McFarlane J, Parker B, Soeken K, Bullock L. Assessing for abuse during pregnancy. Severity and frequency of injuries and associated entry into prenatal care. JAMA 1992; 267:3176.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6738 Version 20.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-217.117.136.88-094BD8D684-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_2_22569=[""].join("\n");
var outline_f22_2_22569=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H28\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INCIDENCE AND ETIOLOGY OF TRAUMA IN PREGNANT WOMEN",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PREGNANCY-RELATED CONSIDERATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Changes in major organ systems",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Increased risk of IVC compression",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Cardiopulmonary resuscitation (CPR)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Increased vascularity and blood flow",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Changes in the abdomen",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      EVALUATION AND MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Assessment/stabilization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Fetal monitoring",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Diagnostic imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Respiratory support",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Volume replacement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Cesarean delivery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Blunt abdominal trauma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Obstetrical issues",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Uterine rupture",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Penetrating abdominal trauma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Abruptio placentae",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Fetomaternal hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Preterm labor and premature rupture of membranes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      OUTCOME",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Influence of gestational age",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Influence of trauma severity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Overall outcome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/6738\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/6738|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?36/59/37821\" title=\"figure 1A\">",
"      Hemodynamic changes in normal pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?9/32/9742\" title=\"figure 1B\">",
"      Blood volume in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?37/50/38703\" title=\"figure 1C\">",
"      Cardiac output in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/6738|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/22/2411\" title=\"table 1\">",
"      Blood gases in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?22/8/22668\" title=\"table 2\">",
"      Pregnancy outcome after trauma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?25/36/26188\" title=\"table 3\">",
"      Pregnancy outcome after assault",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?20/38/21099\" title=\"table 4\">",
"      Outcome pregnancy after MVA",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/33/13850?source=related_link\">",
"      Advanced cardiac life support (ACLS) in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/38/41575?source=related_link\">",
"      Alcohol intake and pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/55/31610?source=related_link\">",
"      Antenatal corticosteroid therapy for reduction of neonatal morbidity and mortality from preterm delivery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/25/36248?source=related_link\">",
"      Basic life support (BLS) in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/10/5290?source=related_link\">",
"      Choosing the route of delivery after cesarean birth",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/16/18696?source=related_link\">",
"      Community violence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/45/3800?source=related_link\">",
"      Diagnosis and management of massive fetomaternal hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/29/28120?source=related_link\">",
"      Diagnostic imaging procedures during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/12/21703?source=related_link\">",
"      Hematologic changes in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/5/19545?source=related_link\">",
"      Initial evaluation and management of blunt abdominal trauma in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/11/35002?source=related_link\">",
"      Initial management of trauma in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/15/6393?source=related_link\">",
"      Intimate partner violence: Diagnosis and screening",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/41/5784?source=related_link\">",
"      Intimate partner violence: Epidemiology and health consequences",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/1/27672?source=related_link\">",
"      Limit of viability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/22/20840?source=related_link\">",
"      Management of cardiopulmonary arrest in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/40/20105?source=related_link\">",
"      Maternal cardiovascular and hemodynamic adaptations to pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/60/9160?source=related_link\">",
"      Maternal gastrointestinal tract adaptation to pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/12/6346?source=related_link\">",
"      Overview of illicit drug use in pregnant women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/30/5608?source=related_link\">",
"      Overview of preterm labor and birth",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/46/29417?source=related_link\">",
"      Placental abruption: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/54/34663?source=related_link\">",
"      Placental abruption: Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/18/41256?source=related_link\">",
"      Placental development and physiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/47/34553?source=related_link\">",
"      Prenatal assessment of gestational age",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/31/15866?source=related_link\">",
"      Preterm premature rupture of membranes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/44/40648?source=related_link\">",
"      Prevention of Rh(D) alloimmunization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/32/24072?source=related_link\">",
"      Renal and urinary tract physiology in normal pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/37/32340?source=related_link\">",
"      Respiratory tract changes during pregnancy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_2_22570="Overview of radiation therapy for gynecologic malignancies";
var content_f22_2_22570=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of radiation therapy for gynecologic malignancies",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/2/22570/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/2/22570/contributors\">",
"     Kristin A Bradley, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/2/22570/contributors\">",
"     Derek R McHaffie, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/2/22570/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/2/22570/contributors\">",
"     Barbara Goff, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/2/22570/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/2/22570/contributors\">",
"     Don S Dizon, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?22/2/22570/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 15, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radiation therapy (RT) represents an important therapeutic component in the management of many gynecologic malignancies. Based upon evidence-based treatment guidelines, epidemiologic analysis suggests that radiation therapy is indicated for 60 percent of cervical cancer patients, 45 percent of endometrial cancer patients, 35 percent of vulvar cancer patients, 100 percent of vaginal cancer patients, and 5 percent of patients with ovarian cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?22/2/22570/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An overview of the modalities, indications, and techniques of RT for gynecologic malignancies will be reviewed here. A more detailed discussion of the indications for RT for specific cancer sites and stages can be found in topic reviews for each cancer site. A discussion of general principles of radiation therapy can be found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/7/17525?source=see_link\">",
"     \"General principles of radiation therapy for head and neck cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EXTERNAL BEAM RT",
"    </span>",
"    &nbsp;&mdash;&nbsp;External beam radiation therapy (EBRT) is delivered with photons, electrons, or protons from a source outside the body. Photons are the radiation modality of choice for treating pelvic tumors due to the optimal tissue penetration and dose distribution characteristics. A radiation machine called a linear accelerator (LINAC) is used to treat gynecologic cancers with photons. Less frequently, electrons, which penetrate a short distance and then deposit their energy, are employed for treating gynecologic cancers. Electrons may be used in treating vulvar cancer both to supplement dose to the inguinal lymph nodes or to deliver a boost to the primary tumor. Protons are a radiation therapy modality rarely used in treating gynecologic malignancies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Conventional EBRT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Conventional external beam radiation therapy, 2DXRT, is so named because it is planned with the assistance of two-dimensional, fluoroscopic radiographs. Beam arrangements are designed in reference to bony landmarks to encompass regions of interest to be treated. This technique is well established, quick, and reliable, but does not allow for the visualization of soft tissue to account for variations in individual patient anatomy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Three-dimensional conformal RT",
"    </span>",
"    &nbsp;&mdash;&nbsp;With the development of computed tomography (CT), three-dimensional conformal radiation therapy (3DCRT) has become the most widely used method of treatment planning and delivery. CT simulation allows for delineation of the tumor and normal structure in three-dimensions. In addition, 3DCRT is delivered through a variable number of beams, each of which can be shaped in order to best conform to the shape of the tumor.",
"   </p>",
"   <p>",
"    The treatment planning process begins with a CT scan of the patient in therapy position to create a virtual, three-dimensional simulation of daily treatment. Additional imaging studies, CT, magnetic resonance imaging (MRI), or positron emission tomography (PET), can be fused with the treatment planning CT to better delineate the tumor and normal tissues. With the aid of sophisticated computer planning stations and software, the physician selects beam arrangements and geometries that generate the optimal dose distribution with the goal of conforming the delivered radiation to the tumor or region at risk, while minimizing the dose to surrounding normal tissues.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Intensity-modulated RT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intensity-modulated radiation therapy (IMRT) represents an emerging and more specialized form of 3DCRT. Compared to most other treatment techniques, IMRT can achieve an even more highly conformal radiation plan than with standard 3DCRT, thus further reducing dose and toxicity to normal tissues. The advantages of IMRT are particularly evident when the target volumes have complex shapes or concave regions.",
"   </p>",
"   <p>",
"    IMRT shares many of the treatment planning principles of 3DCRT; however, for treatment delivery, it utilizes variable computer-controlled intensities within each RT beam in contrast to the uniform doses within each 3DCRT beam. This allows the treating physician to define the clinical target volume and to set dose constraints to surrounding normal structures [",
"    <a class=\"abstract\" href=\"UTD.htm?22/2/22570/abstract/3\">",
"     3",
"    </a>",
"    ]. Computer algorithms are used to modulate the intensity of the radiation beams to optimize the treatment plan. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/55/32630?source=see_link\">",
"     \"Intensity-modulated radiation therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For gynecologic malignancies, IMRT allows for dose escalation to sites of gross disease or nodal involvement while reducing the radiation dose to the small bowel, rectum, bladder, and bone marrow [",
"    <a class=\"abstract\" href=\"UTD.htm?22/2/22570/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. Dosimetric studies have demonstrated benefit, and clinical outcomes data are still emerging. Retrospective series have suggested preserved clinical efficacy and reduced acute and late toxicity with the use of IMRT in some settings [",
"    <a class=\"abstract\" href=\"UTD.htm?22/2/22570/abstract/6-10\">",
"     6-10",
"    </a>",
"    ]. IMRT offers potential advantages in the management of specific gynecologic malignancies; these are addressed below [",
"    <a class=\"abstract\" href=\"UTD.htm?22/2/22570/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The high-precision planning and radiation delivery associated with IMRT have amplified concerns over patient and organ motion, and have limited wider implementation [",
"    <a class=\"abstract\" href=\"UTD.htm?22/2/22570/abstract/12\">",
"     12",
"    </a>",
"    ]. The feasibility of broadly implementing IMRT in the management of gynecologic malignancies will be addressed through the recently completed RTOG 0418 [",
"    <a class=\"abstract\" href=\"UTD.htm?22/2/22570/abstract/13\">",
"     13",
"    </a>",
"    ]. Consensus guidelines for the delineation of the clinical target volume in the adjuvant management of cervix and endometrial cancer have been developed through collaboration of the major research cooperative groups [",
"    <a class=\"abstract\" href=\"UTD.htm?22/2/22570/abstract/3\">",
"     3",
"    </a>",
"    ]. Patient immobilization and precise positioning are essential for daily reproducibility. Image-guided RT, which uses a daily low-dose CT scan or orthogonal Kv radiographs in the treatment planning position to verify setup before each treatment, has been introduced to combat these concerns, though adequately controlling for variations in daily bladder filling and bowel distention remain a challenge.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Target volume and dose",
"    </span>",
"    &nbsp;&mdash;&nbsp;The dose of radiation required to treat solid tumors with definitive EBRT ranges from 60 to 80 gray (Gy) and for adjuvant therapy, 45 to 60 Gy. The goal is to target the area of gross tumor volume with the highest radiation dose. Surrounding tissues at high-risk for microscopic tumor extension are targeted with lower doses, as are postoperative tumor beds and regional nodes. By precisely targeting or conforming the treatment volume, conformal therapy allows higher doses of radiation to be delivered to the tumor with reduced dose, and as a result, reduced toxicity, to the surrounding normal tissues.",
"   </p>",
"   <p>",
"    The total dose is typically fractionated or spread out over time. Standard EBRT is delivered in once daily fractions, typically 1.8 to 2 Gy, five days a week, for a period of weeks. Fractionation decreases the amount of toxicity to healthy tissues by exploiting their innate capacity for sublethal damage repair and repopulation compared to malignant tissues. Throughout the course of treatment, tumor cells undergo reoxygenation and reassortment into more sensitive phases of the cell cycle. Both of these processes increase their sensitivity to fractionated regimens.",
"   </p>",
"   <p>",
"    Despite the merits of fractionation, concerns exist over unnecessarily extending treatment. Tumors of various disease sites and histologies have been shown to manifest accelerated repopulation of tumor clonogens, which negatively impacts tumor control. As an example, in the definitive management of locally advanced cervical cancer, evidence suggests that extending treatment beyond 55 days decreases survival by 0.6 percent per day [",
"    <a class=\"abstract\" href=\"UTD.htm?22/2/22570/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     BRACHYTHERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Brachytherapy, or local application of radiation, represents an integral component of treatment for cervical, endometrial, and vaginal carcinoma. It can be used as monotherapy or in conjunction with EBRT, depending upon the situation.",
"   </p>",
"   <p>",
"    Because of the close treatment distance and rapid dose fall off, which is governed by the inverse square law, brachytherapy allows for the precise delivery of high-dose radiation to the target tissue and sparing of the surrounding normal tissue, notably, the small bowel, rectum, and bladder. It can often be delivered in a shorter time and in a safer manner than EBRT. Brachytherapy is well suited for small tumors with well-defined limits or to boost the radiation dose to the primary tumor after EBRT. EBRT may supplement brachytherapy to address peripheral areas such as pelvic lymph nodes.",
"   </p>",
"   <p>",
"    Brachytherapy is performed by placing a radioactive source in close proximity to the tumor or tissues at risk for harboring occult disease. It requires insertion of the source or instruments through which the brachytherapy source is applied. Placement of the applicators and delivery of brachytherapy may be performed under sedation or anesthesia to minimize patient discomfort. Modern brachytherapy utilizes afterloading, in which inert needles, catheters, or custom applicators are inserted before the radioactive source is advanced. A variety of applicators can be used and are selected based upon disease site, patient anatomy, and physician preference. Other treatment variables include dose-rate, mode of implantation, and whether the implant is permanent or temporary.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Low dose and high dose rate intracavitary brachytherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Brachytherapy can be delivered with either a low dose rate (LDR) or high dose rate (HDR) system. The International Commission on Radiation Units (ICRU) defines LDR as 0.4 to 2 Gy per hour, whereas HDR is delivered at &gt;12 Gy per hour. The most common LDR sources used to treat gynecologic malignancies are Cesium-137 and Iridium-192, and the most common HDR source is Iridium-192.",
"   </p>",
"   <p>",
"    LDR brachytherapy is typically given in one to two insertions over a 48 to 72 hour period during an inpatient hospitalization in a shielded room. HDR cervical brachytherapy involves three to five outpatient procedures, delivered once or twice weekly, with each procedure lasting two to three hours. Due to the discomfort associated with the procedure, the instruments are placed into the uterus and vagina with the patient under sedation, which can range from conscious sedation to general anesthesia. For most patients the procedure is well tolerated with only mild pain and distress [",
"    <a class=\"abstract\" href=\"UTD.htm?22/2/22570/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Traditionally, brachytherapy techniques in gynecologic oncology, most commonly cervical cancer, evolved using LDR sources primarily due to perceived radiobiologic advantages over HDR [",
"    <a class=\"abstract\" href=\"UTD.htm?22/2/22570/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. HDR brachytherapy has come into favor with the development of remote afterloading technology. A remote afterloader stores a single HDR radioactive source, typically Iridium-192, and through a computer controlled mechanism, advances it to the various dwell positions required for treatment (",
"    <a class=\"graphic graphic_picture graphicRef69225 \" href=\"UTD.htm?18/20/18758\">",
"     picture 1",
"    </a>",
"    ). This results in less radiation exposure to healthcare workers.",
"   </p>",
"   <p>",
"    In addition, HDR offers several other advantages, largely as a consequence of significantly reduced treatment times. Outpatient treatment is convenient for patients and provides a potential cost savings [",
"    <a class=\"abstract\" href=\"UTD.htm?22/2/22570/abstract/18\">",
"     18",
"    </a>",
"    ]. Prolonged immobilization required for LDR can lead to perioperative complications, such as thromboembolic events [",
"    <a class=\"abstract\" href=\"UTD.htm?22/2/22570/abstract/19\">",
"     19",
"    </a>",
"    ]. Furthermore, the shorter treatment times with HDR permit rigid immobilization to combat patient and instrument movement, and more aggressive vaginal packing to displace adjacent bowel and bladder. Also, the ability to vary dwell times and positions of the HDR source allows for improved dosimetric optimization [",
"    <a class=\"abstract\" href=\"UTD.htm?22/2/22570/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    HDR and LDR appear to have similar efficacy and late complications in the management of cervical carcinoma, as suggested by retrospective single institution reports, randomized trials, and a meta-analysis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/2/22570/abstract/21-27\">",
"     21-27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to standard HDR and LDR brachytherapy, pulsed dose rate brachytherapy can be utilized to treat gynecologic cancers. This technique uses a single Iridium-192 source that is programmed to move through various dwell positions in placed applicators, using remote afterloading technology. The movement of the source through the positions constitutes a single pulse, and the dose delivered per pulse, the time interval between pulses, and the total pulse duration can be varied. Pulsed dose rate brachytherapy delivers a treatment in which the goal is to draw from the advantages of both HDR brachytherapy and traditional LDR brachytherapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Interstitial implantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;While intracavitary brachytherapy is used most commonly for gynecologic malignancies, interstitial brachytherapy also may be used. With intracavitary brachytherapy, applicators that will be loaded with the radioactive source are placed inside a pre-existing body cavity, such as the vagina or uterus. With interstitial brachytherapy, needles are placed into the tissues at risk, such as the parametria or paravaginal tissues. The radiation source(s) are then inserted into the needles. Interstitial brachytherapy can be temporary, such as for advanced cervical cancers, or permanent, such as is the case with prostate seed implants for prostate cancer.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     TREATMENT-RELATED TOXICITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence and severity of radiation therapy side effects depend upon the site and volume of tissue exposed; the dose, type of radiation, and schedule; and modifying factors such as previous surgery, concomitant chemotherapy, and condition of the patient. Acute and subacute side effects occur during radiotherapy and for the first six months after treatment. These can include injury to the skin and mucosal surfaces, fatigue, edema, and sequelae of implantation such as fever, thromboembolism, uterine perforation, and vaginal laceration. Late effects, occurring after six months, include fibrosis, stricture, fistula, second malignancies [",
"    <a class=\"abstract\" href=\"UTD.htm?22/2/22570/abstract/28-31\">",
"     28-31",
"    </a>",
"    ], radiation enteritis, intestinal malabsorption, hematuria, and urinary incontinence [",
"    <a class=\"abstract\" href=\"UTD.htm?22/2/22570/abstract/32\">",
"     32",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/42/20137?source=see_link\">",
"     \"Gastrointestinal toxicity of radiation therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The normal tissues of the cervix and corpus of the uterus can tolerate high doses of radiation and can recover remarkably well from radiation injury [",
"    <a class=\"abstract\" href=\"UTD.htm?22/2/22570/abstract/33\">",
"     33",
"    </a>",
"    ]. In contrast, the large bowel and bladder are quite susceptible to radiation injury, and portions of these organs should not be exposed to doses exceeding 70 and 75 Gy, respectively.",
"   </p>",
"   <p>",
"    Although normal small bowel motion helps to reduce exposure to pelvic radiation, it can be at risk for late toxicity (diarrhea, malabsorption, small bowel obstruction) if excessive bowel is within the radiation portals, such as when adhesions from previous surgeries immobilize small bowel within the pelvis. The risk for small bowel toxicity is a function of both total dose and volume irradiated. As part of the recent Quantitative Analyses of Normal Tissue Effects in the Clinic (QUANTEC) project, limiting the volume receiving &gt;45 Gy to &lt;195 cc substantially reduces the risk of acute grade &gt;3 GI toxicity. These",
"    <span class=\"nowrap\">",
"     dose/volume",
"    </span>",
"    constraints are likely to translate to reduced late toxicity as well, although a correlation has not yet been established [",
"    <a class=\"abstract\" href=\"UTD.htm?22/2/22570/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As a result of irradiation of the distal ileum, malabsorption can develop and lead to vitamin B12 deficiency. Vitamin B12 deficiency after irradiation for cervical cancer occurs in 12 to 20 percent, and usually develops over a period of several years [",
"    <a class=\"abstract\" href=\"UTD.htm?22/2/22570/abstract/33,35-37\">",
"     33,35-37",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/42/20137?source=see_link\">",
"     \"Gastrointestinal toxicity of radiation therapy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/32/11786?source=see_link\">",
"     \"Etiology and clinical manifestations of vitamin B12 and folate deficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other tissues at risk of injury with radiation for gynecologic malignancies include skin, bowel, bladder, vagina, ovaries, and bones:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Skin reactions range from erythema and soreness to moist desquamation, ulceration, and necrosis.",
"     </li>",
"     <li>",
"      Symptoms of bowel wall mucosal injury include cramping, diarrhea, rectal discomfort, and occasionally rectal bleeding. Severe bowel injury may lead to ulceration, perforation, fibrosis, and fistula formation.",
"     </li>",
"     <li>",
"      Acute and transient radiation cystitis (dysuria, frequency, and nocturia) and bladder spasms may occur with lower doses of radiation; high doses are associated with a risk of hematuria, severe chronic cystitis, ureteral stricture, and vesicovaginal fistula.",
"     </li>",
"     <li>",
"      Many women experience acute vaginal mucositis following pelvic RT, but the incidence has not been well documented. Vaginal ulceration and necrosis are uncommon. Vaginal stenosis, which can be seen following pelvic radiation",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      brachytherapy, can result in a shortened vaginal length and impaired sexual functioning.",
"     </li>",
"     <li>",
"      Radiation to the ovaries may lead to infertility or premature menopause.",
"     </li>",
"     <li>",
"      Uncommon complications of pelvic irradiation also include pelvic or sacral insufficiency fractures [",
"      <a class=\"abstract\" href=\"UTD.htm?22/2/22570/abstract/38-40\">",
"       38-40",
"      </a>",
"      ] and rarely, radiation-induced lumbosacral plexopathy [",
"      <a class=\"abstract\" href=\"UTD.htm?22/2/22570/abstract/41\">",
"       41",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Supportive and preventive measures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some supportive and preventive measures are described below, with varying levels of clinical evidence to support their use [",
"    <a class=\"abstract\" href=\"UTD.htm?22/2/22570/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Vulvar dermatitis and vaginal mucositis and ulceration can be treated with vulvar cleansing, vaginal douche (diluted",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/41/41617?source=see_link\">",
"       hydrogen peroxide",
"      </a>",
"      and water), and intravaginal estrogen cream. A systematic review of randomized trials and observational studies evaluated treatments for acute postradiation vaginal mucositis [",
"      <a class=\"abstract\" href=\"UTD.htm?22/2/22570/abstract/43\">",
"       43",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Use of a",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/45/6867?source=see_link\">",
"       benzydamine",
"      </a>",
"      vaginal douche (eg, 1 percent; initiated 24 to 48 hours after beginning radiation; twice daily for 15 days) significantly reduced the rate of vaginitis symptoms in two randomized, placebo-controlled trials; benzydamine is a local anesthetic and antiinflammatory agent that is available only outside of the United States.",
"     </li>",
"     <li>",
"      Topical estrogen (one to three times weekly) reduced postradiation vaginal bleeding in one randomized trial and one prospective series. However, not all patients are good candidates for intravaginal estrogen therapy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Although many guidelines suggest daily use of a vaginal dilator to prevent postradiation vaginal stenosis, compliance is poor [",
"      <a class=\"abstract\" href=\"UTD.htm?22/2/22570/abstract/44-46\">",
"       44-46",
"      </a>",
"      ] and few data support the efficacy of this approach [",
"      <a class=\"abstract\" href=\"UTD.htm?22/2/22570/abstract/47\">",
"       47",
"      </a>",
"      ]. Two case series and a comparative study using historical controls suggest that dilation might be associated with a longer vaginal length [",
"      <a class=\"abstract\" href=\"UTD.htm?22/2/22570/abstract/48-50\">",
"       48-50",
"      </a>",
"      ], but at least two small randomized trials from one institution showed no improvement in sexual scores or global sexual health in women who were encouraged to practice dilation [",
"      <a class=\"abstract\" href=\"UTD.htm?22/2/22570/abstract/44,45\">",
"       44,45",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/14/9449?source=see_link&amp;anchor=H28#H28\">",
"       \"Management of early stage cervical cancer\", section on 'Sexual dysfunction'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Some preliminary reports suggest benefit for topical",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/16/38144?source=see_link\">",
"       mitomycin",
"      </a>",
"      (which prevents DNA cross-linkage, and thus, might affect scarring) to prevent or treat radiation-induced vaginal stricture [",
"      <a class=\"abstract\" href=\"UTD.htm?22/2/22570/abstract/51,52\">",
"       51,52",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Skin erythema or dry or moist desquamation can be treated with skin hygiene, water-based creams or ointments such as lanolin.",
"     </li>",
"     <li>",
"      Cystitis and bladder spasm may respond to fluids and antispasmodics, such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/59/10167?source=see_link\">",
"       oxybutynin",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/9/29846?source=see_link\">",
"       hyoscyamine",
"      </a>",
"      &nbsp;(see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/39/23161?source=see_link&amp;anchor=H9#H9\">",
"       \"Cystitis in patients with cancer\", section on 'Radiation cystitis'",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Diarrhea and abdominal cramping have been treated with diphenoxylate-atropine,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/53/16214?source=see_link\">",
"       loperamide",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/3/35893?source=see_link\">",
"       tincture of opium",
"      </a>",
"      . In contrast,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"       octreotide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/29/29141?source=see_link\">",
"       sucralfate",
"      </a>",
"      , mesalazine, and glutamine have failed to reduce gastrointestinal toxicity. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/42/20137?source=see_link\">",
"       \"Gastrointestinal toxicity of radiation therapy\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      In",
"      <a class=\"drug drug_general\" href=\"UTD.htm?13/37/13907?source=see_link\">",
"       selenium",
"      </a>",
"      -deficient patients (whole blood selenium concentration &lt;84",
"      <span class=\"nowrap\">",
"       microg/L)",
"      </span>",
"      undergoing RT for cancer of the cervix or uterus, a phase III trial showed a potential cytoprotective effect of selenium supplementation through a reduction in the rates of grade 2 or higher diarrhea [",
"      <a class=\"abstract\" href=\"UTD.htm?22/2/22570/abstract/53\">",
"       53",
"      </a>",
"      ]. Independent confirmation and validation of these results is needed before this approach can be considered standard.",
"     </li>",
"     <li>",
"      Proctitis and rectal discomfort often respond to small enemas with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/49/32528?source=see_link\">",
"       hydrocortisone",
"      </a>",
"      or cod liver oil, antiinflammatory suppositories, and a low-residue diet with no grease, spices, or insoluble fiber (",
"      <a class=\"graphic graphic_table graphicRef51448 \" href=\"UTD.htm?17/2/17453\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/29/25049?source=see_link\">",
"       \"Clinical features, diagnosis, and treatment of radiation proctitis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Radiation-induced fibrosis may respond to oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?13/28/13765?source=see_link\">",
"       pentoxifylline",
"      </a>",
"      and alpha-tocopherol (vitamin E) [",
"      <a class=\"abstract\" href=\"UTD.htm?22/2/22570/abstract/54\">",
"       54",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/46/17129?source=see_link\">",
"       \"Clinical manifestations and treatment of radiation-induced fibrosis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     ISSUES RELEVANT TO SPECIFIC SITES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Cervical cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of cervical cancer depends upon stage of disease and can be approached with surgery often followed by adjuvant RT or definitive RT with or without concurrent chemotherapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Adjuvant RT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adjuvant radiotherapy (RT), usually with concurrent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    -based chemotherapy, offers benefit to patients with high-risk pathologic factors; these include",
"    <span class=\"nowrap\">",
"     &gt;1/3",
"    </span>",
"    cervical stromal invasion, tumor diameter &ge;4 cm, lymph node involvement, lymphovascular space invasion, evidence of microscopic parametrial extension, or a positive resection margin [",
"    <a class=\"abstract\" href=\"UTD.htm?22/2/22570/abstract/55-57\">",
"     55-57",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/14/9449?source=see_link\">",
"     \"Management of early stage cervical cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/50/7976?source=see_link\">",
"     \"Management of locally advanced cervical cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Adjuvant EBRT targets the at-risk tissues in the pelvis to eradicate potential occult sites of disease. Traditionally, treatment has been delivered using a four-field technique, which employs equally weighted anteroposterior-posteroanterior (AP-PA) and opposed lateral beams. With conventional 2DXRT, radiation field borders and design were described relative to skeletal anatomy. With the use of three-dimensional imaging, 3DCRT plans should be designed to adequately cover soft tissue regions at risk, including nearby parametrial and vaginal tissue and the pelvic lymph nodes. It is important to take into account variations in patient anatomy and postsurgical changes.",
"   </p>",
"   <p>",
"    It is necessary to adequately cover all locoregionally draining lymphatics, which include obturator, internal iliac, presacral, external iliac, and common iliac lymph nodes through their coalescence at the inferior vena cava, which roughly corresponds to a superior field border at the L4-L5 disk space. Inferiorly, the field edge should extend 3 to 4 cm below the lowest extent of disease or to the bottom of the obturator foramen. The lateral margin should be set 1.5 to 2 cm lateral to the pelvic brim and is designed to give a margin on the pelvic vessels and lymphatics (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef78210 \" href=\"UTD.htm?29/33/30229\">",
"     image 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The recommended dose is 45 to 50.4 Gy given in standard 1.8 to 2 Gy fractions over five to six weeks. If there is any gross residual disease or positive nodes, the dose should be boosted to 54 to 60 Gy, as permitted by tolerance of adjacent normal tissues.",
"   </p>",
"   <p>",
"    Adjuvant RT, particularly when combined with concurrent chemotherapy, increases toxicity over surgery alone [",
"    <a class=\"abstract\" href=\"UTD.htm?22/2/22570/abstract/55,57\">",
"     55,57",
"    </a>",
"    ]. There is significant interest in the use of IMRT to reduce toxicity; an early report suggests significantly improved tolerance to adjuvant concurrent chemoradiotherapy with the use of IMRT [",
"    <a class=\"abstract\" href=\"UTD.htm?22/2/22570/abstract/58\">",
"     58",
"    </a>",
"    ]. The results of a recently completed phase II cooperative group study (RTOG 0418) evaluating the feasibility of more broadly implementing postoperative IMRT for cervical and endometrial cancer are awaited [",
"    <a class=\"abstract\" href=\"UTD.htm?22/2/22570/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Definitive RT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Definitive radiotherapy with concurrent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    -based chemotherapy is a recommended treatment for patients with International Federation of Gynecology and Obstetrics (FIGO) stage IIB to IVA and is often preferred over surgery in earlier FIGO stage IB to IIA patients [",
"    <a class=\"abstract\" href=\"UTD.htm?22/2/22570/abstract/59-64\">",
"     59-64",
"    </a>",
"    ]. Definitive radiation therapy may also be employed for patients with early stage IA-IB1 disease if they are not appropriate surgical candidates due to medical comorbidities. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/14/9449?source=see_link\">",
"     \"Management of early stage cervical cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/50/7976?source=see_link\">",
"     \"Management of locally advanced cervical cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Definitive radiotherapy and chemoradiotherapy include both EBRT and brachytherapy. Whole pelvis fields are employed similar to those described above in the adjuvant setting. CT-based planning should be used to adequately visualize the cervix, rectum, bladder, small bowel, and nodal stations. The inferior border should be lowered to the ischial tuberosity to effectively cover the vagina, which can be aided by the placement of a vaginal marker at the time of simulation (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef63554 \" href=\"UTD.htm?22/44/23236\">",
"     image 2",
"    </a>",
"    ). A gold seed can also be placed clinically in the vaginal mucosa to mark the distal extent of disease and help ensure adequate coverage. The presence of distal vaginal disease into the lower one-third of the vagina places the inguinal lymph nodes at risk and they should be included in the treatment field. Patients may be treated in prone or supine positions. For the prone position, a \"belly board\" is used to displace small bowel superiorly from the pelvis and reduce toxicity.",
"   </p>",
"   <p>",
"    Typically, the whole pelvis is treated to 45 Gy in 25 once-daily fractions of 1.8 Gy. MRI and PET are useful for radiation treatment planning to evaluate the size and extent of the primary tumor and the presence and extent of parametrial involvement, bladder or rectal invasion, and nodal disease. These regions are boosted with external beam radiation to 50.4 to 60 Gy, often employing a customized central block to shield the uterus and vagina, which will be treated further with brachytherapy (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef57654 \" href=\"UTD.htm?19/61/20434\">",
"     image 3",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Extended field RT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Extended field radiation therapy (EFRT) consists of extending the superior pelvic field border to the level of the T12 to L1 disk space in order to include the para-aortic nodes (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef59921 \" href=\"UTD.htm?21/22/21863\">",
"     image 4",
"    </a>",
"    ). Other than the presence of distant metastasis at diagnosis, known para-aortic disease represents the strongest negative prognostic factor in the management of cervical cancer and is a major treatment challenge for radiation oncologists [",
"    <a class=\"abstract\" href=\"UTD.htm?22/2/22570/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The role of prophylactic para-aortic radiation is controversial [",
"    <a class=\"abstract\" href=\"UTD.htm?22/2/22570/abstract/66,67\">",
"     66,67",
"    </a>",
"    ]. In the era of concurrent chemoradiation, prophylactic para-aortic nodal irradiation is typically avoided due to concerns over excessive toxicity. EFRT is reserved for patients with known para-aortic nodal disease. In this case, the recommendation is for EFRT combined with weekly low-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    More advanced techniques such as IMRT may limit the bowel and bone marrow toxicity associated with EFRT. Furthermore, IMRT may allow for selectively boosting the dose to sites of node positivity, as is done for pelvic lymph nodes, without an increased probability of bowel toxicity. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/50/7976?source=see_link&amp;anchor=H30045461#H30045461\">",
"     \"Management of locally advanced cervical cancer\", section on 'Treatment of para-aortic nodes'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Consolidative brachytherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Consolidative or \"boost\" intracavitary brachytherapy allows for the delivery of high doses of radiation to the tumor while sparing the bladder and rectum due to rapid dose fall off. Either LDR, HDR, or pulsed dose rate techniques are used, largely based upon institutional preference. For advanced presentations or disease that do not respond promptly to EBRT, intracavitary techniques are often inadequate. In this case, interstitial needle brachytherapy may be required to adequately encompass gross disease.",
"   </p>",
"   <p>",
"    Brachytherapy is initiated during EBRT once optimal tumor reduction is achieved. Adequate cervical regression typically occurs between two to five weeks of therapy depending on presenting tumor stage and size and response to therapy. LDR brachytherapy requires one or two insertions and can begin near or after the completion of EBRT. The number of HDR insertions is variable across institutions, but most commonly is given as three to six insertions. The dose delivered per brachytherapy procedure is adjusted to account for the total number of insertions.",
"   </p>",
"   <p>",
"    With intracavitary brachytherapy, a variety of applicators can be employed. These include the placement of an intrauterine tandem with vaginal ovoids, vaginal cylinders, or a vaginal ring (",
"    <a class=\"graphic graphic_picture graphicRef51083 \" href=\"UTD.htm?1/46/1762\">",
"     picture 2",
"    </a>",
"    ). The addition of the ovoids or ring to the tandem applicator provides a dose distribution that encompasses the at-risk paracervical tissues while providing a lower dose distribution to the bladder and rectum. In addition, dose to the bladder and rectum can be reduced further with the use of shielded ovoids and vigorous packing. The choice of applicator is governed by physician preference and comfort level, as well as patient anatomical considerations. We prefer ovoids, when possible, due to improved dosimetry and dosing to the vaginal fornices and parametria. Vaginal cylinders are employed when distal vaginal disease is present.",
"   </p>",
"   <p>",
"    With interstitial brachytherapy, needles are placed with a variety of freehanded and template-based techniques, often with laparoscopic guidance (",
"    <a class=\"graphic graphic_picture graphicRef79505 \" href=\"UTD.htm?34/57/35730\">",
"     picture 3",
"    </a>",
"    ). The most common presentation necessitating the use of interstitial therapy is extensive vaginal involvement. Interstitial implants most commonly use LDR sources, but HDR may be used, as well.",
"   </p>",
"   <p>",
"    Applicator placement typically requires intravenous conscious sedation or general anesthesia for patient comfort. Once the applicators are in place, treatments are traditionally planned using orthogonal radiographs to define prescription and normal tissue points of interest (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef51717 \" href=\"UTD.htm?35/27/36274\">",
"     image 5",
"    </a>",
"    ). Three-dimensional techniques with CT- or MRI-based brachytherapy planning are currently employed at some institutions, but their use is still evolving [",
"    <a class=\"abstract\" href=\"UTD.htm?22/2/22570/abstract/68,69\">",
"     68,69",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the most common brachytherapy planning methodology, the total dose is prescribed to point A, which represents the paracervical tissues (",
"    <a class=\"graphic graphic_figure graphicRef66135 \" href=\"UTD.htm?22/43/23216\">",
"     figure 1",
"    </a>",
"    ). The prescribed brachytherapy dose depends on tumor stage, initial disease bulk and response to pelvic radiation, ability to displace bladder and rectum, and use of LDR, HDR or pulse dose rate technique. The total prescription dose to point A is 80 to 90 Gy LDR equivalent, depending on tumor stage [",
"    <a class=\"abstract\" href=\"UTD.htm?22/2/22570/abstract/70,71\">",
"     70,71",
"    </a>",
"    ]. A biologically effective dose is calculated and used when comparing HDR and LDR brachytherapy. The choice of dose for HDR also depends upon the number of fractions, for which there are multiple accepted regimens [",
"    <a class=\"abstract\" href=\"UTD.htm?22/2/22570/abstract/71\">",
"     71",
"    </a>",
"    ]. We prescribe a total brachytherapy dose of 26.25 Gy in five fractions when given with concurrent chemotherapy or 30 Gy in five fractions with radiation alone.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Endometerial cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endometrial carcinoma is primarily a surgically managed disease. Due to the presence of early symptoms, most commonly vaginal bleeding, the majority of women with endometrial carcinoma are diagnosed with uterine-confined disease. The need for adjuvant postoperative therapy is governed by the pathologic findings at the time of surgery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     FIGO stage I and II",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no consensus on recommendations for adjuvant radiation therapy, and patterns of care continue to evolve [",
"    <a class=\"abstract\" href=\"UTD.htm?22/2/22570/abstract/72-74\">",
"     72-74",
"    </a>",
"    ]. Potential approaches include pelvic EBRT, vaginal cuff brachytherapy, or a combination of both. The analysis of pelvic recurrence risk is complex and includes depth of myometrial invasion, tumor grade, the adequacy of surgical staging and lymph node assessment, the presence of lymphovascular space invasion, and the patient's age. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/23/18810?source=see_link\">",
"     \"Endometrial carcinoma: Pretreatment evaluation, staging and surgical treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H964235401\">",
"    <span class=\"h4\">",
"     Adjuvant whole pelvic RT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early data from randomized trials showed that pelvic EBRT reduced the risk of locoregional relapse in appropriately selected patients. However, the value of whole pelvis RT in comparison to vaginal brachytherapy alone in women with high-intermediate risk disease has been called into question by the results of the PORTEC-2 trial [",
"    <a class=\"abstract\" href=\"UTD.htm?22/2/22570/abstract/75\">",
"     75",
"    </a>",
"    ]. Adjuvant pelvic radiation is sometimes recommended for patients with low intermediate-risk disease, such as deeply invasive tumors and other high-risk pathologic features, such as the presence of cervical stromal invasion, &gt;50 percent myometrial invasion with grade 3 histology or lymphovascular space invasion, even if they have undergone complete surgical staging, including lymph node evaluation. However, the use of EBRT should be limited to those at high risk of pelvic relapse or nodal failure not adequately managed by vaginal cuff brachytherapy alone. Fifteen-year quality-of-life data show that whole pelvis RT in the adjuvant management of endometrial cancer is associated with long-term urinary and bowel symptoms and lower physical functioning scores [",
"    <a class=\"abstract\" href=\"UTD.htm?22/2/22570/abstract/76\">",
"     76",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/41/8855?source=see_link\">",
"     \"Approach to adjuvant treatment of endometrial cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/62/13287?source=see_link&amp;anchor=H568079343#H568079343\">",
"     \"Adjuvant treatment of intermediate-risk endometrial cancer\", section on 'Radiation therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Planning and delivery techniques are similar to those described for cervical cancer, including the use of a standard four-field beam arrangement. Care should be taken to ensure that the vaginal cuff and all locoregionally-draining lymphatics are included in the treatment fields. The typical dose in this setting is 45 to 50.4 Gy given in 1.8 to 2.0 Gy fractions over five to six weeks. Treatment generally is initiated four to six weeks after surgery to allow for adequate wound healing.",
"   </p>",
"   <p>",
"    Here, too, IMRT is a promising method of delivering external beam radiotherapy that may limit bowel, bladder, and bone marrow toxicity in the adjuvant setting [",
"    <a class=\"abstract\" href=\"UTD.htm?22/2/22570/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H964235393\">",
"    <span class=\"h4\">",
"     Adjuvant vaginal cuff brachytherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 75 percent of recurrences in patients with stage I, uterine-confined disease, are located at the vaginal apex, and vaginal cuff brachytherapy is very effective in reducing this risk of local recurrence [",
"    <a class=\"abstract\" href=\"UTD.htm?22/2/22570/abstract/77-86\">",
"     77-86",
"    </a>",
"    ]. In contrast to EBRT, which encompasses at risk nodal volumes, brachytherapy is only effective at reducing the risk of vaginal relapse. Outside of patients with cervical stromal invasion (stage II), there is no additional benefit of adding brachytherapy to patients already receiving EBRT.",
"   </p>",
"   <p>",
"    Vaginal cuff brachytherapy is typically accomplished using HDR therapy with an Iridium-192 source, but also can be delivered using LDR therapy. Treatment is initiated three to six weeks following surgery and consists of three to five fractions given once- or twice-weekly on an outpatient basis. In general, the upper one-half to upper two-thirds of the vagina is treated and both vaginal ovoids or a vaginal cylinder can be used as applicators for vaginal cuff brachytherapy (",
"    <a class=\"graphic graphic_picture graphicRef54105 \" href=\"UTD.htm?26/53/27476\">",
"     picture 4",
"    </a>",
"    ). The prescription dose depends upon the number of fractions and dose specification point (to the vaginal mucosa or to a depth of 5 mm), and several published fractionation schedules are accepted. The American Brachytherapy Society has published its recommendations for HDR brachytherapy in the management of endometrial carcinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?22/2/22570/abstract/87\">",
"     87",
"    </a>",
"    ]. One of the more common dose fractionation schedules employed is three, once-weekly fractions of 7 Gy each, delivered to a depth of 5 mm from the vaginal mucosal surface.",
"   </p>",
"   <p>",
"    Treatment is very well tolerated with minimal appreciable acute or late toxicity and does not require conscious sedation or general anesthesia. Overall, it is a cost-effective, convenient, and efficacious adjuvant strategy with an evolving role in the management of endometrial carcinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?22/2/22570/abstract/88\">",
"     88",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H964235379\">",
"    <span class=\"h4\">",
"     Definitive RT for medically inoperable patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;Obesity and increasing age are significant risk factors for the development of endometrial cancer and both are often accompanied by serious complicating comorbidities that can preclude definitive surgery. For these inoperable patients, definitive radiation therapy can be used as treatment. A combination of pelvic EBRT and intrauterine brachytherapy is recommended for patients at risk for extrauterine or nodal disease spread. For clinical stage I patients with low risk for extrauterine or nodal spread, HDR intracavitary brachytherapy alone can be used with high local control and disease-specific survival rates with effective amelioration of vaginal bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?22/2/22570/abstract/89,90\">",
"     89,90",
"    </a>",
"    ]. Treatment is delivered using a uterine tandem with vaginal ovoids or cylinder, similar to cervical cancer. There are various treatment prescriptions reported in the literature. For clinical stage I patients, as an example, we use 45 Gy HDR brachytherapy in five, once-weekly fractions of 9 Gy prescribed to two-thirds the depth of myometrial thickness at various points as determined by pretreatment MRI and intraoperative ultrasound (",
"    <a class=\"graphic graphic_figure graphicRef57633 \" href=\"UTD.htm?20/62/21487\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/2/22570/abstract/89,91\">",
"     89,91",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     FIGO stage III through IV",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although historically, adjuvant RT played a prominent role in the management of locally advanced endometrial carcinoma, adjuvant chemotherapy has been shown to improve survival compared to whole-abdominal radiotherapy with a pelvic boost [",
"    <a class=\"abstract\" href=\"UTD.htm?22/2/22570/abstract/92\">",
"     92",
"    </a>",
"    ]. However, the persistently high recurrence rates have driven interest in the use of combined modality therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?22/2/22570/abstract/93\">",
"     93",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/23/18810?source=see_link\">",
"     \"Endometrial carcinoma: Pretreatment evaluation, staging and surgical treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We routinely use vaginal cuff brachytherapy in addition to adjuvant chemotherapy, and sometimes integrate whole pelvic radiation in the adjuvant treatment course for those patients at particularly high risk for locoregional recurrence.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Vaginal cuff recurrence",
"    </span>",
"    &nbsp;&mdash;&nbsp;When recurrence is isolated to the vagina, the typical salvage treatment includes both EBRT and intracavitary brachytherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?22/2/22570/abstract/94\">",
"     94",
"    </a>",
"    ]. Pelvic EBRT doses are similar to those used in the adjuvant setting, but the brachytherapy doses used in this situation are generally higher, as an example, 28 Gy in four fractions of 7 Gy prescribed to the mucosal surface using HDR techniques [",
"    <a class=\"abstract\" href=\"UTD.htm?22/2/22570/abstract/87\">",
"     87",
"    </a>",
"    ]. Use of lead shielded cylinders or an interstitial implant are techniques available to reduce the dose to uninvolved regions of the vagina in an effort to limit toxicity. If pelvic radiotherapy has been given adjuvantly, brachytherapy can be used as monotherapy. With bulky recurrences or those that fail to respond promptly to EBRT, intracavitary techniques may not adequately encompass gross disease. In this case, interstitial needle brachytherapy may be required.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Vulvar cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vulvar cancer, when diagnosed at an early stage, is treated surgically, while RT is used for women with more advanced disease [",
"    <a class=\"abstract\" href=\"UTD.htm?22/2/22570/abstract/95\">",
"     95",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Adjuvant radiotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adjuvant RT is used in the setting of close or positive margins, large, deeply invasive lesions with lymphovascular space invasion, and in patients with positive inguinal lymph nodes [",
"    <a class=\"abstract\" href=\"UTD.htm?22/2/22570/abstract/96,97\">",
"     96,97",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/14/20714?source=see_link\">",
"     \"Vulvar cancer: Staging, treatment, and prognosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with vulvar cancer have traditionally been treated in the supine, frog-legged position using opposed AP-PA beams with use of electrons to supplement dose to the vulva or inguinal nodes. Wires can be placed clinically at the time of CT scan to adequately define the region of interest and ensure effective coverage of the postoperative bed. The standard dose is 45 to 50.4 Gy with a boost provided for microscopic or gross residual disease. A thermoluminescent dosimeter (TLD) should be placed externally over the vulvar surface and internally within the vulva for the initial fractions to ensure that the dose received matches the treatment plan, as surface dosing can be challenging with the use of megavoltage photons.",
"   </p>",
"   <p>",
"    If the surgical margins on the primary vulvar tumor are adequate, the vulva can be blocked from the field and treatment delivered to the pelvic and inguinal lymph nodes only to minimize morbidity. Various techniques for encompassing the inguinal lymph nodes are used, including a modified AP-PA method. The AP field is expanded laterally while the PA field is kept narrower, just medial to the femoral necks and heads. The AP field includes the inguino-femoral lymph node chains with careful attention to the three-dimensional soft tissue anatomy.",
"   </p>",
"   <p>",
"    Electrons, which penetrate tissue only superficially, are used to supplement the dose to the inguinal nodes and spare the femur from unnecessary radiation. The use of IMRT may be particularly advantageous in this situation, as it may reduce dose to the femoral head and neck and small bowel. The following figure shows axial and coronal CT images from an IMRT treatment plan targeting the pelvic and inguinal lymph nodes for vulvar cancer (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef58008 \" href=\"UTD.htm?24/3/24628\">",
"     image 6",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Chemoradiation",
"    </span>",
"    &nbsp;&mdash;&nbsp;When tumor involves the urethra, clitoris, vagina or anus, definitive or preoperative chemoradiation provides an alternative treatment to radical and debilitating surgical resection [",
"    <a class=\"abstract\" href=\"UTD.htm?22/2/22570/abstract/98-101\">",
"     98-101",
"    </a>",
"    ]. Typically, treatment includes EBRT directed at the pelvis, vulva, and inguinal nodes to 45 Gy with all gross disease receiving 54 to 60 Gy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/14/20714?source=see_link\">",
"     \"Vulvar cancer: Staging, treatment, and prognosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Vaginal cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary vaginal cancer is rare, with most disease representing local extension from another gynecologic malignancy (cervix or vulva) or distant metastases from other primary malignancies. The low incidence has limited clinical trials. RT is typically used to avoid exenterative surgery and to preserve sexual function. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/30/31208?source=see_link\">",
"     \"Vaginal cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Select patients with small lesions confined to the vaginal mucosa may be treated with vaginal brachytherapy alone [",
"    <a class=\"abstract\" href=\"UTD.htm?22/2/22570/abstract/102-104\">",
"     102-104",
"    </a>",
"    ]. Concurrent chemoradiation is an option for treatment of locally advanced or node-positive vaginal cancer based upon the success of chemoradiation in the cervical cancer literature.",
"   </p>",
"   <p>",
"    The treatment approach involves a combination of EBRT and brachytherapy. The sequencing of both modalities is similar to that employed with cervical cancer, with a goal of achieving maximum attainable EBRT response before proceeding with brachytherapy without unnecessarily prolonging treatment.",
"   </p>",
"   <p>",
"    The choice of consolidative brachytherapy technique is highly dependent upon local disease extent and patient anatomy. When intracavitary brachytherapy is indicated, vaginal cylinders are typically used for adequate dosing of the distal vagina. With bulky and more extensive tumors, interstitial needle brachytherapy is often required to cover gross disease involving the paravaginal tissues without overdosing the mucosa, which can be accomplished with either freehanded or template-based techniques.",
"   </p>",
"   <p>",
"    A total external radiation dose of 40 to 50 Gy is adequate for treatment of the primary tumor and the regional lymphatics. Whole pelvic radiation is usually administered to 20 to 40 Gy, followed by an additional parametrial treatment field with a midline block. Consolidative brachytherapy boosts the total tumor dose to 75 Gy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H67812012\">",
"    <span class=\"h2\">",
"     Ovarian cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radiation plays a limited role in the treatment of ovarian cancer and is commonly reserved for palliation at the time of recurrence [",
"    <a class=\"abstract\" href=\"UTD.htm?22/2/22570/abstract/105\">",
"     105",
"    </a>",
"    ]. Intraperitoneal radiocolloid 32P and whole-abdominal radiotherapy were used historically as postoperative treatment strategies, but have fallen out of favor due to effective chemotherapy that can be given with lower toxicity profiles.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?23/35/24114?source=see_link\">",
"       \"Patient information: Brachytherapy (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?39/32/40450?source=see_link\">",
"       \"Patient information: Radiation therapy (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radiation therapy (RT) plays an important and evolving role as definitive and adjuvant therapy for gynecologic malignancies. External beam RT (EBRT) and brachytherapy are used individually and in tandem according to cancer site, histology, and extent of disease.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Advances in treatment planning and delivery of external beam radiation therapy (EBRT), including three-dimensional conformal radiation therapy (3DCRT), intensity-modulated radiation therapy (IMRT), and image-guided radiation therapy, provide the technology to precisely plan, target, and deliver radiation therapy with the goal of optimizing the radiation dose to the target while sparing normal tissue. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'External beam RT'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Brachytherapy, with the development of high dose rate (HDR) systems and remote afterloaders, also allows for the precise delivery of high-dose radiation to the target tissue with sparing of the surrounding normal tissue, in a safe and efficient manner. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Brachytherapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The integration of concurrent chemotherapy is also improving treatment outcomes.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Further study is needed to refine and standardize these techniques, demonstrate efficacy, and reduce toxicity.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22570/abstract/1\">",
"      Delaney G, Jacob S, Barton M. Estimation of an optimal radiotherapy utilization rate for gynecologic carcinoma: part II--carcinoma of the endometrium. Cancer 2004; 101:682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22570/abstract/2\">",
"      Delaney G, Jacob S, Barton M. Estimation of an optimal radiotherapy utilization rate for gynecologic carcinoma: part I--malignancies of the cervix, ovary, vagina and vulva. Cancer 2004; 101:671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22570/abstract/3\">",
"      Small W Jr, Mell LK, Anderson P, et al. Consensus guidelines for delineation of clinical target volume for intensity-modulated pelvic radiotherapy in postoperative treatment of endometrial and cervical cancer. Int J Radiat Oncol Biol Phys 2008; 71:428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22570/abstract/4\">",
"      Heron DE, Gerszten K, Selvaraj RN, et al. Conventional 3D conformal versus intensity-modulated radiotherapy for the adjuvant treatment of gynecologic malignancies: a comparative dosimetric study of dose-volume histograms small star, filled. Gynecol Oncol 2003; 91:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22570/abstract/5\">",
"      Mell LK, Tiryaki H, Ahn KH, et al. Dosimetric comparison of bone marrow-sparing intensity-modulated radiotherapy versus conventional techniques for treatment of cervical cancer. Int J Radiat Oncol Biol Phys 2008; 71:1504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22570/abstract/6\">",
"      Mundt AJ, Lujan AE, Rotmensch J, et al. Intensity-modulated whole pelvic radiotherapy in women with gynecologic malignancies. Int J Radiat Oncol Biol Phys 2002; 52:1330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22570/abstract/7\">",
"      Beriwal S, Jain SK, Heron DE, et al. Clinical outcome with adjuvant treatment of endometrial carcinoma using intensity-modulated radiation therapy. Gynecol Oncol 2006; 102:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22570/abstract/8\">",
"      Jhingran A, Winter K, Portelance L, et al. A phase II study of intensity modulated radiation therapy (IMRT) to the pelvic for post-operative patients with endometrial cancer (RTOG 0418). Int J Radiat Oncol Biol Phys 2008; 72:S16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22570/abstract/9\">",
"      Roeske JC, Lujan A, Rotmensch J, et al. Intensity-modulated whole pelvic radiation therapy in patients with gynecologic malignancies. Int J Radiat Oncol Biol Phys 2000; 48:1613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22570/abstract/10\">",
"      Mundt AJ, Mell LK, Roeske JC. Preliminary analysis of chronic gastrointestinal toxicity in gynecology patients treated with intensity-modulated whole pelvic radiation therapy. Int J Radiat Oncol Biol Phys 2003; 56:1354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22570/abstract/11\">",
"      Jhingran A. Potential advantages of intensity-modulated radiation therapy in gynecologic malignancies. Semin Radiat Oncol 2006; 16:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22570/abstract/12\">",
"      Ahamad A, D'Souza W, Salehpour M, et al. Intensity-modulated radiation therapy after hysterectomy: comparison with conventional treatment and sensitivity of the normal-tissue-sparing effect to margin size. Int J Radiat Oncol Biol Phys 2005; 62:1117.",
"     </a>",
"    </li>",
"    <li>",
"     Clinical trial details on RTOG 0418 available online at file://clinicaltrials.gov/ct2/show/NCT00331760?term=RTOG+0418&amp;rank=1 (Accessed on August 09, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22570/abstract/14\">",
"      Petereit DG, Sarkaria JN, Chappell R, et al. The adverse effect of treatment prolongation in cervical carcinoma. Int J Radiat Oncol Biol Phys 1995; 32:1301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22570/abstract/15\">",
"      Kwekkeboom KL, Dendaas NR, Straub M, Bradley KA. Patterns of pain and distress during high-dose-rate intracavity brachytherapy for cervical cancer. J Support Oncol 2009; 7:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22570/abstract/16\">",
"      Brenner DJ, Hall EJ. Fractionated high dose rate versus low dose rate regimens for intracavitary brachytherapy of the cervix. I. General considerations based on radiobiology. Br J Radiol 1991; 64:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22570/abstract/17\">",
"      Erickson B, Eifel P, Moughan J, et al. Patterns of brachytherapy practice for patients with carcinoma of the cervix (1996-1999): a patterns of care study. Int J Radiat Oncol Biol Phys 2005; 63:1083.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22570/abstract/18\">",
"      Bastin K, Buchler D, Stitt J, et al. Resource utilization. High dose rate versus low dose rate brachytherapy for gynecologic cancer. Am J Clin Oncol 1993; 16:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22570/abstract/19\">",
"      Jhingran A, Eifel PJ. Perioperative and postoperative complications of intracavitary radiation for FIGO stage I-III carcinoma of the cervix. Int J Radiat Oncol Biol Phys 2000; 46:1177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22570/abstract/20\">",
"      Houdek PV, Schwade JG, Abitbol AA, et al. Optimization of high dose-rate cervix brachytherapy; Part I: Dose distribution. Int J Radiat Oncol Biol Phys 1991; 21:1621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22570/abstract/21\">",
"      Petereit DG, Sarkaria JN, Potter DM, Schink JC. High-dose-rate versus low-dose-rate brachytherapy in the treatment of cervical cancer: analysis of tumor recurrence--the University of Wisconsin experience. Int J Radiat Oncol Biol Phys 1999; 45:1267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22570/abstract/22\">",
"      Lertsanguansinchai P, Lertbutsayanukul C, Shotelersuk K, et al. Phase III randomized trial comparing LDR and HDR brachytherapy in treatment of cervical carcinoma. Int J Radiat Oncol Biol Phys 2004; 59:1424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22570/abstract/23\">",
"      Hareyama M, Sakata K, Oouchi A, et al. High-dose-rate versus low-dose-rate intracavitary therapy for carcinoma of the uterine cervix: a randomized trial. Cancer 2002; 94:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22570/abstract/24\">",
"      Falkenberg E, Kim RY, Meleth S, et al. Low-dose-rate vs. high-dose-rate intracavitary brachytherapy for carcinoma of the cervix: The University of Alabama at Birmingham (UAB) experience. Brachytherapy 2006; 5:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22570/abstract/25\">",
"      Parker K, Gallop-Evans E, Hanna L, Adams M. Five years' experience treating locally advanced cervical cancer with concurrent chemoradiotherapy and high-dose-rate brachytherapy: results from a single institution. Int J Radiat Oncol Biol Phys 2009; 74:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22570/abstract/26\">",
"      Hellebust TP, Kristensen GB, Olsen DR. Late effects after radiotherapy for locally advanced cervical cancer: comparison of two brachytherapy schedules and effect of dose delivered weekly. Int J Radiat Oncol Biol Phys 2010; 76:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22570/abstract/27\">",
"      Wang X, Liu R, Ma B, et al. High dose rate versus low dose rate intracavity brachytherapy for locally advanced uterine cervix cancer. Cochrane Database Syst Rev 2010; :CD007563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22570/abstract/28\">",
"      Pothuri B, Ramondetta L, Martino M, et al. Development of endometrial cancer after radiation treatment for cervical carcinoma. Obstet Gynecol 2003; 101:941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22570/abstract/29\">",
"      Chaturvedi AK, Engels EA, Gilbert ES, et al. Second cancers among 104,760 survivors of cervical cancer: evaluation of long-term risk. J Natl Cancer Inst 2007; 99:1634.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22570/abstract/30\">",
"      Kumar S, Shah JP, Bryant CS, et al. Second neoplasms in survivors of endometrial cancer: impact of radiation therapy. Gynecol Oncol 2009; 113:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22570/abstract/31\">",
"      Wright JD, St Clair CM, Deutsch I, et al. Pelvic radiotherapy and the risk of secondary leukemia and multiple myeloma. Cancer 2010; 116:2486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22570/abstract/32\">",
"      Samper-Ternent R, Zhang D, Kuo YF, et al. Late GI and bladder toxicities after radiation for uterine cancer. Gynecol Oncol 2011; 120:198.",
"     </a>",
"    </li>",
"    <li>",
"     Yashar CM. Basic principle in gynecologic radiotherapy. In: Clinical Gynecologic Oncology, 7th, DiSaia P, Creasman W (Eds), Elsevier, Amsterdam 2007. p.775.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22570/abstract/34\">",
"      Kavanagh BD, Pan CC, Dawson LA, et al. Radiation dose-volume effects in the stomach and small bowel. Int J Radiat Oncol Biol Phys 2010; 76:S101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22570/abstract/35\">",
"      Vistad I, Kristensen GB, Foss&aring; SD, et al. Intestinal malabsorption in long-term survivors of cervical cancer treated with radiotherapy. Int J Radiat Oncol Biol Phys 2009; 73:1141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22570/abstract/36\">",
"      Snijders-Keilholz A, Griffioen G, Davelaar J, et al. Vitamin B12 malabsorption after irradiation for gynaecological tumours. Anticancer Res 1993; 13:1877.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22570/abstract/37\">",
"      Schreurs WH, Odink J, Egger RJ, et al. The influence of radiotherapy and chemotherapy on the vitamin status of cancer patients. Int J Vitam Nutr Res 1985; 55:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22570/abstract/38\">",
"      Ikushima H, Osaki K, Furutani S, et al. Pelvic bone complications following radiation therapy of gynecologic malignancies: clinical evaluation of radiation-induced pelvic insufficiency fractures. Gynecol Oncol 2006; 103:1100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22570/abstract/39\">",
"      Oh D, Huh SJ, Nam H, et al. Pelvic insufficiency fracture after pelvic radiotherapy for cervical cancer: analysis of risk factors. Int J Radiat Oncol Biol Phys 2008; 70:1183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22570/abstract/40\">",
"      Schmeler KM, Jhingran A, Iyer RB, et al. Pelvic fractures after radiotherapy for cervical cancer: implications for survivors. Cancer 2010; 116:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22570/abstract/41\">",
"      Georgiou A, Grigsby PW, Perez CA. Radiation induced lumbosacral plexopathy in gynecologic tumors: clinical findings and dosimetric analysis. Int J Radiat Oncol Biol Phys 1993; 26:479.",
"     </a>",
"    </li>",
"    <li>",
"     Halperin EC, Perez CA, Brady LW. Perez and Brady's principles and practice of radiation oncology, 5th, Lippincott Williams &amp; Wilkins, Philadelphia 2004.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22570/abstract/43\">",
"      Denton AS, Maher EJ. Interventions for the physical aspects of sexual dysfunction in women following pelvic radiotherapy. Cochrane Database Syst Rev 2003; :CD003750.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22570/abstract/44\">",
"      Jeffries SA, Robinson JW, Craighead PS, Keats MR. An effective group psychoeducational intervention for improving compliance with vaginal dilation: a randomized controlled trial. Int J Radiat Oncol Biol Phys 2006; 65:404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22570/abstract/45\">",
"      Robinson JW, Faris PD, Scott CB. Psychoeducational group increases vaginal dilation for younger women and reduces sexual fears for women of all ages with gynecological carcinoma treated with radiotherapy. Int J Radiat Oncol Biol Phys 1999; 44:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22570/abstract/46\">",
"      Friedman LC, Abdallah R, Schluchter M, et al. Adherence to vaginal dilation following high dose rate brachytherapy for endometrial cancer. Int J Radiat Oncol Biol Phys 2011; 80:751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22570/abstract/47\">",
"      Miles T, Johnson N. Vaginal dilator therapy for women receiving pelvic radiotherapy. Cochrane Database Syst Rev 2010; :CD007291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22570/abstract/48\">",
"      Decruze SB, Guthrie D, Magnani R. Prevention of vaginal stenosis in patients following vaginal brachytherapy. Clin Oncol (R Coll Radiol) 1999; 11:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22570/abstract/49\">",
"      Bruner DW, Lanciano R, Keegan M, et al. Vaginal stenosis and sexual function following intracavitary radiation for the treatment of cervical and endometrial carcinoma. Int J Radiat Oncol Biol Phys 1993; 27:825.",
"     </a>",
"    </li>",
"    <li>",
"     Velaskar, SM, Martha, R, Mahantashetty, U, et al. Use of indigenous vaginal dilator in rdiation induced vaginal stenosis. Indian J Occulational Ther 2007; 39:3.Full text  available online at  file://medind.nic.in/iba/t07/i1/ibat07i1p3.pdf (Accessed on September 17, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22570/abstract/51\">",
"      Sobotkowski J, Markowska J, Fijuth J, Pietraszek A. Preliminary results of mitomycin C local application as post-treatment prevention of vaginal radiation-induced morbidity in women with cervical cancer. Eur J Gynaecol Oncol 2006; 27:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22570/abstract/52\">",
"      Betalli P, De Corti F, Minucci D, et al. Successful topical treatment with mitomycin-C in a female with post-brachytherapy vaginal stricture. Pediatr Blood Cancer 2008; 51:550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22570/abstract/53\">",
"      Muecke R, Schomburg L, Glatzel M, et al. Multicenter, phase 3 trial comparing selenium supplementation with observation in gynecologic radiation oncology. Int J Radiat Oncol Biol Phys 2010; 78:828.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22570/abstract/54\">",
"      Gothard L, Cornes P, Brooker S, et al. Phase II study of vitamin E and pentoxifylline in patients with late side effects of pelvic radiotherapy. Radiother Oncol 2005; 75:334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22570/abstract/55\">",
"      Rotman M, Sedlis A, Piedmonte MR, et al. A phase III randomized trial of postoperative pelvic irradiation in Stage IB cervical carcinoma with poor prognostic features: follow-up of a gynecologic oncology group study. Int J Radiat Oncol Biol Phys 2006; 65:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22570/abstract/56\">",
"      Sedlis A, Bundy BN, Rotman MZ, et al. A randomized trial of pelvic radiation therapy versus no further therapy in selected patients with stage IB carcinoma of the cervix after radical hysterectomy and pelvic lymphadenectomy: A Gynecologic Oncology Group Study. Gynecol Oncol 1999; 73:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22570/abstract/57\">",
"      Peters WA 3rd, Liu PY, Barrett RJ 2nd, et al. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J Clin Oncol 2000; 18:1606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22570/abstract/58\">",
"      Chen MF, Tseng CJ, Tseng CC, et al. Clinical outcome in posthysterectomy cervical cancer patients treated with concurrent Cisplatin and intensity-modulated pelvic radiotherapy: comparison with conventional radiotherapy. Int J Radiat Oncol Biol Phys 2007; 67:1438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22570/abstract/59\">",
"      Landoni F, Maneo A, Colombo A, et al. Randomised study of radical surgery versus radiotherapy for stage Ib-IIa cervical cancer. Lancet 1997; 350:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22570/abstract/60\">",
"      Newton M. Radical hysterectomy or radiotherapy for stage I cervical cancer. A prospective comparison with 5 and 10 years follow-up. Am J Obstet Gynecol 1975; 123:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22570/abstract/61\">",
"      Keys HM, Bundy BN, Stehman FB, et al. Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. N Engl J Med 1999; 340:1154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22570/abstract/62\">",
"      Morris M, Eifel PJ, Lu J, et al. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N Engl J Med 1999; 340:1137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22570/abstract/63\">",
"      Rose PG, Bundy BN, Watkins EB, et al. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med 1999; 340:1144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22570/abstract/64\">",
"      Whitney CW, Sause W, Bundy BN, et al. Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study. J Clin Oncol 1999; 17:1339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22570/abstract/65\">",
"      Stehman FB, Bundy BN, DiSaia PJ, et al. Carcinoma of the cervix treated with radiation therapy. I. A multi-variate analysis of prognostic variables in the Gynecologic Oncology Group. Cancer 1991; 67:2776.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22570/abstract/66\">",
"      Haie C, Pejovic MH, Gerbaulet A, et al. Is prophylactic para-aortic irradiation worthwhile in the treatment of advanced cervical carcinoma? Results of a controlled clinical trial of the EORTC radiotherapy group. Radiother Oncol 1988; 11:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22570/abstract/67\">",
"      Rotman M, Pajak TF, Choi K, et al. Prophylactic extended-field irradiation of para-aortic lymph nodes in stages IIB and bulky IB and IIA cervical carcinomas. Ten-year treatment results of RTOG 79-20. JAMA 1995; 274:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22570/abstract/68\">",
"      Nag, S, Cardenes, H, Chang, S, et al. Proposed guidelines for image-based intracavitary brachytherapy for cervical carcinoma: report from Image-Guided Brachytherapy Working Group. Int J Radiat Oncol Biol Phys 2004; 60:1160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22570/abstract/69\">",
"      Zwahlen D, Jezioranski J, Chan P, et al. Magnetic resonance imaging-guided intracavitary brachytherapy for cancer of the cervix. Int J Radiat Oncol Biol Phys 2009; 74:1157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22570/abstract/70\">",
"      Nag S, Chao C, Erickson B, et al. The American Brachytherapy Society recommendations for low-dose-rate brachytherapy for carcinoma of the cervix. Int J Radiat Oncol Biol Phys 2002; 52:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22570/abstract/71\">",
"      Nag S, Erickson B, Thomadsen B, et al. The American Brachytherapy Society recommendations for high-dose-rate brachytherapy for carcinoma of the cervix. Int J Radiat Oncol Biol Phys 2000; 48:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22570/abstract/72\">",
"      Lee CM, Szabo A, Shrieve DC, et al. Descriptive nomograms of adjuvant radiotherapy use and patterns of care analysis for stage I and II endometrial adenocarcinoma: A surveillance, epidemiology, and end results population study. Cancer 2007; 110:2092.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22570/abstract/73\">",
"      Creasman WT, Morrow CP, Bundy BN, et al. Surgical pathologic spread patterns of endometrial cancer. A Gynecologic Oncology Group Study. Cancer 1987; 60:2035.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22570/abstract/74\">",
"      Keys HM, Roberts JA, Brunetto VL, et al. A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2004; 92:744.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22570/abstract/75\">",
"      Nout RA, Smit VT, Putter H, et al. Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial. Lancet 2010; 375:816.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22570/abstract/76\">",
"      Nout RA, van de Poll-Franse LV, Lybeert ML, et al. Long-term outcome and quality of life of patients with endometrial carcinoma treated with or without pelvic radiotherapy in the post operative radiation therapy in endometrial carcinoma 1 (PORTEC-1) trial. J Clin Oncol 2011; 29:1692.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22570/abstract/77\">",
"      Creutzberg CL, van Putten WL, Koper PC, et al. Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post Operative Radiation Therapy in Endometrial Carcinoma. Lancet 2000; 355:1404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22570/abstract/78\">",
"      Scholten AN, van Putten WL, Beerman H, et al. Postoperative radiotherapy for Stage 1 endometrial carcinoma: long-term outcome of the randomized PORTEC trial with central pathology review. Int J Radiat Oncol Biol Phys 2005; 63:834.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22570/abstract/79\">",
"      Alektiar KM, Venkatraman E, Chi DS, Barakat RR. Intravaginal brachytherapy alone for intermediate-risk endometrial cancer. Int J Radiat Oncol Biol Phys 2005; 62:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22570/abstract/80\">",
"      Anderson JM, Stea B, Hallum AV, et al. High-dose-rate postoperative vaginal cuff irradiation alone for stage IB and IC endometrial cancer. Int J Radiat Oncol Biol Phys 2000; 46:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22570/abstract/81\">",
"      Chadha M, Nanavati PJ, Liu P, et al. Patterns of failure in endometrial carcinoma stage IB grade 3 and IC patients treated with postoperative vaginal vault brachytherapy. Gynecol Oncol 1999; 75:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22570/abstract/82\">",
"      Eltabbakh GH, Piver MS, Hempling RE, Shin KH. Excellent long-term survival and absence of vaginal recurrences in 332 patients with low-risk stage I endometrial adenocarcinoma treated with hysterectomy and vaginal brachytherapy without formal staging lymph node sampling: report of a prospective trial. Int J Radiat Oncol Biol Phys 1997; 38:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22570/abstract/83\">",
"      R&ouml;per B, Astner ST, Heydemann-Obradovic A, et al. Ten-year data on 138 patients with endometrial carcinoma and postoperative vaginal brachytherapy alone: no need for external-beam radiotherapy in low and intermediate risk patients. Gynecol Oncol 2007; 107:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22570/abstract/84\">",
"      Jolly S, Vargas C, Kumar T, et al. Vaginal brachytherapy alone: an alternative to adjuvant whole pelvis radiation for early stage endometrial cancer. Gynecol Oncol 2005; 97:887.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22570/abstract/85\">",
"      Lin LL, Mutch DG, Rader JS, et al. External radiotherapy versus vaginal brachytherapy for patients with intermediate risk endometrial cancer. Gynecol Oncol 2007; 106:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22570/abstract/86\">",
"      Solhjem MC, Petersen IA, Haddock MG. Vaginal brachytherapy alone is sufficient adjuvant treatment of surgical stage I endometrial cancer. Int J Radiat Oncol Biol Phys 2005; 62:1379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22570/abstract/87\">",
"      Nag S, Erickson B, Parikh S, et al. The American Brachytherapy Society recommendations for high-dose-rate brachytherapy for carcinoma of the endometrium. Int J Radiat Oncol Biol Phys 2000; 48:779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22570/abstract/88\">",
"      Nout RA, Creutzberg CL. Point: Vaginal brachytherapy should be a standard adjuvant treatment for intermediate-risk endometrial cancer. Brachytherapy 2011; 10:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22570/abstract/89\">",
"      Nguyen TV, Petereit DG. High-dose-rate brachytherapy for medically inoperable stage I endometrial cancer. Gynecol Oncol 1998; 71:196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22570/abstract/90\">",
"      Niazi TM, Souhami L, Portelance L, et al. Long-term results of high-dose-rate brachytherapy in the primary treatment of medically inoperable stage I-II endometrial carcinoma. Int J Radiat Oncol Biol Phys 2005; 63:1108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22570/abstract/91\">",
"      Anderson, B, Bentzen, S, Das, R, et al. Single institution experience treating medically inoperable stage I endometrial cancer with high-dose rate intracavitary brachytherapy. Int J Radiat Oncol Biol Phys 2008; 72:S370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22570/abstract/92\">",
"      Randall ME, Filiaci VL, Muss H, et al. Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol 2006; 24:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22570/abstract/93\">",
"      Alvarez Secord A, Havrilesky LJ, Bae-Jump V, et al. The role of multi-modality adjuvant chemotherapy and radiation in women with advanced stage endometrial cancer. Gynecol Oncol 2007; 107:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22570/abstract/94\">",
"      Jhingran A, Burke TW, Eifel PJ. Definitive radiotherapy for patients with isolated vaginal recurrence of endometrial carcinoma after hysterectomy. Int J Radiat Oncol Biol Phys 2003; 56:1366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22570/abstract/95\">",
"      Stroup AM, Harlan LC, Trimble EL. Demographic, clinical, and treatment trends among women diagnosed with vulvar cancer in the United States. Gynecol Oncol 2008; 108:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22570/abstract/96\">",
"      Heaps JM, Fu YS, Montz FJ, et al. Surgical-pathologic variables predictive of local recurrence in squamous cell carcinoma of the vulva. Gynecol Oncol 1990; 38:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22570/abstract/97\">",
"      Homesley HD, Bundy BN, Sedlis A, Adcock L. Radiation therapy versus pelvic node resection for carcinoma of the vulva with positive groin nodes. Obstet Gynecol 1986; 68:733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22570/abstract/98\">",
"      Lupi G, Raspagliesi F, Zucali R, et al. Combined preoperative chemoradiotherapy followed by radical surgery in locally advanced vulvar carcinoma. A pilot study. Cancer 1996; 77:1472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22570/abstract/99\">",
"      Wahlen SA, Slater JD, Wagner RJ, et al. Concurrent radiation therapy and chemotherapy in the treatment of primary squamous cell carcinoma of the vulva. Cancer 1995; 75:2289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22570/abstract/100\">",
"      Eifel PJ, Morris M, Burke TW, et al. Prolonged continuous infusion cisplatin and 5-fluorouracil with radiation for locally advanced carcinoma of the vulva. Gynecol Oncol 1995; 59:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22570/abstract/101\">",
"      Moore DH, Thomas GM, Montana GS, et al. Preoperative chemoradiation for advanced vulvar cancer: a phase II study of the Gynecologic Oncology Group. Int J Radiat Oncol Biol Phys 1998; 42:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22570/abstract/102\">",
"      Lian J, Dundas G, Carlone M, et al. Twenty-year review of radiotherapy for vaginal cancer: an institutional experience. Gynecol Oncol 2008; 111:298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22570/abstract/103\">",
"      Frank SJ, Jhingran A, Levenback C, Eifel PJ. Definitive radiation therapy for squamous cell carcinoma of the vagina. Int J Radiat Oncol Biol Phys 2005; 62:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22570/abstract/104\">",
"      Perez CA, Grigsby PW, Garipagaoglu M, et al. Factors affecting long-term outcome of irradiation in carcinoma of the vagina. Int J Radiat Oncol Biol Phys 1999; 44:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/2/22570/abstract/105\">",
"      Tinger A, Waldron T, Peluso N, et al. Effective palliative radiation therapy in advanced and recurrent ovarian carcinoma. Int J Radiat Oncol Biol Phys 2001; 51:1256.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3225 Version 14.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-197.136.42.3-27C422A60D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_2_22570=[""].join("\n");
var outline_f22_2_22570=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H27\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EXTERNAL BEAM RT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Conventional EBRT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Three-dimensional conformal RT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Intensity-modulated RT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Target volume and dose",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      BRACHYTHERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Low dose and high dose rate intracavitary brachytherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Interstitial implantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      TREATMENT-RELATED TOXICITY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Supportive and preventive measures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      ISSUES RELEVANT TO SPECIFIC SITES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Cervical cancer",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Adjuvant RT",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Definitive RT",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Extended field RT",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Consolidative brachytherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Endometerial cancer",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - FIGO stage I and II",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H964235401\">",
"      Adjuvant whole pelvic RT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H964235393\">",
"      Adjuvant vaginal cuff brachytherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H964235379\">",
"      Definitive RT for medically inoperable patients",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - FIGO stage III through IV",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Vaginal cuff recurrence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Vulvar cancer",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Adjuvant radiotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Chemoradiation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Vaginal cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H67812012\">",
"      Ovarian cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/3225\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/3225|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?29/33/30229\" title=\"diagnostic image 1\">",
"      Convent AP and lat rt port",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?22/44/23236\" title=\"diagnostic image 2\">",
"      Pelvic rt field",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?19/61/20434\" title=\"diagnostic image 3\">",
"      Paramet boost stgIIB cc",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?21/22/21863\" title=\"diagnostic image 4\">",
"      RT portal paraaortic nodes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?35/27/36274\" title=\"diagnostic image 5\">",
"      HDR cerv brachyther plan",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?24/3/24628\" title=\"diagnostic image 6\">",
"      IMRT plan pelvic inguinalLN",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/3225|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?22/43/23216\" title=\"figure 1\">",
"      Dose rates cervical ca",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?20/62/21487\" title=\"figure 2\">",
"      Dose points HDR brachyther",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/3225|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?18/20/18758\" title=\"picture 1\">",
"      Remote afterloader",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?1/46/1762\" title=\"picture 2\">",
"      Intrauterine tandem apps",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?34/57/35730\" title=\"picture 3\">",
"      Cerv interstit brachyther",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?26/53/27476\" title=\"picture 4\">",
"      Vaginal cuff brachythr apps",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/3225|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?17/2/17453\" title=\"table 1\">",
"      Dietary fiber in foods",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/62/13287?source=related_link\">",
"      Adjuvant treatment of intermediate-risk endometrial cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/41/8855?source=related_link\">",
"      Approach to adjuvant treatment of endometrial cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/29/25049?source=related_link\">",
"      Clinical features, diagnosis, and treatment of radiation proctitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/46/17129?source=related_link\">",
"      Clinical manifestations and treatment of radiation-induced fibrosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/39/23161?source=related_link\">",
"      Cystitis in patients with cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/23/18810?source=related_link\">",
"      Endometrial carcinoma: Pretreatment evaluation, staging and surgical treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/32/11786?source=related_link\">",
"      Etiology and clinical manifestations of vitamin B12 and folate deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/42/20137?source=related_link\">",
"      Gastrointestinal toxicity of radiation therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/7/17525?source=related_link\">",
"      General principles of radiation therapy for head and neck cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/55/32630?source=related_link\">",
"      Intensity-modulated radiation therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/14/9449?source=related_link\">",
"      Management of early stage cervical cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/50/7976?source=related_link\">",
"      Management of locally advanced cervical cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?23/35/24114?source=related_link\">",
"      Patient information: Brachytherapy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?39/32/40450?source=related_link\">",
"      Patient information: Radiation therapy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/30/31208?source=related_link\">",
"      Vaginal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/14/20714?source=related_link\">",
"      Vulvar cancer: Staging, treatment, and prognosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_2_22571="Adverse effects of atypical antipsychotic medications";
var content_f22_2_22571=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F80747&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F80747&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Selected adverse effects of atypical antipsychotic medications",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Acute",
"       </td>",
"       <td class=\"subtitle1\">",
"        Chronic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Clozapine",
"       </td>",
"       <td>",
"        Seizures",
"       </td>",
"       <td>",
"        NMS, Agranulocytosis, Myocarditis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Risperidone",
"       </td>",
"       <td>",
"        Prolonged QT, dystonia",
"       </td>",
"       <td>",
"        EPS, TD, NMS",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Olanzapine",
"       </td>",
"       <td>",
"        Seizures, dystonia",
"       </td>",
"       <td>",
"        EPS, TD, NMS, Agranulocytosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Quetiapine",
"       </td>",
"       <td>",
"        Seizures, dystonia",
"       </td>",
"       <td>",
"        EPS, TD, NMS",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ziprasidone",
"       </td>",
"       <td>",
"        Prolonged QT, dystonia",
"       </td>",
"       <td>",
"        EPS",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Aripiprazole",
"       </td>",
"       <td>",
"        Gastrointestinal (vomiting)",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     NMS: neuroleptic malignant syndrome; TD: tardive dyskinesia; EPS: extrapyramidal side effects.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_2_22571=[""].join("\n");
var outline_f22_2_22571=null;
var title_f22_2_22572="Knee examination part II";
var content_f22_2_22572=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F64541&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F64541&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Detailed examination of the knee part II",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Examination signs",
"       </td>",
"       <td class=\"subtitle1\">",
"        Diagnosis",
"       </td>",
"       <td class=\"subtitle1\">",
"        Confirmation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tenderness over the lateral tibial plateau extending along a line to the lateral joint line**",
"       </td>",
"       <td colspan=\"1\" rowspan=\"3\">",
"        Lateral collateral ligament injury",
"       </td>",
"       <td colspan=\"1\" rowspan=\"3\">",
"        Improvement with 3 to 4 weeks of straight leg immobilization; local anesthetic block placed just over the ligament (optional)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pain aggravated by varus stress testing",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pain aggravated by internal rotation of the tibia on the femur",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Painful anterior drawer sign**",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Anterior cruciate ligament injury",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Arthroscopy or MRI",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Painful or inability to fully squat or duck waddle",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Joint line tenderness and mechanical locking or joint line popping**",
"       </td>",
"       <td colspan=\"1\" rowspan=\"3\">",
"        Meniscal tear",
"       </td>",
"       <td colspan=\"1\" rowspan=\"3\">",
"        Arthroscopy or MRI",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Inability to duck waddle",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Popping with squatting",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Palpable cyst in the medial side of the popliteal fossa**",
"       </td>",
"       <td colspan=\"1\" rowspan=\"3\">",
"        Baker's cyst",
"       </td>",
"       <td colspan=\"1\" rowspan=\"3\">",
"        Characteristic aspirate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Incomplete range of motion if the cyst is large",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Distal edema",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Patellar apprehension sign with lateral subluxation**",
"       </td>",
"       <td>",
"        Patellar subluxation or dislocation",
"       </td>",
"       <td>",
"        Clinical diagnosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lateral femoral condyle tenderness**",
"       </td>",
"       <td colspan=\"1\" rowspan=\"3\">",
"        Iliotibial band syndrome",
"       </td>",
"       <td colspan=\"1\" rowspan=\"3\">",
"        Local anesthetic block",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Normal lateral collateral ligament examination",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        No active evidence of lateral compartment osteoarthritis",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     ** Is used to identify the hallmark sign; that is, the sign that has the greatest specificity for the diagnosis listed.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_2_22572=[""].join("\n");
var outline_f22_2_22572=null;
var title_f22_2_22573="Etiologic clues to pediatric pneumonia";
var content_f22_2_22573=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F52021&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F52021&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Clinical and radiographic clues to the etiology of pneumonia in children*",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Etiology",
"       </td>",
"       <td class=\"subtitle1\">",
"        Clinical features",
"       </td>",
"       <td class=\"subtitle1\">",
"        Radiographic features",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bacteria",
"        <br/>",
"        (most commonly",
"        <em>",
"         Streptococcus pneumoniae",
"        </em>",
"        )",
"       </td>",
"       <td>",
"        <ul>",
"         <li>",
"          Children of all ages",
"         </li>",
"         <li>",
"          Abrupt onset",
"         </li>",
"         <li>",
"          Ill-appearance",
"         </li>",
"         <li>",
"          Chills",
"         </li>",
"         <li>",
"          Moderate to severe respiratory distress",
"         </li>",
"         <li>",
"          Focal auscultatory findings",
"         </li>",
"         <li>",
"          Localized chest pain",
"         </li>",
"         <li>",
"          WBC count &gt;15,000/microL (if obtained)",
"         </li>",
"         <li>",
"          Elevated acute phase reactants (if obtained)",
"         </li>",
"        </ul>",
"       </td>",
"       <td>",
"        <ul>",
"         <li>",
"          Alveolar infiltrates",
"         </li>",
"         <li>",
"          Segmental consolidation",
"         </li>",
"         <li>",
"          Lobar consolidation",
"         </li>",
"         <li>",
"          \"Round\" pneumonia",
"         </li>",
"        </ul>",
"        <br/>",
"        Complications:",
"        <ul>",
"         <li>",
"          Pleural effusion/empyema",
"         </li>",
"         <li>",
"          Lung abscess",
"         </li>",
"         <li>",
"          Necrotizing pneumonia",
"         </li>",
"         <li>",
"          Pneumatocele",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Atypical bacterial",
"        <br/>",
"        (",
"        <em>",
"         Mycoplasma pneumoniae",
"        </em>",
"        ,",
"        <em>",
"         Chlamydophila pneumoniae",
"        </em>",
"        )",
"       </td>",
"       <td>",
"        <ul>",
"         <li>",
"          Children of all ages (most common in children &gt;5 years)",
"         </li>",
"         <li>",
"          Abrupt onset with constitutional findings (malaise, myalgia, headache, conjunctivitis, photophobia, sore throat, headache)",
"         </li>",
"         <li>",
"          Gradually worsening nonproductive cough",
"         </li>",
"         <li>",
"          Wheezing",
"         </li>",
"         <li>",
"          Extrapulmonary manifestations or complications (eg, Stevens-Johnson syndrome, hemolytic anemia, hepatitis, etc)",
"         </li>",
"        </ul>",
"       </td>",
"       <td>",
"        Interstitial infiltrates",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Viral",
"       </td>",
"       <td>",
"        <ul>",
"         <li>",
"          Usually children &lt;5 years",
"         </li>",
"         <li>",
"          Gradual onset",
"         </li>",
"         <li>",
"          Preceding upper airway symptoms",
"         </li>",
"         <li>",
"          Non-toxic appearing",
"         </li>",
"         <li>",
"          Diffuse, bilateral auscultatory findings",
"         </li>",
"         <li>",
"          Wheezing",
"         </li>",
"         <li>",
"          May have associated rash (eg, measles, varicella)",
"         </li>",
"        </ul>",
"       </td>",
"       <td>",
"        Interstitial infiltrates",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Afebrile pneumonia of infancy (most commonly",
"        <em>",
"         Chlamydia trachomatis",
"        </em>",
"        )",
"       </td>",
"       <td>",
"        <ul>",
"         <li>",
"          Usually in infants 2 weeks to 4 months",
"         </li>",
"         <li>",
"          Insidious onset",
"         </li>",
"         <li>",
"          Rhinorrhea",
"         </li>",
"         <li>",
"          Staccato cough pattern",
"         </li>",
"         <li>",
"          Peripheral eosinophilia (if CBC obtained)",
"         </li>",
"        </ul>",
"       </td>",
"       <td>",
"        Hyperinflation with interstitial process",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fungal",
"       </td>",
"       <td>",
"        <ul>",
"         <li>",
"          Appropriate geographic or environmental exposure",
"         </li>",
"        </ul>",
"       </td>",
"       <td>",
"        Mediastinal or hilar adenopathy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mycobacterium tuberculosis",
"       </td>",
"       <td>",
"        <ul>",
"         <li>",
"          Children of any age",
"         </li>",
"         <li>",
"          Chronic cough",
"         </li>",
"         <li>",
"          Constitutional symptoms",
"         </li>",
"         <li>",
"          Exposure history",
"         </li>",
"        </ul>",
"       </td>",
"       <td>",
"        Mediastinal or hilar adenopathy",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     WBC: white blood cell; CBC: complete blood count.",
"     <br/>",
"     * The clinical features frequently overlap and cannot reliably distinguish between bacterial, atypical bacterial, and viral etiologies; up to one-half of community-acquired pneumonias in children may be mixed bacterial/viral infections. Chest radiography generally is not helpful in determining the potential causative agent of pneumonia. Nonetheless, these features may facilitate decisions regarding empiric therapy.",
"    </div>",
"    <div class=\"reference\">",
"     Data from:",
"     <br/>",
"     <ol>",
"      <li>",
"       Bartlett JG, Mundy LM. Community-acquired pneumonia. N Engl J Med 1995; 333:1618.",
"      </li>",
"      <li>",
"       Boyer KM. Nonbacterial pneumonia. In: Textbook of Pediatric Infectious Diseases, 6th ed, Feigin RD, Cherry JD, Demmler-Harrison GJ, Kaplan SL (Eds), Saunders, Philadelphia 2009. p.289.",
"      </li>",
"      <li>",
"       Broughton RA. Infections due to Mycoplasma pneumoniae in childhood. Pediatr Infect Dis 1986; 5:71.",
"      </li>",
"      <li>",
"       McIntosh K. Community-acquired pneumonia in children. N Engl J Med 2002; 346:429.",
"      </li>",
"     </ol>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_2_22573=[""].join("\n");
var outline_f22_2_22573=null;
var title_f22_2_22574="R-CHOP21 regimen for non-Hodgkin lymphoma";
var content_f22_2_22574=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F63586&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F63586&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP21) for non-Hodgkin lymphoma",
"    <sup>",
"     [1]",
"    </sup>",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"4\" width=\"25%\">",
"     </colgroup>",
"     <tbody>",
"      <tr class=\"divider_bottom\">",
"       <td colspan=\"4\">",
"        Cycle length: 21 days.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Drug",
"       </td>",
"       <td class=\"subtitle1\">",
"        Dose and route",
"       </td>",
"       <td class=\"subtitle1\">",
"        Administration",
"       </td>",
"       <td class=\"subtitle1\">",
"        Given on days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Rituximab",
"        </strong>",
"       </td>",
"       <td>",
"        375 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        IV",
"       </td>",
"       <td>",
"        Dilute in normal saline (NS) or 5 percent dextrose in water (D5W) to a final concentration of 1 to 4 mg/mL. Initial infusion: start at 50 mg/hour; escalate in 50 mg/hour increments every 30 minutes to a maximum of 400 mg/hour, as tolerated",
"        <sup>",
"         [2]",
"        </sup>",
"        . For subsequent infusions, administer 20 percent of the total dose over the first 30 minutes and the remaining 80 percent over 60 minutes, as tolerated. The 90-minute infusion schedule should NOT be used in patients who have clinically significant cardiovascular disease or have a circulating lymphocyte count &ge;5000/mm",
"        <sup>",
"         3",
"        </sup>",
"        .",
"       </td>",
"       <td>",
"        Day 1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Cyclophosphamide",
"        </strong>",
"       </td>",
"       <td>",
"        750 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        IV",
"       </td>",
"       <td>",
"        Dilute in 250 mL NS or D5W and administer over 30 minutes.",
"       </td>",
"       <td>",
"        Day 1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Doxorubicin",
"        </strong>",
"       </td>",
"       <td>",
"        50 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        IV",
"       </td>",
"       <td>",
"        Dilute in 50 mL NS or D5W and administer over three to five minutes.",
"       </td>",
"       <td>",
"        Day 1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Vincristine",
"        </strong>",
"       </td>",
"       <td>",
"        1.4 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        IV (max dose 2 mg)",
"       </td>",
"       <td>",
"        Dilute in 50 mL NS or D5W and administer over 15 to 20 minutes.",
"       </td>",
"       <td>",
"        Day 1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Prednisone",
"        </strong>",
"       </td>",
"       <td>",
"        100 mg orally",
"       </td>",
"       <td>",
"        Administer 30 minutes prior to chemotherapy on day 1, then every 24 hours on days 2 to 5.",
"       </td>",
"       <td>",
"        Days 1 to 5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Pretreatment considerations:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Emesis risk:",
"        </strong>",
"        HIGH (&gt;90 percent frequency of emesis). Refer to UpToDate topic on \"Prevention and treatment of chemotherapy-induced nausea and vomiting\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Prophylaxis for infusion reactions:",
"        </strong>",
"        Premedicate with acetaminophen and diphenhydramine, with or without an H2 blocker, 30 minutes prior to at least the first and second infusions of rituximab",
"        <sup>",
"         [2]",
"        </sup>",
"        . Refer to UpToDate topic on \"Infusion reactions to therapeutic monoclonal antibodies used for cancer therapy\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Vesicant/irritant properties:",
"        </strong>",
"        Doxorubicin and vincristine are vesicants. Refer to UpToDate topic on \"Extravasation injury from chemotherapy and other non-neoplastic vesicants\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Infection prophylaxis:",
"        </strong>",
"        The risk of febrile neutropenia with this regimen is 10 to 20 percent",
"        <sup>",
"         [1]",
"        </sup>",
"        ; primary prophylaxis with hematopoietic growth factors should be considered on an individual basis, particularly for high-risk patients such as those with preexisting neutropenia, advanced disease, poor performance status, or patients over age 65 years. Refer to UpToDate topic on the \"Use of granulocyte colony stimulating factors in patients with chemotherapy-induced neutropenia\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Dose adjustment for baseline liver or renal dysfunction:",
"        </strong>",
"        Adjustment of initial cyclophosphamide, doxorubicin, and vincristine doses may be needed for preexisting liver dysfunction",
"        <sup>",
"         [3-5]",
"        </sup>",
"        . In addition, dose adjustment of cyclophosphamide may be required for renal dysfunction. Refer to UpToDate topics on \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\" and \"Chemotherapy-related nephrotoxicity and dose modification in patients with renal insufficiency\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Hepatitis screening:",
"        </strong>",
"        Patients should be screened for hepatitis B and C prior to starting rituximab, and if positive, considered for lamivudine prophylaxis. Refer to UpToDate topic on \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Cardiac screening:",
"        </strong>",
"        LVEF should be evaluated prior to initiation of therapy. Dose alterations should be considered for LVEF &lt;50 percent, and doxorubicin therapy is contraindicated in patients with LVEF &lt;30 percent at initiation. Infusion times and schedule may be adjusted to decrease the risk of cardiotoxicity in individuals at high risk for its development. Refer to UpToDate topic on \"Cardiotoxicity of anthracycline-like chemotherapy agents\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Monitoring parameters:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; CBC with differential and platelet count weekly during treatment.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; Assess basic metabolic panel (creatinine and electrolytes) and liver function prior to each subsequent treatment cycle.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; LVEF should be evaluated periodically based on LVEF at initiation of therapy and cumulative dose of doxorubicin. Refer to UpToDate topic on \"Cardiotoxicity of anthracycline-like chemotherapy agents\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; Carriers of hepatitis B or C should be monitored for clinical and laboratory signs of active infection during and following completion of therapy. Rituximab should be discontinued if reactivation occurs. Refer to UpToDate topic on \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Suggested dose modifications for toxicity:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Myelotoxicity:",
"        </strong>",
"        Treatment should be delayed until ANC is greater than 1500/mm",
"        <sup>",
"         3",
"        </sup>",
"        and platelet count is greater than 100,000/mm",
"        <sup>",
"         3",
"        </sup>",
"        . If a patient develops grade 4 (ANC &lt;500) neutropenia or febrile neutropenia with any cycle, G-CSF support is added to the regimen for subsequent cycles. If grade 4 neutropenia or febrile neutropenia occurs despite G-CSF support, or if the patient develops grade 3 (25,000 to 50,000 platelets) or 4 (&lt;25,000 platelets) thrombocytopenia with any cycle, the doses of cyclophosphamide and doxorubicin should be decreased by 50 percent for subsequent cycles.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Neuropathy:",
"        </strong>",
"        Dose adjustment of vincristine may be necessary if the severity of neuropathy persists or worsens. No specific guidelines are available for dose adjustments.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"4\">",
"        <strong>",
"         If there is a change in body weight of at least 10 percent, dose should be recalculated for all drugs.",
"        </strong>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <strong>",
"     This table is provided as an example of how to administer this regimen; there may be other acceptable methods. This regimen must be administered by a clinician trained in the use of chemotherapy. The clinician is expected to use his or her independent medical judgment in the context of individual circumstances to make adjustments, as necessary.",
"    </strong>",
"    <div class=\"footnotes\">",
"     IV: intravenous; LVEF: left ventricular ejection fraction; CBC: complete blood count; ANC: absolute neutrophil count; G-CSF: granulocyte-colony-stimulating factor.",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <br/>",
"     <ol>",
"      <li>",
"       Coiffier B, et al. N Engl J Med 2002; 346:235.",
"      </li>",
"      <li>",
"       Rituxan (rituximab) injection. US FDA-approved manufacturer's package insert. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on October 23, 2012).",
"      </li>",
"      <li>",
"       Cytoxan (cyclophosphamide) injection. US FDA-approved manufacturer's package insert. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on October 23, 2012).",
"      </li>",
"      <li>",
"       Adriamycin (doxorubicin hydrochloride) injection. US FDA-approved manufacturer's package insert. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on October 23, 2012).",
"      </li>",
"      <li>",
"       Vincristine (vincristine sulfate) injection. FDA-approved product information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on October 23, 2012).",
"      </li>",
"     </ol>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_2_22574=[""].join("\n");
var outline_f22_2_22574=null;
var title_f22_2_22575="Aortic dissection TTE";
var content_f22_2_22575=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F51784&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F51784&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Aortic dissection",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 319px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A parasternal long-axis view of the aortic root during systole with transthoracic echocardiography demonstrating intimal flaps (arrows) within the aortic root.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     From: Xie SW, Picard MH, Weissman NJ. J Clin Ultrasound 1995; 23:382.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_2_22575=[""].join("\n");
var outline_f22_2_22575=null;
